Novel heterocyclic compounds as inhibitors of monoacylglycerol lipase

By developing novel heterocyclic compounds to inhibit MAGL and regulate the endocannabinoid system, the problems of difficulty in controlling neuroinflammation and neurodegenerative diseases in existing technologies have been solved, achieving the effects of inhibiting the production of pro-inflammatory mediators and neuroprotection.

CN112867720BActive Publication Date: 2026-11-17F HOFFMANN LA ROCHE & CO AG
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN201980053749.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-08-13
Filing Date
2019-08-12
Publication Date
2026-11-17
Estimated Expiration
2039-08-12

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit the activity of monoacylglycerol lipase (MAGL), leading to difficulty in controlling the progression and symptoms of diseases such as neuroinflammation, neurodegenerative diseases, pain, cancer, and mental disorders.

Method used

A new class of heterocyclic compounds was developed that, by interacting with MAGL, inhibit its activity, thereby modulating the endocannabinoid system, reducing the production of pro-inflammatory mediators, alleviating inflammatory responses, and promoting myelin regeneration and neuroprotection.

Benefits of technology

This compound can significantly inhibit MAGL activity, increase 2-AG levels, reduce the production of pro-inflammatory mediators, alleviate neuroinflammation, improve symptoms of neurodegenerative diseases, relieve pain and mental disorders, and has potential neuroprotective and cancer treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112867720B_ABST
    Figure CN112867720B_ABST
Patent Text Reader

Abstract

This invention provides novel heterocyclic compounds having the general formula (I), wherein A, L, X, m, n, R 1 and R 2 As described herein; compositions comprising the said compounds; methods for producing the said compounds; and methods for using the said compounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to organic compounds that can be used for the treatment or prevention of neurodegenerative diseases in mammals, and more particularly to monoacylglycerol lipase (MAGL) inhibitors for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine and / or depression in mammals. Background Technology

[0002] Endocannabinoids (ECs) are lipid signaling molecules that exert their biological effects through interactions with cannabinoid receptors (CBRs), CB1, and CB2. They regulate a variety of physiological processes, including neuroinflammation, neurodegenerative diseases, and tissue regeneration (Iannotti, FA et al., Progress in Lipid Research 2016, 62, 107-28). In the brain, the major endocannabinoid 2-arachidonicylglycerol (2-AG) is produced by diacylglycerol lipase (DAGL) and hydrolyzed by monoacylglycerol lipase (MAGL). MAGL hydrolyzes 85% of 2-AG; the remaining 15% is hydrolyzed by ABHD6 and ABDH12 (Nomura, DK et al., Science 2011, 334, 809). MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes, and microglia (Chanda, PK et al., Molecular pharmacology 2010, 78, 996; Viarder, A. et al., Cell reports 2015, 12, 798.). 2-AG hydrolysis forms arachidonic acid (AA), a precursor to prostaglandins (PG) and leukotrienes (LT). AA oxidation metabolism is increased in inflamed tissues. The inflammatory process involves two major enzymatic pathways of arachidonic acid oxidation: cyclooxygenase, which produces PG, and 5-lipoxygenase, which produces LT. Among the various cyclooxygenase products formed during inflammation, PGE2 is one of the most important. These products have been detected at sites of inflammation (e.g., in the cerebrospinal fluid of patients with neurodegenerative diseases) and are thought to contribute to inflammatory responses and disease progression. In mice lacking MAGL (Mgll- / -), the activity of 2-AG hydrolases in the nervous system was significantly reduced, while 2-AG levels were increased, and other arachidonic acid-containing phospholipids and neutral lipids (including arachidonic acid ethanolamine (AEA) and other free fatty acids) remained unchanged. Conversely, levels of AA-derived and AA-derived prostaglandins and other arachidic acids (including prostaglandin E2 (PGE2), D2 (PGD2), F2 (PGF2), and thromboxane B2 (TXB2)) were greatly reduced. Phospholipase A2 (PLA2) has been considered a major source of AA, but AA levels were unchanged in the brains of cPLA2-deficient mice, thus enhancing the key role of MAGL in regulating AA production and brain inflammatory processes in the brain.

[0003] Neuroinflammation is a common pathological feature of brain diseases, including but not limited to neurodegenerative diseases (e.g., multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, and mental disorders such as anxiety and migraine). In the brain, the production of arachidic acid and prostaglandins controls the neuroinflammatory process. The pro-inflammatory agent lipopolysaccharide (LPS) leads to a stable, time-dependent increase in brain arachidic acid production, a phenomenon significantly attenuated in Mg11- / - mice. LPS treatment also induces a general increase in pro-inflammatory cytokines, including interleukin-1-a (IL-1-a), IL-1b, and IL-6, and tumor necrosis factor-a (TNF-a) (which is suppressed in Mg11- / - mice).

[0004] Neuroinflammation is characterized by the activation of innate immune cells, microglia, and astrocytes in the central nervous system. Anti-inflammatory drugs have been reported to inhibit glial cell activation and disease progression (including Alzheimer's disease and multiple sclerosis) in preclinical models (Lleo A., Cell Mol Life Science. 2007, 64, 1403.). Importantly, genetic and / or pharmacological disruption of MAGL activity also blocks LPS-induced activation of microglia in the brain (Nomura, DK et al., Science 2011, 334, 809.).

[0005] Furthermore, in animal models of various neurodegenerative diseases (including but not limited to Alzheimer's disease, Parkinson's disease, and multiple sclerosis), the genetic and / or pharmacological disruption of MAGL activity has been demonstrated to be protective. For example, irreversible MAGL inhibitors have been widely used in preclinical models of neuroinflammation and neurodegenerative diseases (Long, JZ et al., Nature Chemical Biology 2009, 5, 37). Systemic injection of such inhibitors reproduces the Mgll- / - mouse phenotype in the brain, including elevated 2-AG levels, decreased AA levels, and associated arachidic acid production, and prevents LPS-induced neuroinflammation from leading to cytokine production and microglia activation (Nomura, DK et al., Science 2011, 334, 809), fully confirming MAGL as a drug target.

[0006] As MAGL activity is genetically and / or pharmacologically disrupted, the endogenous levels of the natural MAGL substrate 2-AG in the brain increase. 2-AG has been reported to have beneficial effects on pain, such as analgesia in mice (Ignatowska-Jankowska B. et al., J. Pharmacol. Exp. Ther. 2015, 353, 424), and also beneficial effects on mental disorders (e.g., depression in a chronic stress model) (Zhong P. et al., Neuropsychopharmacology 2014, 39, 1763.).

[0007] Furthermore, oligodendrocytes (OLs), myelin cells of the central nervous system, and their precursors (OPCs) express cannabinoid receptor 2 (CB2) on their membranes. 2-AG is an endogenous ligand for both CB1 and CB2 receptors. Pharmacological inhibition of cannabinoids and MAGLs has been reported to weaken the excitatory toxicity of OLs and OPCs, thus potentially possessing neuroprotective effects (Bernal-Chico, A. et al., Glia 2015, 63, 163). In addition, pharmacological inhibition of MAGLs increased the number of myelinated OLs in the mouse brain, suggesting that MAGL inhibition can promote the differentiation of OPCs in myelinated OLs in vivo (Alpar, A. et al., Nature Communications 2014, 5, 4421). In a mouse model of progressive multiple sclerosis, MAGL inhibition also promoted myelin regeneration and functional recovery (Feliu A. et al., Journal of Neuroscience 2017, 37(35), 8385).

[0008] Finally, in recent years, metabolism, especially lipid metabolism, has received high attention in cancer research. Researchers believe that de novo synthesis of fatty acids plays an important role in tumor development. Many studies have shown that endocannabinoids have anti-tumor effects, including anti-proliferation, apoptosis induction, and anti-metastasis. MAGL, as an important degradative enzyme in lipid metabolism and the endocannabinoid system, and as a component of gene expression characteristics, affects different aspects of tumorigenesis (Qin, H. et al., Cell Biochem. Biophys. 2014, 70, 33; Nomura DK et al., Cell 2009, 140(1), 49-61; Nomura DK et al., Chem. Biol. 2011, 18(7), 846-856).

[0009] In summary, inhibiting the action and / or activation of MAGL represents a promising new therapeutic strategy for treating or preventing neuroinflammation, neurodegenerative diseases, pain, cancer, and mental disorders. Furthermore, inhibiting the action and / or activation of MAGL offers promising new therapeutic strategies for providing neuroprotection and myelin regeneration. Therefore, there is an urgent unmet medical need for novel MAGL inhibitors. Summary of the Invention

[0010] In a first aspect, the present invention provides a compound of formula (I).

[0011]

[0012] Or its medicinal salt, wherein A, L, X, m, n, R 1 and R 2 As described in this article.

[0013] In one aspect, the present invention provides a method for producing urea compounds of formula (I) as described herein, the method comprising:

[0014] Make the first amine of formula 1

[0015]

[0016] The second amine of Formula 2 reacts with a base and a urea forming agent in the presence of a base to form the compound of Formula (I);

[0017]

[0018] Where R 1 As described herein, preferably R 1 It is hydrogen, where A, L, m, n, X and R 2 As described in this article.

[0019] In another aspect, the present invention provides a compound of formula (I) as described herein, which is produced according to the methods described herein.

[0020] In another aspect, the present invention provides a compound of formula (I) as described herein, which is used as a therapeutically active substance.

[0021] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.

[0022] In another aspect, the present invention provides the use of compounds of formula (I) as described herein or pharmaceutical compositions described herein for the inhibition of mammalian monoacylglycerol lipase (MAGL).

[0023] In another aspect, the present invention provides the use of compounds of formula (I) as described herein or pharmaceutical compositions described herein for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

[0024] In another aspect, the present invention provides the use of compounds of formula (I) as described herein or pharmaceutical compositions thereof for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms in mammals.

[0025] In another aspect, the present invention provides compounds of formula (I) as described herein or pharmaceutical compositions as described herein for use in methods of inhibiting monoacylglycerol lipases in mammals.

[0026] In another aspect, the present invention provides compounds of formula (I) as described herein or pharmaceutical compositions as described herein for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

[0027] In another aspect, the present invention provides compounds of formula (I) as described herein or pharmaceutical compositions as described herein for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms in mammals.

[0028] In another aspect, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for inhibiting monoacylglycerol lipases in mammals.

[0029] In another aspect, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

[0030] In another aspect, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms in mammals.

[0031] In another aspect, the present invention provides a method for inhibiting monoacylglycerol lipase in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein or a pharmaceutical composition as described herein.

[0032] In another aspect, the present invention provides a method for treating or preventing neuroinflammation, neurodegenerative diseases, pain, cancer, and / or mental disorders in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein or a pharmaceutical composition as described herein.

[0033] In another aspect, the present invention provides a method for treating or preventing multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasms in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein or a pharmaceutical composition as described herein. Detailed Implementation

[0034] definition

[0035] Features, integers, properties, compounds, chemical parts, or groups described in connection with specific aspects, embodiments, or examples of the invention should be understood to be applicable to any other aspect, embodiment, or example described herein, unless incompatible therewith. All features disclosed in this specification (including any appended claims, abstract, and drawings) and / or all steps of any method or process disclosed therefrom may be combined in any form, except for mutually exclusive combinations of such features / steps. The invention is not limited to the details of any of the foregoing embodiments. The invention is extendable to any new feature or any new combination of features disclosed in this specification (including any appended claims, abstract, and drawings), or to any new step or any new combination of steps in any method or process disclosed therefrom.

[0036] The term "alkyl" refers to a monovalent or polyvalent (e.g., monovalent or divalent) straight-chain or branched saturated hydrocarbon group containing 1 to 12 carbon atoms. In some preferred embodiments, the alkyl group contains 1 to 6 carbon atoms ("C12"). 1-6 The alkyl group ("alkyl") has, for example, 1, 2, 3, 4, 5, or 6 carbon atoms. In other embodiments, the alkyl group contains 1 to 3 carbon atoms, for example, 1, 2, or 3 carbon atoms. Some non-limiting examples of alkyl groups include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, isobutyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl. Particularly preferred but non-limiting examples of alkyl groups are methyl and tert-butyl.

[0037] The term "alkoxy group" refers to an alkyl group as defined above, which is attached to a portion of the parent molecule via an oxygen atom. Unless otherwise specified, an alkoxy group contains 1 to 12 carbon atoms. In some preferred embodiments, the alkoxy group contains 1 to 6 carbon atoms ("C12"). 1-6 -alkoxy group”). In other embodiments, the alkoxy group contains 1 to 4 carbon atoms. In other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and tert-butoxy. A particularly preferred but non-limiting example of an alkoxy group is methoxy.

[0038] The term "halogen" or "halogenated" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I). Preferably, the term "halogen" or "halogenated" refers to fluorine (F), chlorine (Cl), or bromine (Br). Particularly preferred, but non-limiting, examples of "halogen" or "halogenated" are fluorine (F) and chlorine (Cl).

[0039] As used herein, the term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or bicyclic hydrocarbon group having 3 to 10 ring carbon atoms. In some preferred embodiments, the cycloalkyl group is a saturated monocyclic hydrocarbon group having 3 to 8 ring carbon atoms. "Bicyclic cycloalkyl" refers to a cycloalkyl moiety consisting of two saturated carbon rings having two common carbon atoms, i.e., the bridge separating the two rings is a single bond or a chain of one or two ring atoms, and a spirocyclic moiety, i.e., the two rings are connected by a common ring atom. Preferably, the cycloalkyl group is a saturated monocyclic hydrocarbon group having 3 to 6 ring carbon atoms (e.g., 3, 4, 5, or 6 carbon atoms). Some non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

[0040] As used herein, the terms "heterocyclic group" and "heterocyclic alkyl group" are used interchangeably and refer to a saturated or partially unsaturated monocyclic or bicyclic, preferably monocyclic system, having 3 to 10 ring atoms, preferably 3 to 8 ring atoms, wherein 1, 2, or 3 of the ring atoms are heteroatoms selected from N, O, and S, and the remaining ring atoms are carbon. Preferably, 1-2 of the ring atoms are selected from N and O, and the remaining ring atoms are carbon. A "bicyclic heterocyclic group" refers to a heterocyclic portion consisting of two rings having two common ring atoms, i.e., the bridge separating the two rings is a single bond or a chain of one or two ring atoms, and a spirocyclic portion, i.e., the two rings are connected by a common ring atom. Some non-limiting examples of monocyclic heterocyclic groups include aziridine-3-yl, aziridine-2-yl, oxadiazine-3-yl, oxadiazine-2-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-oxopyrrolidine-1-yl, 2-oxopyrrolidine-3-yl, 5-oxopyrrolidine-2-yl, 5-oxopyrrolidine-3-yl, 2-oxo-1-piperidinyl, 2-oxo-3-piperidinyl, 2-oxo-4-piperidinyl, 6-oxo-2-piperidinyl, 6-oxo-3-piperidinyl, morpholinyl, morpholin-2-yl, and morpholin-3-yl.

[0041] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic system having a total of 6 to 14 ring members, preferably 6 to 12 ring members, and more preferably 6 to 10 ring members, wherein at least one ring in the system is an aromatic ring. Some non-limiting examples of aryl include phenyl and 9H-fluorenyl (e.g., 9H-fluoren-9-yl). A particularly preferred but non-limiting example of aryl is phenyl.

[0042] The term "heteroaryl" refers to a monovalent or polyvalent monocyclic or bicyclic ring system having a total of 5 to 14 ring members, preferably 5 to 12 ring members, and more preferably 5 to 10 ring members, wherein at least one ring in the system is an aromatic ring, and at least one ring in the system contains one or more heteroatoms. Preferably, "heteroaryl" refers to a 5- to 10-membered heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from O, S, and N. Most preferably, "heteroaryl" refers to a 5- to 10-membered heteroaryl containing 1 to 2 heteroatoms independently selected from O, S, and N. Some preferred but non-limiting examples of heteroaryl groups include thiazolyl (e.g., thiazolyl-2-yl); oxazolyl (e.g., oxazol-2-yl); 5,6-dihydro-4H-cyclopentadien[d]thiazolyl-2-yl; 1,2,4-oxadiazol-5-yl; pyridinyl (e.g., 2-pyridinyl); pyrazolyl (e.g., pyrazol-1-yl); imidazole (e.g., imidazole-1-yl); benzoxazolyl (e.g., benzoxazol-2-yl); and oxazolo[5,4-c]pyridin-2-yl.

[0043] The term "hydroxyl group" refers to the -OH group.

[0044] The term "cyano" refers to the -CN (nitrile) group.

[0045] As used herein, the term "haloalkyl" refers to an alkyl group in which at least one hydrogen atom of the alkyl group has been replaced by a halogen atom (preferably fluorine). Preferably, "haloalkyl" refers to an alkyl group in which one, two, or three hydrogen atoms of the alkyl group have been replaced by a halogen atom (preferably fluorine). Particularly preferred but non-limiting examples of haloalkyl are trifluoromethyl (CF3) and trifluoroethyl (e.g., 2,2,2-trifluoroethyl).

[0046] As used herein, the term "haloalkoxy" refers to an alkoxy group in which at least one hydrogen atom of the alkoxy group has been substituted with a halogen atom (preferably fluorine). Preferably, "haloalkoxy" refers to an alkoxy group in which one, two, or three hydrogen atoms of the alkoxy group have been substituted with a halogen atom (preferably fluorine). A particularly preferred but non-limiting example of a haloalkoxy group is trifluoromethoxy (-OCF3).

[0047] As used herein, the term "hydroxyalkyl" refers to an alkyl group in which at least one hydrogen atom of the alkyl group has been replaced by a hydroxyl group. Preferably, "hydroxyalkyl" refers to an alkyl group in which one, two, or three hydrogen atoms, and most preferably one hydrogen atom, have been replaced by a hydroxyl group. Particularly preferred, but non-limiting, examples of hydroxyalkyl are hydroxymethyl and hydroxyethyl (e.g., 2-hydroxyethyl). A particularly preferred, but non-limiting example of hydroxyalkyl is hydroxymethyl.

[0048] As used herein, the term "halogenated aryl" refers to an aryl group in which at least one hydrogen atom has been substituted with a halogen atom. Preferably, "halogenated aryl" refers to an aryl group in which one, two, or three hydrogen atoms, more preferably one or two hydrogen atoms, and most preferably one hydrogen atom, has been substituted with a halogen atom. A particularly preferred, but non-limiting, example of a halogenated aryl is a chlorophenyl, especially a 4-chlorophenyl.

[0049] The term "aryloxy group" refers to an aryl group, as defined above, that is attached to a portion of a parent molecule via an oxygen atom. A preferred, but not limiting, example of an aryloxy group is a phenoxy group.

[0050] The term "haloaryloxy group" refers to a haloaryl group, as defined above, that is attached to a parent molecule via an oxygen atom. A preferred, but not limiting, example of a haloaryloxy group is 4-fluorophenoxy.

[0051] The term "medicinal salts" refers to salts that retain the biological effectiveness and properties of free bases or free acids and are biologically or otherwise desirable. These salts are formed using inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. (especially hydrochloric acid) and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethylsulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine, etc. Furthermore, these salts can be prepared by adding inorganic or organic bases to free acids. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, and magnesium salts. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and salts of basic ion exchange resins (such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimide resins, etc.). Specific pharmaceutical salts of compounds of formula (I) are hydrochloride salts.

[0052] The term "pharmaceutical ester" refers to esters that hydrolyze in vivo, including those that readily decompose in the body, leaving behind a parent compound or its salts. Suitable ester groups include, for example, those derived from pharmaceutical aliphatic carboxylic acids, particularly alkanonic, alkenonic, cycloalkanonic, and alkanedic acids, wherein each alkyl or alkenyl moiety advantageously has no more than six carbon atoms. Representative examples of specific esters include, but are not limited to, formate, acetate, propionate, butyrate, acrylate, and ethyl succinate. Examples of pharmaceutical prodrug types are described in: Higuchi and Stella, Pro-drugs as Novel Delivery Systems, ACS Symposium Proceedings, Vol. 14; and Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.

[0053] As used herein, the term "protecting group" (PG) refers to a group that selectively blocks a reaction site in a multifunctional compound so that a chemical reaction can selectively occur at another unprotected reaction site typically associated with it in synthetic chemistry. The protecting group can be removed at an appropriate time point. Exemplary protecting groups are amino, carboxyl, or hydroxyl protecting groups. Specific protecting groups are tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc), and benzyl (Bn). Other specific protecting groups are tert-butoxycarbonyl (Boc) and fluorenylmethoxycarbonyl (Fmoc). A more specific protecting group is tert-butoxycarbonyl (Boc). Exemplary protecting groups and their applications in organic synthesis are described, for example, in: TW Greene and PGM Utts, Protective Groups in Organic Chemistry, 5th Edition, 2014, John Wiley & Sons, NY

[0054] As used herein, the term "urea forming agent" refers to a compound capable of converting a first amine into a substance that can react with a second amine to form a urea derivative. Non-limiting examples of urea forming agents include bis(trichloromethyl) carbonate, phosgene, trichloroformate, (4-nitrophenyl) carbonate, and 1,1′-carbonyldiimidazole. Urea forming agents as described by G. Sartori et al. (Green Chemistry 2000, 2, 140), which is incorporated herein by reference.

[0055] Compounds of formula (I) may contain multiple asymmetric centers and may exist as optically pure enantiomers, mixtures of enantiomers (such as racemates), optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, or mixtures of diastereomeric racemates. In a preferred embodiment, the compounds of formula (I) according to the invention are cis enantiomers of formula (Ia) or formula (Ib) as described herein.

[0056] According to the Cahn-Ingold-Prelog specification, asymmetric carbon atoms can have either an "R" or an "S" configuration.

[0057] The abbreviation "MAGL" refers to monoacylglycerol lipase. The terms "MAGL" and "monoacylglycerol lipase" are used interchangeably in this document.

[0058] As used herein, the term “treatment” includes: (1) suppressing a state, disease, or symptom (e.g., suppressing, alleviating, or delaying the progression of a disease or maintaining treatment against relapse of a state with at least one clinical or subclinical symptom); and / or (2) alleviating a symptom (i.e., resulting in the resolution of a state, disease, or symptom or at least one clinical or subclinical symptom). The benefit to the patient treated is statistically significant, or at least perceptible to the patient or physician. However, it should be understood that when a drug is administered to a patient to treat a disease, the result may not always be an effective treatment.

[0059] As used herein, the term “prevention” includes: preventing or delaying the onset of clinical symptoms of a state, disease, or condition in mammals and, in particular, in persons who may have or be susceptible to such a state, disease, or condition but have not yet developed or are exhibiting clinical or subclinical symptoms of such a state, disease, or condition.

[0060] As used herein, the term "neuritis" refers to acute and chronic inflammation of the neural tissue that is the main tissue component of the two parts of the nervous system: the brain and spinal cord of the central nervous system (CNS) and the peripheral nerves, branches of the peripheral nervous system (PNS). Chronic neuroinflammation is associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Acute neuroinflammation usually occurs immediately after injury to the central nervous system, for example, caused by traumatic brain injury (TBI).

[0061] As used in this article, the term “traumatic brain injury” (“TBI”, also known as “intracranial injury”) refers to brain damage caused by external mechanical forces such as rapid acceleration or deceleration, impact, shock wave, or projectile penetration.

[0062] As used in this article, the term "neurodegenerative disease" refers to... neurons Diseases associated with the progressive loss of structure or function (including neuronal death). Examples of neurodegenerative diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

[0063] As used herein, the term "mental disorder" (also known as psychosis or mental illness) refers to a pattern of behavior or mental state that may cause distress or impair daily living. Such features may be persistent, recurrent, or intermittent, or may be an isolated event. Examples of mental disorders include, but are not limited to, anxiety disorders and depression.

[0064] As used herein, the term "pain" refers to an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Examples of pain include, but are not limited to, nociceptive pain, chronic pain (including idiopathic pain), neuropathic pain (including chemotherapy-induced neuropathy), phantom pain, and psychogenic pain. A specific example of pain is neuropathic pain, which is caused by damage or disease affecting any part of the nervous system involved in bodily sensation (i.e., the somatosensory system). In one embodiment, "pain" is neuropathic pain caused by amputation or open-chest surgery. In another embodiment, "pain" is chemotherapy-induced neuropathy.

[0065] As used herein, the term "neurotoxicity" refers to toxicity of the nervous system. This occurs when exposed to natural or man-made toxic substances (neurotoxins) that alter the normal functioning of the nervous system, thereby causing damage to nerve tissue. Examples of neurotoxicity include, but are not limited to, neurotoxicity resulting from exposure to substances used in chemotherapy, radiation therapy, drug therapy, drug abuse, and organ transplantation, as well as exposure to heavy metals, certain foods and food additives, pesticides, industrial and / or cleaning solvents, cosmetics, and some natural substances.

[0066] As used herein, the term "cancer" refers to a disease characterized by the presence of growths or tumors resulting from the abnormal, uncontrolled growth of cells (these cells are "cancer cells"). As used herein, the term cancer explicitly includes, but is not limited to, hepatocellular carcinoma, colon cancer, and ovarian cancer.

[0067] As used herein, the term "mammal" includes both humans and non-humans, and includes, but is not limited to, humans, non-human primates, canines, felines, rodents, bovines, equines, and pigs. In a particularly preferred embodiment, the term "mammal" refers to humans.

[0068] The compounds of the present invention

[0069] In a first aspect, the present invention provides a compound of formula (I).

[0070]

[0071] Or its medicinal salt,

[0072] in:

[0073] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -、-O-、-OCH2-、-CH2O-、-CH2OCH2-、-CF2CH2- and -CH2CF2-; or

[0074] (ii) X is N; m is 1; n is 1 or 2; and L is -(CH2). p -or -CF2CH2-;

[0075] p is selected from 1, 2, and 3;

[0076] A is selected from:

[0077] (i) by R 4 R 5 and R 6 Substituted aryl groups;

[0078] (ii) by R 7 R 8 and R 9 Substituted heteroaryl groups; and

[0079] (iii) by R 10 R 11 and R 12 Substituted heterocyclic alkyl groups;

[0080] R 1 It is hydrogen or C 1-6 -alkyl;

[0081] R 2 Selected from hydrogen, C 1-6 -alkyl and hydroxy-C 1-6 -alkyl;

[0082] R 3 Selected from hydrogen, halogen, hydroxyl, C 1-6 -alkoxy group, C 1-6 -alkyl and halogenated-C 1-6 -alkyl;

[0083] R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 and R 12 Each group is independently selected from hydrogen, halogen, cyano, hydroxyl, C 1-6 -alkyl, halo-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, halo-C 1-5 -alkyl-CH(OH)-, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy group, SF5, CH3SO2, C 3-10 -cycloalkyl, R 13 Replacement C 3-10 -cycloalkyl, heterocycloalkyl, R14 Substituted heterocyclic alkyl, heteroaryl, aryl, and haloaryl groups; and

[0084] R 13 and R 14 Each of them is independently C 1-6 -alkyl, halo-C 1-6 -alkyl or hydroxyl.

[0085] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein the compound of formula (I) is a compound of formula (Ia):

[0086]

[0087] Where A, L, X, m, n, R 1 and R 2 As defined herein, preferably, the enantiomeric excess (ee) of the compound of formula (Ia) is >80%, more preferably >90%, and particularly >99%.

[0088] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein the compound of formula (I) is a compound of formula (Ib):

[0089]

[0090] Where A, L, X, m, n, R 1 and R 2 As defined herein, preferably, the enantiomeric excess (ee) of the compound of formula (Ib) is >80%, more preferably >90%, and particularly >99%.

[0091] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein the compound of formula (I) is a compound of formula (Ic):

[0092]

[0093] Where A, L, X, m, n, R 1 and R 2 As defined herein, preferably, the enantiomeric excess (ee) of the compound of formula (Ic) is >80%, more preferably >90%, and particularly >99%.

[0094] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein the compound of formula (I) is a compound of formula (Id):

[0095]

[0096] Where A, L, X, m, n, R 1 and R 2 As defined herein, preferably, the enantiomeric excess (ee) of the compound of formula (Id) is >80%, more preferably >90%, and particularly >99%.

[0097] In one embodiment, a compound of formula (I) as described herein is provided, wherein when X is CR 3 And R 3 When L is hydroxyl or halogen, it is not -O- or -CH2O-.

[0098] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0099] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -、-O-、-OCH2-、-CH2O- and -CH2OCH2-; or

[0100] (ii) X is N; both m and n are 1; and L is -(CH2). p -

[0101] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0102] X is CR 3 ;

[0103] Both m and n are 0; or

[0104] Both m and n are 1; and

[0105] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-.

[0106] In another preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0107] X is CR 3 ;

[0108] Both m and n are 0; or

[0109] Both m and n are 1;

[0110] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0111] R 3 Selected from hydrogen, C1-6 -alkyl and halogen; and

[0112] p is 1 or 2.

[0113] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0114] X is CR 3 ;

[0115] Both m and n are 0; or

[0116] Both m and n are 1;

[0117] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0118] R 3 It is hydrogen; and

[0119] p is 1 or 2.

[0120] In one embodiment, the present invention provides a compound of formula (I) as described herein or a pharmaceutical salt thereof, wherein p is 1 or 2.

[0121] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is selected from:

[0122] (i) by R 4 R 5 and R 6 Substituted aryl groups; and

[0123] (ii) by R 7 R 8 and R 9 Substituted heteroaryl groups.

[0124] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is selected from:

[0125] (i) by R 4 R 5 and R 6 Substituted phenyl; and

[0126] (ii) by R 7 R 8 and R 9 Substituted oxazolyl group.

[0127] In another preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is a derivative of R. 4 R 5and R 6 Substituted aryl groups.

[0128] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is a derivative of R. 4 R 5 and R 6 Substituted phenyl groups.

[0129] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0130] A is selected from:

[0131] (i) by R 4 R 5 and R 6 Substituted aryl groups; and

[0132] (ii) by R 7 R 8 and R 9 Substituted heteroaryl groups;

[0133] R 4 Selected from hydrogen, halogen, halogen-C 1-6 -alkoxy and halogenated-C 1-6 -alkyl;

[0134] R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, C 1-6 -alkoxy, heterocyclic alkyl, C 3-10 -cycloalkyl, heteroaryl and haloaryl;

[0135] R 6 It is hydrogen or halogen;

[0136] R 7 Selected from hydrogen, C 1-6 -alkyl, aryl and halogenated-C 1-6 -alkyl;

[0137] R 8 It is hydrogen or C 1-6 -alkyl; and

[0138] R 9 It is hydrogen.

[0139] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0140] A is selected from:

[0141] (i) by R 4 R 5 and R6 Substituted aryl groups; and

[0142] (ii) by R 7 R 8 and R 9 Substituted heteroaryl groups;

[0143] R 4 Selected from halogens, halogenated -C 1-6 -alkoxy and halogenated-C 1-6 -alkyl;

[0144] R 5 Selected from hydrogen, cyano, halogen, heterocyclic alkyl, C 3-10 -Cycloalkyl and haloaryl;

[0145] R 6 It is hydrogen;

[0146] R 7 C 1-6 -alkyl;

[0147] R 8 It is hydrogen; and

[0148] R 9 It is hydrogen.

[0149] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0150] A is selected from:

[0151] (i) by R 4 R 5 and R 6 Substituted phenyl; and

[0152] (ii) by R 7 R 8 and R 9 Substituted oxazolyl group;

[0153] R 4 Selected from chlorine, OCF3, and CF3;

[0154] R 5 Selected from hydrogen, cyano, fluorine, chlorine, pyrrolyl, cyclopentyl, cyclopropyl, and chlorophenyl;

[0155] R 6 It is hydrogen;

[0156] R 7 For tert-butyl;

[0157] R 8 It is hydrogen; and

[0158] R9 It is hydrogen.

[0159] In a further particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is selected from phenyl, 4-tert-butylthiazol-2-yl, 4-tert-butyloxazol-2-yl, 2-chloro-4-fluorophenyl, 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl, 4-chlorophenyl, 5,6-dihydro-4H-cyclopentadien[d]thiazol-2-yl, 3-phenyl-1,2,4-oxadiazol-5-yl, 5-(trifluoromethyl)-2-pyridyl, 4-(trifluoromethyl)pyrazol-1-yl, 2-fluoro-4-(trifluoromethyl)phenyl, 2,4-difluorophenyl, 4-chloro-3-fluorophenyl, 4-benzonitrile, 4,4-difluorophenyl -1-piperidinyl, 5-tert-butyloxazol-2-yl, 4-methoxy-2-fluoro-phenyl, 2-chloro-4-(trifluoromethyl)phenyl, 6-(trifluoromethyl)-3-pyridyl, 3-(trifluoromethyl)phenyl, 2-chloro-4-(trifluoromethoxy)phenyl, 4-chloro-2-fluoro-phenyl, 4-fluoro-2-(trifluoromethyl)phenyl, 2-pyrrolidone-1-yl-4-(trifluoromethyl)phenyl, 4-fluoro-3-cyano-phenyl, 2-cyclopentyl-4-(trifluoromethyl)phenyl, 2-chloro-4-benzonitrile, 4-(trifluoromethyl)imidazol-1-yl, 4-fluoro-2-methyl-phenyl, 4-tert-butylpyrazol-1-yl, 1,3-benzoxazol-2-yl, 4-chloro-3 -(4-chlorophenyl)phenyl, 2-(1H-pyrazol-4-yl)-4-(trifluoromethyl)phenyl, 2,4-dichlorophenyl, 3-methoxy-4-(trifluoromethyl)phenyl, 5-methyl-6-(trifluoromethyl)-3-pyridyl, 3-chlorophenyl, 2-chlorophenyl, 2-cyclopropyl-4-(trifluoromethyl)phenyl, 2-methyl-4-(trifluoromethyl)phenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 2-fluoro-6-(trifluoromethyl)phenyl, 3-chloro-4-(trifluoromethyl)phenyl, 2,4-difluoro-5-(trifluoromethyl)phenyl, 2-fluoro-5-(trifluoromethyl)phenyl, 2-methoxy-4-(trifluoromethyl)phenyl, 4-chloro-2-(trifluoro)phenyl methyl)phenyl, 4-chloro-3-(trifluoromethyl)phenyl, 4-chloro-3-cyclopropyl-phenyl, 4-chloro-3-morpholinyl-phenyl, 2-cyano-4-(trifluoromethyl)phenyl, oxazolo[5,4-c]pyridin-2-yl, 4-methyl-3-(trifluoromethyl)phenyl, 3-cyclopropyl-4-(trifluoromethyl)phenyl, 2-fluoro-4-methyl-phenyl, 4-methoxy-2-(trifluoromethyl)phenyl, 4-methyl-2-(trifluoromethyl)phenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 4,5-bis(trifluoromethyl)-2-pyridyl, 2-fluoro-4-(trifluoromethyl)phenyl, 2-fluoro-4-(pentafluoro-λ6-thioalkyl)phenyl, 2,4-Bis(trifluoromethyl)phenyl, 2-methyl-3-(trifluoromethyl)phenyl, 2-methyl-4-(trifluoromethoxy)phenyl, 3-chloro-4-(trifluoromethyl)phenyl, 2-chloro-3-(trifluoromethyl)phenyl, 2-chloro-3-cyclopropyl-phenyl, 3-(2-azaspiro[3.3]heptane-2-yl)-4-(trifluoromethyl)phenyl, 2-chloro-3-(2-azaspiro[3.3]heptane-2-yl)phenyl, 2-chloro-3-(5-oxa-2-azaspiro[3.5]nonane-2-yl)phenyl, 2-fluoro-4-(trifluoromethyl)phenyl, 2-fluoro-4-methyl-phenyl, 2-fluoro-6-(trifluoromethyl)phenyl, and 2-(trifluoromethyl)-4-methyl-phenyl.

[0160] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 1 It can be hydrogen or methyl.

[0161] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 1 It is hydrogen.

[0162] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 2 It is hydrogen or C 1-6 -alkyl.

[0163] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 2 It can be hydrogen or methyl.

[0164] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 3 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl.

[0165] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 3 Selected from hydrogen, halogens and C 1-6 -alkyl.

[0166] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 3 Selected from hydrogen, fluorine, and methyl.

[0167] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 3 Selected from hydrogen, methyl, fluorine and trifluoromethyl.

[0168] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from hydrogen, halogen, halogen-C 1-6 -alkoxy and halogenated-C 1-6 -alkyl.

[0169] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from halogens, halogenated -C 1-6 -alkoxy and halogenated-C 1-6 -alkyl.

[0170] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from chlorine, OCF3 and CF3.

[0171] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from hydrogen, chlorine, fluorine, OCF3 and CF3.

[0172] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, C 1-6 -alkoxy, heterocyclic alkyl, C 3-10 -Cycloalkyl, heteroaryl and haloaryl.

[0173] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 Selected from hydrogen, cyano, halogen, heterocyclic alkyl, C 3-10 -Cycloalkyl and haloaryl.

[0174] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 It is selected from hydrogen, cyano, fluorine, chlorine, pyrrolyl, cyclopentyl, cyclopropyl and chlorophenyl.

[0175] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 It is selected from hydrogen, methyl, methoxy, cyano, fluorine, chlorine, pyrrolyl, morpholino, pyrazolyl, cyclopentyl, cyclopropyl and 4-chlorophenyl.

[0176] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 6 It is hydrogen or halogen.

[0177] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 6 It is either hydrogen or fluorine.

[0178] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 6 It is hydrogen.

[0179] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 Selected from hydrogen, C 1-6 -alkyl, aryl and halogenated-C 1-6 -alkyl.

[0180] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 C 1-6 -alkyl.

[0181] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 It is tert-butyl.

[0182] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 Selected from hydrogen, tert-butyl, phenyl and CF3.

[0183] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 8 It is hydrogen or C 1-6 -alkyl.

[0184] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 8 It can be hydrogen or methyl.

[0185] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 8 It is hydrogen.

[0186] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 9 It is hydrogen.

[0187] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 10 It is a halogenated form.

[0188] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 10 It is fluorine.

[0189] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 11 It is a halogen.

[0190] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 11 It is fluorine.

[0191] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 10 and R 11 Both are fluorine.

[0192] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 12 It is hydrogen.

[0193] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0194] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -、-O-、-OCH2-、-CH2O- and -CH2OCH2-; or

[0195] (ii) X is N; both m and n are 1; and L is -(CH2). p -;

[0196] p is 1 or 2;

[0197] A is selected from:

[0198] (i) by R 4 R 5 and R 6 Substituted aryl groups;

[0199] (ii) by R 7 R 8 and R 9 Substituted heteroaryl groups; and

[0200] (iii) by R 10 R 11 and R 12 Substituted heterocyclic alkyl groups;

[0201] R 1 It is hydrogen or C1-6 -alkyl;

[0202] R 2 Selected from hydrogen or C 1-6 -alkyl;

[0203] R 3 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl;

[0204] R 4 Selected from hydrogen, halogen, halogen-C 1-6 -alkoxy and halogenated-C 1-6 -alkyl;

[0205] R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, C 1-6 -alkoxy, heterocyclic alkyl, C 3-10 -cycloalkyl, heteroaryl and haloaryl;

[0206] R 6 It is hydrogen or halogen;

[0207] R 7 Selected from hydrogen, C 1-6 -alkyl, aryl and halogenated-C 1-6 -alkyl;

[0208] R 8 It is hydrogen or C 1-6 -alkyl;

[0209] R 9 It is hydrogen;

[0210] R 10 It is a halogen;

[0211] R 11 It is halogen, and

[0212] R 12 It is hydrogen.

[0213] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0214] X is CR 3 ;

[0215] Both m and n are 0; or

[0216] Both m and n are 1;

[0217] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0218] p is 1 or 2;

[0219] A is selected from:

[0220] (i) by R 4 R 5 and R 6 Substituted aryl groups; and

[0221] (ii) by R 7 R 8 and R 9 Substituted heteroaryl groups;

[0222] R 1 It is hydrogen;

[0223] R 2 Selected from hydrogen or C 1-6 -alkyl;

[0224] R 3 Selected from hydrogen, halogens and C 1-6 -alkyl;

[0225] R 4 Selected from halogens, halogenated -C 1-6 -alkoxy and halogenated-C 1-6 -alkyl;

[0226] R 5 Selected from hydrogen, cyano, halogen, heterocyclic alkyl, C 3-10 -Cycloalkyl and haloaryl;

[0227] R 6 It is hydrogen;

[0228] R 7 C 1-6 -alkyl;

[0229] R 8 It is hydrogen; and

[0230] R 9 It is hydrogen.

[0231] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0232] X is CR 3 ;

[0233] Both m and n are 0; or

[0234] Both m and n are 1;

[0235] L is selected from -(CH2) p-、-O-、-OCH2- and -CH2O-;

[0236] p is 1 or 2;

[0237] A is selected from:

[0238] (i) by R 4 R 5 and R 6 Substituted phenyl; and

[0239] (ii) by R 7 R 8 and R 9 Substituted oxazolyl group;

[0240] R 1 It is hydrogen;

[0241] R 2 Selected from hydrogen or methyl;

[0242] R 3 Selected from hydrogen, fluorine, and methyl;

[0243] R 4 Selected from chlorine, OCF3, and CF3;

[0244] R 5 Selected from hydrogen, cyano, fluorine, chlorine, pyrrolyl, cyclopentyl, cyclopropyl, and chlorophenyl;

[0245] R 6 It is hydrogen;

[0246] R 7 For tert-butyl;

[0247] R 8 It is hydrogen; and

[0248] R 9 It is hydrogen.

[0249] In one aspect, the present invention provides a compound of formula (I) or a pharmaceutical salt thereof, wherein:

[0250] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -, -O-, -OCH2-, -CH2OCH2-, -CF2CH2-, -CH2=CH2-, -(CR 16 R 17 ) q -CH2O- and -CH2CF2-; or

[0251] (ii) X is N; m is 1; n is 1 or 2; and L is -(CH2). p-or -CF2CH2-;

[0252] p is selected from 1, 2, and 3;

[0253] q is 0 or 1;

[0254] A is selected from:

[0255] (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aryl;

[0256] (ii) by R 7 R 8 and R 9 Substituted 5- to 14-member heteroaryl groups; and

[0257] (iii) by R 10 R 11 and R 12 Substituted 3- to 14-membered heterocyclic alkyl groups;

[0258] R 1 It is hydrogen or C 1-6 alkyl;

[0259] R 2 Selected from hydrogen, C 1-6 -alkyl and hydroxy-C 1-6 -alkyl;

[0260] R 3 Selected from hydrogen, halogen, hydroxyl, C 1-6 -alkoxy group, C 1-6 -alkyl and halogenated-C 1-6 -alkyl;

[0261] R 4 R 5 R 6 R 7 R 8 R 9 R 10 R 11 and R 12 Each group is independently selected from hydrogen, halogen, cyano, hydroxyl, C 1-6 -alkyl, halo-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -alkanoyl group, halo-C 1-5 -alkyl-CH(OH)-, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy group, SF5, CH3SO2, C 3-10 -cycloalkyl, R13 Replacement C 3-10 -cycloalkyl, 3- to 14-membered heterocycloalkyl, R 14 and R 15 Substituted 3- to 14-membered heterocyclic alkyl groups, 5- to 14-membered heteroaryl groups, C6-C 14 -Aryl, C6-C 14 -Aryloxy group, halogenated-C6-C 14 -Aryl and halogenated-C6-C 14 -Aryloxy;

[0262] R 13 R 14 and R 15 Each of them is independently selected from C 1-6 -alkyl, C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, halo-C 1-6 -alkoxy, halogen, and hydroxyl groups; and

[0263] R 16 and R 17 Together with the carbon atoms they are attached to, they form C 3-10 -Cycloalkyl.

[0264] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0265] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -, -O-, -OCH2-, -CF2CH2-, -CH2=CH2-, -(CR 16 R 17 ) q -CH2O- and -CH2OCH2-; or

[0266] (ii) X is N; both m and n are 1; and L is -(CH2). p -

[0267] In one embodiment, the present invention provides a compound of formula (I) as described herein or a pharmaceutical salt thereof, wherein p is 2.

[0268] In one embodiment, the present invention provides a compound of formula (I) as described herein or a pharmaceutical salt thereof, wherein q is 0 or 1.

[0269] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein or a pharmaceutical salt thereof, wherein q is 0.

[0270] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is selected from:

[0271] (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aromatic; and

[0272] (ii) by R 7 R 8 and R 9 Replaced by 5 to 14-member heteroaryl groups.

[0273] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein A is selected from:

[0274] (i) by R 4 R 5 and R 6 Substituted phenyl;

[0275] (ii) by R 7 R 8 and R 9 Substituted oxazolyl group; and

[0276] (iii) by R 7 R 8 and R 9 Substituted pyridinyl group.

[0277] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from hydrogen, halogen, hydroxyl, cyano, C 1-6 -alkyl, C 1-6 -alkanoyl group, SF5, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl, 3- to 14-membered heterocyclic groups, R 14 and R 15 Substituted 3- to 14-membered heterocyclic alkyl groups, 5- to 14-membered heteroaryl groups, C6-C 14 -Aryloxy groups and halogenated-C6-C 14 -Aryl.

[0278] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from halogens, SF5, C 1-6 -alkyl, C 1-6 -alkoxy, halogenated-C 1-6-alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -Cycloalkyl and 3- to 14-membered heterocycloalkyl.

[0279] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 4 Selected from chlorine, SF5, methyl, methoxy, OCF3, CF3, cyclopropyl and 2-azaspiro[3.3]heptane-2-yl.

[0280] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1-6 -alkoxy, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl, 5- to 14-membered heteroaryl and halogenated -C6-C 14 -Aryl.

[0281] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl and halogenated-C6-C 14 -Aryl.

[0282] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 5 It is selected from hydrogen, cyano, fluorine, chlorine, methyl, CF3, pyrrolyl, cyclopentyl, cyclopropyl and chlorophenyl.

[0283] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 Selected from hydrogen, C 1-6 -alkyl, C6-C 14 -Aryl, halogenated-C6-C 14 -Aryl, halogenated-C6-C 14 -Aryloxy groups and halogenated-C 1-6 -alkyl.

[0284] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 C 1-6 -alkyl or halogenated-C 1-6 -alkyl.

[0285] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 7 It is tert-butyl or CF3.

[0286] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 8 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl.

[0287] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 8 Hydrogen or halogenated -C 1-6 -alkyl.

[0288] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 8 It is hydrogen or CF3.

[0289] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 14 Selected from C 1-6 -alkyl, C 1-6 -Alkyl groups and halogens.

[0290] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein R 15 It is hydrogen or halogen.

[0291] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0292] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -、-O-、-OCH2-、-(CR 16 R 17 ) q -CH2O-, -CH2OCH2-, -CF2CH2- and -CH2=CH2-; or

[0293] (ii) X is N; both m and n are 1; and L is -(CH2). p -;

[0294] p is 1 or 2;

[0295] q is 0 or 1;

[0296] A is selected from:

[0297] (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aryl;

[0298] (ii) by R 7 R 8 and R 9 Substituted 5- to 14-member heteroaryl groups; and

[0299] (iii) by R 10 R 11 and R 12 Substituted 3- to 14-membered heterocyclic alkyl groups;

[0300] R 1 It is hydrogen or C 1-6 -alkyl;

[0301] R 2 It is hydrogen or C 1-6 -alkyl;

[0302] R 3 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl;

[0303] R 4 Selected from hydrogen, halogen, cyano, SF5, C 1-6 -alkyl, C 1-6 -alkylyl group, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl, 3- to 14-membered heterocycloalkyl, R 14 and R 15 Substituted 3- to 14-membered heterocyclic alkyl groups, 5- to 14-membered heteroaryl groups, halogenated -C6-C 14 -Aryl and C6-C 14 -Aryloxy;

[0304] R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1-6 -alkoxy, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl, 5- to 14-membered heteroaryl and halogenated -C6-C 14 -Aryl;

[0305] R 6 It is hydrogen or a halide;

[0306] R7 Selected from hydrogen, C 1-6 -alkyl, C6-C 14 -Aryl, halogenated-C6-C 14 -Aryl, halogenated-C6-C 14 -Aryloxy groups and halogenated-C 1-6 -alkyl;

[0307] R 8 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl;

[0308] R 9 It is hydrogen;

[0309] R 10 It is a halogen;

[0310] R 11 It is a halogen;

[0311] R 12 It is hydrogen;

[0312] R 14 Selected from halogens, C 1-6 -alkyl and C 1-6 -alkoxy group;

[0313] R 15 It is hydrogen or halogen; and

[0314] R 16 and R 17 Together with the carbon atoms they are attached to, they form C 3-10 -Cycloalkyl.

[0315] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0316] X is CR 3 ;

[0317] Both m and n are 0; or

[0318] Both m and n are 1;

[0319] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0320] p is 1 or 2;

[0321] A is selected from:

[0322] (i) by R 4 R 5 and R 6 Replacement C6-C14 -Aromatic; and

[0323] (ii) by R 7 R 8 and R 9 Substituted 5- to 14-member heteroaryl groups;

[0324] R 1 It is hydrogen;

[0325] R 2 It is hydrogen or C 1-6 -alkyl;

[0326] R 3 Selected from hydrogen, halogens and C 1-6 -alkyl;

[0327] R 4 Selected from halogens, SF5, C 1-6 -alkyl, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl and 3- to 14-membered heterocycloalkyl;

[0328] R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl and halogenated-C6-C 14 -Aryl;

[0329] R 6 It is hydrogen;

[0330] R 7 C 1-6 -alkyl or halogenated-C 1-6 -alkyl;

[0331] R 8 Hydrogen or halogenated -C 1-6 -alkyl; and

[0332] R 8 It is hydrogen.

[0333] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0334] X is CR 3 ;

[0335] Both m and n are 0; or

[0336] Both m and n are 1;

[0337] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0338] p is 1 or 2;

[0339] A is selected from:

[0340] (i) by R 4 R 5 and R 6 Substituted phenyl;

[0341] (ii) by R 7 R 8 and R 9 Substituted oxazolyl group; and

[0342] (iii) by R 7 R 8 and R 9 Substituted pyridinyl group;

[0343] R 1 It is hydrogen;

[0344] R 2 It can be hydrogen or methyl;

[0345] R 3 Selected from hydrogen, fluorine, and methyl;

[0346] R 4 Selected from chlorine, SF5, methyl, methoxy, OCF3, CF3, cyclopropyl and 2-azaspiro[3.3]heptane-2-yl;

[0347] R 5 Selected from hydrogen, cyano, fluorine, chlorine, methyl, CF3, pyrrolyl, cyclopentyl, cyclopropyl, and chlorophenyl;

[0348] R 6 It is hydrogen;

[0349] R 7 Selected from tert-butyl, methyl and CF3;

[0350] R 8 It is hydrogen or CF3; and

[0351] R 9 It is hydrogen.

[0352] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0353] X is CR 3 ;and

[0354] R3 Selected from hydrogen, halogens and C 1-6 -alkyl.

[0355] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0356] X is CR 3 ;and

[0357] R 3 Selected from hydrogen, fluorine, and methyl.

[0358] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0359] (i)X is CR 3 m is 0 or 1; n is selected from 0, 1, and 2; and L is selected from -(CH2). p -、-O-、-OCH2-、-(CR 16 R 17 ) q -CH2O-, -CH2OCH2-, -CF2CH2- and -CH2=CH2-; or

[0360] (ii) X is N; both m and n are 1; and L is -(CH2). p -;

[0361] p is 1 or 2;

[0362] q is 0 or 1;

[0363] R 3 Selected from hydrogen, halogens and C 1-6 -alkyl; and

[0364] R 16 and R 17 Together with the carbon atoms they are attached to, they form C 3-10 -Cycloalkyl.

[0365] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0366] X is CR 3 ;

[0367] Both m and n are 0; or

[0368] Both m and n are 1;

[0369] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0370] p is 1 or 2; and

[0371] R 3 Selected from hydrogen, halogens and C 1-6 -alkyl.

[0372] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0373] X is CR 3 ;

[0374] Both m and n are 0; or

[0375] Both m and n are 1;

[0376] L is selected from -(CH2) p -、-O-、-OCH2- and -CH2O-;

[0377] p is 1 or 2; and

[0378] R 3 Selected from hydrogen, fluorine, and methyl.

[0379] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0380] A is selected from:

[0381] (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aryl;

[0382] (ii) by R 7 R 8 and R 9 Substituted 5- to 14-member heteroaryl groups; and

[0383] (iii) by R 10 R 11 and R 12 Substituted 3- to 14-membered heterocyclic alkyl groups;

[0384] R 4 Selected from hydrogen, halogen, cyano, SF5, C 1-6 -alkyl, C 1-6 -alkylyl group, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl, 3- to 14-membered heterocycloalkyl, R 14 and R 15Substituted 3- to 14-membered heterocyclic alkyl groups, 5- to 14-membered heteroaryl groups, halogenated -C6-C 14 -Aryl and C6-C 14 -Aryloxy;

[0385] R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1-6 -alkoxy, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl, 5- to 14-membered heteroaryl and halogenated -C6-C 14 -Aryl;

[0386] R 6 It is hydrogen or halogen;

[0387] R 7 Selected from hydrogen, C 1-6 -alkyl, C6-C 14 -Aryl, halogenated-C6-C 14 -Aryl, halogenated-C6-C 14 -Aryloxy groups and halogenated-C 1-6 -alkyl;

[0388] R 8 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl;

[0389] R 9 It is hydrogen;

[0390] R 10 It is a halogen;

[0391] R 11 It is a halogen;

[0392] R 12 It is hydrogen;

[0393] R 14 Selected from halogens, C 1-6 -alkyl and C 1-6 -alkoxy group; and

[0394] R 15 It is hydrogen or halogen.

[0395] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0396] A is selected from:

[0397] (i) by R 4 R 5 and R 6Replacement C6-C 14 -Aromatic; and

[0398] (ii) by R 7 R 8 and R 9 Substituted 5- to 14-member heteroaryl groups;

[0399] R 4 Selected from halogens, SF5, C 1-6 -alkyl, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl and 3- to 14-membered heterocycloalkyl;

[0400] R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl and halogenated-C6-C 14 -Aryl;

[0401] R 6 It is hydrogen;

[0402] R 7 C 1-6 -alkyl or halogenated-C 1-6 -alkyl;

[0403] R 8 Hydrogen or halogenated -C 1-6 -alkyl; and

[0404] R 9 It is hydrogen.

[0405] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0406] A is selected from:

[0407] (i) by R 4 R 5 and R 6 Substituted phenyl;

[0408] (ii) by R 7 R 8 and R 9 Substituted oxazolyl group; and

[0409] (iii) by R 7 R 8 and R 9 Substituted pyridinyl group;

[0410] R 4 Selected from chlorine, SF5, methyl, methoxy, OCF3, CF3, cyclopropyl and 2-azaspiro[3.3]heptane-2-yl;

[0411] R 5 Selected from hydrogen, cyano, fluorine, chlorine, methyl, CF3, pyrrolyl, cyclopentyl, cyclopropyl, and chlorophenyl;

[0412] R 6 It is hydrogen;

[0413] R 7 It consists of tert-butyl, methyl, and CF3;

[0414] R 8 It is hydrogen or CF3; and

[0415] R 9 It is hydrogen.

[0416] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0417] X is CH;

[0418] Both m and n are 0;

[0419] L stands for -CH2O-;

[0420] A is R 4 R 5 and R 6 Replacement C6-C 14 -Aryl;

[0421] R 1 R 2 and R 6 All are hydrogen;

[0422] R 4 Halogenated-C 1-6 -alkyl; and

[0423] R 5 Halogen or C 1-6 -alkyl.

[0424] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0425] X is CH;

[0426] Both m and n are 0;

[0427] L stands for -CH2O-;

[0428] A is R4 R 5 and R 6 Replacement C6-C 14 -Aryl;

[0429] R 1 R 2 and R 6 All are hydrogen;

[0430] R 4 Halogenated-C 1-6 -alkyl; and

[0431] R 5 It is a halogen.

[0432] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0433] X is CH;

[0434] Both m and n are 0;

[0435] L stands for -CH2O-;

[0436] A is R 4 R 5 and R 6 Substituted phenyl;

[0437] R 1 R 2 and R 6 All are hydrogen;

[0438] R 4 For CF3; and

[0439] R 5 It is either fluorine or methyl.

[0440] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, wherein:

[0441] X is CH;

[0442] Both m and n are 0;

[0443] L stands for -CH2O-;

[0444] A is R 4 R 5 and R 6 Substituted phenyl;

[0445] R 1 R 2 and R 6 All are hydrogen;

[0446] R 4 For CF3; and

[0447] R 5 It is fluorine.

[0448] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, selected from the compounds disclosed in Table 1.

[0449] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutical salt thereof, selected from:

[0450] (+)-(4aR,8aS)-6-(4-((4-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0451] (+)-(4aR,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0452] (+)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0453] Racemic-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0454] (+)- or (-)-(4aR, 8aS)-6-(3-((2-chloro-4-fluorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0455] (+)- or (-)-(4aR, 8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0456] (+)- or (-)-(4aR, 8aS)-6-(4-(4-(trifluoromethoxy)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0457] (+)- or (-)-(4aR, 8aS)-6-(4-(4-chloro-3-fluorobenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0458] (+)- or (-)-(4aR,8aS)-6-(4-(2-chloro-4-(trifluoromethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0459] (+)- or (-)-(4aR,8aS)-6-(4-(3-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0460] (+)- or (-)-(4aR,8aS)-6-[4-[[2-chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0461] (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0462] (+)- or (-)-(4aR,8aS)-6-(4-((4-chloro-2-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0463] (+)- or (-)-(4aR,8aS)-6-(4-((4-fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0464] (+)- or (-)-(4aR,8aS)-6-(4-((2-fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0465] (+)- or (-)-(4aR, 8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0466] (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0467] (+)- or (-)-(4aR,8aS)-6-[4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0468] (+)- or (-)-3-chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile;

[0469] (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0470] (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0471] (+)-or (-)-(4aR,8aS)-6-(4-((4′,6-dichloro-[1,1′-biphenyl]-3-yl)oxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0472] (+)- or (-)-(4aR,8aS)-6-(cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0473] (+)- or (-)-(4aR, 8aS)-6-(3-((2-chloro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0474] (+)- or (-)-(4aR, 8aS)-6-(3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0475] (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0476] (4aR,8aS)-6-[3-[(2,4-dichlorophenyl)methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0477] (4aR,8aS)-6-[4-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0478] (4aR,8aS)-6-[4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0479] (4aR,8aS)-6-[3-[[3-chloro-4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0480] (4aR,8aS)-6-[3-[[2-fluoro-5-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0481] (4aR,8aS)-6-[3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0482] (4aR,8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0483] 6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0484] (4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0485] (4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0486] (4aR, 8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0487] (4aR, 8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0488] Racemic-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0489] (4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0490] Racemic-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0491] (4aR, 8aS)-6-(3-((2-fluoro-4-(pentafluoro-6-thioalkyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0492] (4aR, 8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0493] (4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0494] (4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0495] (4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0496] (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0497] (4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0498] (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0499] (4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one;

[0500] Racemic-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0501] Racemic-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0502] (4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0503] (4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0504] (4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0505] (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-2-chloro-phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0506] (4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonane-2-yl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0507] (4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one;

[0508] (4aR, 8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; and

[0509] (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one.

[0510] In one embodiment, the present invention provides a pharmaceutically acceptable salt or ester of a compound of formula (I) as described herein. In a particular embodiment, the present invention provides a pharmaceutically acceptable salt of a compound of formula (I) as described herein, particularly an hydrochloride salt. In another particular embodiment, the present invention provides a pharmaceutically acceptable ester of a compound of formula (I) as described herein. In yet another particular embodiment, the present invention provides a compound of formula (I) as described herein.

[0511] In some embodiments, compounds of formula (I) are isotopically labeled, in which one or more atoms are replaced with atoms having different atomic weights or mass numbers. Such isotopically labeled (i.e., radiolabeled) compounds of formula (I) are considered to fall within the scope of this disclosure. Examples of isotopes that may be incorporated into compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, respectively such as, but not limited to, isotopes of, but not limited to, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine. 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 36 Cl、 123 I and 125 I. Certain isotope-labeled compounds of formula (I), for example those incorporating a radioactive isotope, can be used in drug and / or substrate tissue distribution studies. In terms of ease of incorporation and ease of detection, the radioactive isotope tritium (i.e., 3 H) and carbon-14 (i.e., ... 14 C) Specifically for this purpose. For example, compounds of formula (I) can be enriched to a given isotope having 1%, 2%, 5%, 10%, 25%, 50%, 75%, 90%, 95%, or 99%.

[0512] Using heavier isotopes such as deuterium (i.e., 2 H) substitution can provide certain therapeutic advantages due to greater metabolic stability (e.g., increased half-life in vivo or reduced dose requirements).

[0513] Positron emission isotopes (such as) 11 C 18 F, 15 O and 13Substitution of N) can be used in positron emission tomography (PET) studies to examine substrate acceptor occupancy. Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art, or by processes similar to those described in the examples set forth below, using a suitable isotopically labeled reagent instead of the previously used unlabeled reagent.

[0514] Production methods

[0515] The preparation of compounds of formula (I) of the present invention can be carried out via sequential or concurrent synthetic routes. The synthesis of the present invention is illustrated in the following general scheme. The skills required to perform the reactions and purify the resulting products are known to those skilled in the art. Unless otherwise specified, the substituents and indices used in the following description of the methods have the meanings provided herein.

[0516] If the starting material, intermediate, or one of the compounds of formula (I) contains one or more functional groups that are unstable or reactive under the reaction conditions of one or more reaction steps, a suitable protecting group may be introduced prior to the critical step using methods well-known in the art (as described in the following literature: TW Greene and PGM Utts, “Protective Groups in Organic Chemistry,” 5th edition, 2014, John Wiley & Sons, NY). Such protecting groups may be removed later in the synthesis using standard methods described in the literature.

[0517] If the starting material or intermediate contains a stereoisomeric center, it is possible to obtain a compound of formula (I) in diastereomer or a mixture of enantiomers, which can be separated by methods well known in the art (e.g., chiral HPLC, chiral SFC, or chiral crystallization). Racemic compounds can be separated into their corresponding counterparts, for example, by diastereomeric salts, by crystallization with optically pure acids, or by specific chromatographic methods using chiral adsorbents or chiral eluents. Similarly, starting materials and intermediates containing stereoisomeric centers can be separated to provide diastereomer / enantiomer-enriched starting materials and intermediates. The use of such diastereomer / enantiomer-enriched starting materials and intermediates in the synthesis of compounds of formula (I) generally results in the corresponding diastereomer / enantiomer-enriched compounds of formula (I).

[0518] Those skilled in the art will recognize that, in the synthesis of compounds of formula (I), an "orthogonal protecting group strategy" will be applied (if not desired), which allows for the cleavage of multiple protecting groups at a time without affecting other protecting groups in the molecule. The principle of orthogonal protection is well known in the art and has been reported in the literature (e.g., Barany and R.B. Merrifield, J. Am. Chem. Soc. 1977, 99, 7363; H. Waldmann et al., Angew. Chem. Int. Ed. Engl. 1996, 35, 2056).

[0519] Those skilled in the art will recognize that the reaction sequence can vary depending on the reactivity and properties of the intermediate.

[0520] More specifically, compounds of formula (I) can be produced by the methods described below, the methods described in the examples, or similar methods. Appropriate reaction conditions for each reaction step are known to those skilled in the art. Similarly, for information on reaction conditions affecting the reactions reported in the literature, see, for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock, John Wiley & Sons, New York, NY, 1999. The reaction can be carried out with or without a solvent. There are no particular limitations on the properties of the solvent used, as long as it does not adversely affect the reaction or the reagents involved and is at least partially soluble in the reagents. The reaction can occur over a wide temperature range, and a precise reaction temperature is not critical to this invention. The above reactions can be conveniently carried out in the temperature range from -78°C to reflux. The reaction time can also vary widely depending on many factors, particularly the reaction temperature and the properties of the reagents. However, it typically takes from 0.5 hours to several days to obtain the intermediates and compounds. The reaction sequence is not limited to the sequence shown in the scheme; however, the order of reaction steps can be freely changed depending on the starting materials and their corresponding reactivity.

[0521] If the starting materials or intermediates are not commercially available, or their synthesis has not been reported in the literature, preparation methods similar to those of existing analogues can be used, or preparation can be carried out according to the overview in the experimental section.

[0522] The following abbreviations are used in this article:

[0523] AcOH = acetic acid, ACN = acetonitrile, Bn = benzyl, Boc = tert-butyloxycarbonyl, CAS RN = Chemical Abstracts Service Registry Number, Cbz = benzyloxycarbonyl, Cs2CO3 = cesium carbonate, CO = carbon monoxide, CuCl = cuprous chloride (I), CuCN = cuprous cyanide (I), CuI = cuprous iodide (I), DAST = (diethylamino)sulfur trifluoride, DBU = 1,8-diazabicyclo[5,4,0]undec-7-ene, DCM = dichloromethane, DEAD = diethyl azodiacarboxylate, DIAD = diisopropyl azodiacarboxylate, DMAP = 4-dimethylaminopyridine, DME = dimethoxyethane, DMEDA = N,N′-dimethylethylenediamine, DMF = N,N-dimethylformamide, DIPEA = N,N-diisopropylethylamine, dppf = 1,1-bis(diphenylphosphino)ferrocene, EDC.HCl = N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride, EI = electron impact ionization, ESI = electrospray ionization, EtOAc = ethyl acetate, EtOH = ethanol, h = hours, FA = formic acid, H2O = water, H2SO4 = sulfuric acid, HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate, HBTU = O-benzotriazole-N,N,N′,N′-tetramethyl-ureonium-hexafluorophosphate, HCl = hydrogen chloride, HOBt = 1-hydroxy-1H-benzotriazole; HPLC = high performance liquid chromatography, iPrMgCl =Isopropyl magnesium chloride, I2 = Iodine, IPA = 2-propanol, ISP = Ion spray positive (mode), ISN = Ion spray negative (mode), K2CO3 = Potassium carbonate, KHCO3 = Potassium bicarbonate, KI = Potassium iodide, KOH = Potassium hydroxide, K3PO4 = Tripotassium phosphate, LiAlH4 or LAH = Lithium aluminum hydride, LiHMDS = Lithium bis(trimethylsilyl)amide, LiOH = Lithium hydroxide, MgSO4 = Magnesium sulfate, min = minutes, mL = milliliters, MPLC = Medium pressure liquid chromatography, MS = Mass spectrometry, nBuLi = n-Butyllithium, NaBH3CN = Sodium cyanoborohydride, NaH = Sodium hydride, NaHCO3 = Bicarbonate Sodium, NaNO2 = sodium nitrite, NaBH(OAc)3 = sodium triacetoxyborohydride, NaOH = sodium hydroxide, Na2CO3 = sodium carbonate, Na2SO4 = sodium sulfate, Na2S2O3 = sodium thiosulfate, NBS = N-bromosuccinimide, nBuLi = n-butyllithium, NEt3 = triethylamine (TEA), NH4Cl = ammonium chloride, NMP = N-methyl-2-pyrrolidone, OAc = acetoxy, T3P = propylphosphonic anhydride, PE = petroleum ether, PG = protecting group, Pd-C = palladium on carbon, PdCl2(dppf)-CH2Cl2 = 1,1′-bis(diphenylphosphino)ferrocene-palladium dichloride (I I) Dichloromethane complex, Pd2(dba)3 = tris(dibenzylacetone)dipalladium(0), Pd(OAc)2 = palladium acetate(II), Pd(OH)2 = palladium hydroxide, Pd(PPh3)4 = tetrakis(triphenylphosphine)palladium(0), PTSA = p-toluenesulfonic acid, R = any group, RT = room temperature, SFC = supercritical fluid chromatography, S-PHOS = 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl, TBAI = tetrabutylammonium iodide, TEA = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, TMEDA = N,N,N′,N′-tetramethylethylenediamine, ZnCl2 = zinc chloride, Hal = halogen.

[0524] Where A, L, X, m, n, R 1 and R 2Compounds of Formula I as described herein may be prepared in accordance with methods similar to those described in the literature and / or as described herein. Option 1 The synthesis described in the text.

[0525]

[0526] Option 1

[0527] Therefore, in the presence of a urea-forming agent such as bis(trichloromethyl) carbonate, 4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazine-3-one 1 reacts with intermediate 2 in a suitable base and solvent such as sodium bicarbonate in DCM to produce compound I ( Step a Furthermore, urea-forming agents include, but are not limited to, phosgene, trichloroformate, (4-nitrophenyl) carbonate, or 1,1′-carbonyldiimidazole. Such reactions and the use of these reagents are extensively described in the literature (e.g., G. Sartori et al., Green Chemistry 2000, 2, 140). Those skilled in the art will recognize that the order of addition of reagents can be important in such reactions due to the reactivity and stability of the intermediate carbamoyl chloride and to avoid the formation of undesirable symmetrical urea byproducts.

[0528] According to, for example Option 2 Synthesize intermediate 1 using methods shown and / or similar to those described in the literature.

[0529]

[0530] Option 2

[0531] Therefore, where “PG” represents a suitable protecting group such as Cbz or Boc, the 3-aminopiperidin-4-ol derivative 3 can be acylated, for example, with acyl chloride 4 (using a suitable base such as sodium carbonate or potassium carbonate, sodium hydroxide or sodium acetate in a suitable solvent such as THF, water, acetone or mixtures thereof), where R 1 As defined herein, and where “LG” signifies a suitable leaving group (e.g., Cl or Br) to provide intermediate 5 ( Step a Intermediate 4 is commercially available, or can be prepared as a non-chiral (R) compound according to methods reported in the literature. 1 =H), racemic mixture (R) 1 Not H) or enantiomeric pure form (R) 1 It is not in the form of H).

[0532] Intermediate 5 can be cyclized to intermediate 6 using methods well known in the art, for example, by treating 5 with sodium hydride in THF or IPA and potassium tert-butoxide in water. Step b Such reactions are described in the literature (e.g., Z. Rafinski et al., J. Org. Chem. 2015, 80, 7468; S. Dugar et al., Synthesis 2015, 47(5), 712; WO2005 / 066187).

[0533] The protecting groups in intermediate 6 are removed using methods known in the art (e.g., removal of the Boc group in a DCM solution using TFA at a temperature between 0°C and room temperature; removal of the Cbz group using hydrogen in the presence of a suitable catalyst such as activated carbon-supported Pd or Pd(OH)2 in a suitable solvent such as MeOH, EtOH, EtOAc, or mixtures thereof; and, for example, as described in the following literature: TW Greene and PGM Utts, “Protective Groups in Organic Chemistry”, 4th edition, 2006, Wiley NY), to provide intermediate 1 ( Step c ).

[0534] Intermediate 1 can be obtained as a mixture of diastereomers and enantiomers, or as a single stereoisomer, depending on whether a racemic mixture or the optically pure form of cis or trans-3-aminopiperidin-4-ol derivative 3 or intermediate 4 is used in the synthesis. Intermediate 3 is commercially available, and its synthesis method has been reported in the literature (e.g., WO2005 / 066187; WO2011 / 0059118; WO2016 / 185279). Optically pure cis configuration intermediates 1B and 1C can be obtained, for example, according to... Option 3 Chiral separation of commercially available racemic-(4aR,8aS)-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (1A) (optionally in the form of a salt, such as hydrochloride) was performed using methods known in the art (e.g., by diastereomeric salt crystallization or by chiral chromatography) to obtain ( Step a ).

[0535]

[0536] Option 3

[0537] In some embodiments, intermediate 2 is a type B intermediate. Type B intermediates can be prepared according to methods known to those skilled in the art, and the overall synthesis process is as follows: Option 4 The overview includes A, m, n, and R. 2 As described in this article.

[0538]

[0539] Option 4

[0540] Ketone 7, which is commercially available or prepared by methods known in the art, can undergo, for example, a Wittig reaction with type 8a alkyltriphenylphosphine in a suitable solvent (such as THF, methyl-THF, or DMSO) to give intermediate 9. Step a In a suitable solvent (e.g., THF, dioxane, or methyl-THF), the corresponding phosphate salts are treated with a suitable base (e.g., BuLi, NaH, or KOtBu) to form phosphine 8a, which can then be isolated or used in situ. Phosphate salts can be readily obtained from aryl / heteroaryl / heterocyclic substituted alkyl halides (where the halides are chlorine, bromine, and iodine) and triphenylphosphine in a suitable solvent (e.g., HJ Cristau, F. Plenat in PATAI'S Chemistry of Functional Groups, ed. Frank R. Hartley, August 7, 2006, Series Editor: Prof. Saul Patai).

[0541] Alternatively, intermediate 9 can be obtained by the Horner-Wadsworth-Emmons (HWE) reaction of ketone 7 and phosphonate 8b, wherein R a It is an alkyl group, such as methyl or ethyl. Phosphonate 8b is an in-situ α-metallization using a suitable base and solvent, such as NaH, nBuLi, or KOtBu in THF. Step a Phosphonate 8b is readily prepared by alkylation of aryl / heteroaryl / heterocyclic halides (halides being chlorine, bromine, and iodine) with commercially available trialkyl phosphites, for example by the Arbuzov reaction (e.g., Chem. Rev. 1984, 84, 577).

[0542] The two types of olefination reactions are extensively described in the literature (e.g., Current Org. Chem. 2015, 19(9), p. 744; Chem. Rev. 1989, 89(4), 863; Org. React. 1977, 25, 73; Liebigs Ann. / Recueil 1997, 1283; Acc. Chem. Res. 1983, 16, 411).

[0543] The double bond reduction used in intermediate 9, for example, by using hydrogen in a suitable solvent or solvent mixture (such as EtOAc, MeOH, or AcOH) in the presence of a suitable catalyst (such as palladium supported on activated carbon), yields compound 10. Step b ).

[0544] The protecting groups in intermediate 10 are removed using methods known in the art (e.g., removal of the Boc group using a DCM solution of TFA or a dioxane solution of 4M HCl at temperatures between 0°C and room temperature; removal of the Cbz group using hydrogen in the presence of a suitable catalyst such as activated carbon-supported Pd or Pd(OH)2 in a suitable solvent such as MeOH, EtOH, EtOAc, or mixtures thereof; and, for example, as described in the following literature: TW Greene and PGM Utts, “Protective Groups in Organic Chemistry.” 4th edition, Wiley NY, 2006), to provide intermediate B ( Step c ).

[0545] In some embodiments, intermediate 2 is a C-type intermediate. The C-type intermediate r = 0, 1, or 2 and (m+n) = 2 or 3 can be prepared according to methods well known in the art, and the overall synthesis process is as follows: Option 5 The overview includes A and R. 2 And p as described in this article.

[0546]

[0547] Option 5

[0548] Alkylation of a single-protected piperazine or 1,4-diazazane derivative 11a,b (commercially available or synthesized by methods similar to those described in the literature) with an aryl / heteroaryl / heterocyclic substituted alkyl derivative 12, commercially available or synthesized according to methods described in the literature, wherein LG represents a suitable leaving group (such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate) or OSO2 aryl (e.g., toluenesulfonate). p-Toluenesulfonate is reacted in a suitable solvent with a suitable base (e.g., sodium hydride in DMF) at a temperature between 0°C and the solvent boiling temperature to give intermediate 14a,b. Step a ).

[0549] Alternatively, compounds 11a,b can undergo reducing amination with type 13 aldehydes, using a suitable reducing agent and solvent (such as MeOH, AcOH, or a mixture thereof, such as NaBH3CN) to give intermediates 14a,b. Step a ).

[0550] The protecting group in intermediate 14b is removed using methods known in the art (e.g., removal of the Boc group using a DCM solution of TFA or a dioxane solution of 4M HCl at temperatures between 0°C and room temperature; removal of the Cbz group using hydrogen in the presence of a suitable catalyst such as activated carbon-supported Pd or Pd(OH)2 in a suitable solvent such as MeOH, EtOH, EtOAc, or mixtures thereof; and, for example, as described in the following literature: TW Greene and PGM Watts, “Protective Groups in Organic Chemistry”, 4th edition, Wiley NY, 2006), to provide intermediate C( Step c ).

[0551] In some embodiments, the compound of formula I is a type Ie compound. Wherein A, p, and R... 1 and R 2 As defined in this paper, compounds Ie with (m+n) = 2 or 3 can be obtained by referring to the literature procedure below or Option 6 Prepared by the method described in [the document].

[0552]

[0553] Option 6

[0554] Compound 1 can be coupled with piperazine or 1,4-diazazane derivative 11a, for example, using the conditions outlined in step a of scheme 1, to obtain intermediate 15. Step a ).

[0555] Intermediate 15 can be converted into compound IC, similar to step a in scheme 5. Step b The process described in ().

[0556] Alternatively, compound 1 may be coupled with a monoprotected piperazine or a 1,4-diazazane derivative 11b, wherein PG represents a suitable protecting group, such as a Cbz or Boc protecting group, applied, for example, under the conditions described in step a of scheme 1 to obtain intermediate 16. Step c ).

[0557] Remove the protecting group using the published method or as described in step c of scheme 5 to provide intermediate 15 ( Step d ).

[0558] In some embodiments, intermediate 2 is a D-type intermediate. The D-type intermediate can be prepared according to methods well known in the art, and the overall synthesis process is as follows: Option 7 The overview includes A, m, n, and R. 2 As described in this article, and R 3 Selected from hydrogen, halogens, C1-6 -alkoxy group, C 1-6 -alkyl and halogenated-C 1-6 -alkyl.

[0559]

[0560] Option 7

[0561] Type 17 alcohols can undergo photoelectrophoresis with intermediate 18, where PG is a suitable protecting group, such as Cbz, Boc, or Bn, in a suitable solvent (such as THF) with a suitable phosphine (such as triphenylphosphine) and a dialkyl azodicarboxylic acid ester (such as DEAD or DIAD) to give intermediate 19. Step a That type of photoelongation reaction is widely described in the literature (e.g., Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109(6), 2551).

[0562] The protecting group in intermediate 19 is removed by the method described in step c of method or scheme 3 reported in the literature to provide intermediate D ( Step b ).

[0563] Alternatively, intermediate 19 can be prepared from alcohol 17, which can be alkylated with compound 20, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2 aryl (e.g., p-toluenesulfonate), reacted with a suitable base in a suitable solvent (e.g., sodium hydride in DMF) at a temperature between 0°C and the boiling temperature of the solvent. Step c ).

[0564] Furthermore, under the conditions described in step c, intermediate 19 can be synthesized by alkylation reaction of type 18 alcohols with compound 21. Step d ).

[0565] In another embodiment, intermediate 2 is an E-type intermediate. The E-type intermediate can be prepared according to methods well-known in the art, and the overall synthesis process is as follows: Option 8 The overview includes A, m, n, and R. 2 and R 3 As described in this article. Suppose R 3 If the group is a hydroxyl group, then a suitable protecting group strategy known to those skilled in the art can be adopted.

[0566]

[0567] Option 8

[0568] The carboxylic acid functional group in derivative 22, wherein PG represents a suitable protecting group, such as a Boc, Cbz, or Bn protecting group, which is commercially available or prepared by methods known in the art, is converted to an acyl chloride (LG = Cl) or a Weinreb amide (LG = NMeOMe) by methods widely described in the literature to obtain intermediate 23. Step a ).

[0569] Intermediate 23 can react with compound type 24, which is commercially available or synthesized by methods known in the art, and is described below to produce intermediate 25 ( Step b ).

[0570] If compound 24 is not commercially available, it can be prepared according to literature methods. For example, in the optionally substituted heterocycle 27, the methyl group of the reaction is deprotonated in a suitable solvent (such as THF, hexane, or a mixture thereof) with a suitable base (such as nBuLi or LiHMDS) in the range of -78°C to room temperature to give intermediate 24 in which MX=Li. Step d ).

[0571] Compound 24, in which MX = MgHal (Hal is Cl, Br, or I (Grignard reagent)), can be prepared by reacting a correspondingly substituted benzyl halide 28 with magnesium in a suitable solvent (such as THF, optionally in the presence of a catalytic amount of iodine) over a temperature range from 0 °C to the solvent boiling point. Step d ).

[0572] Use suitable fluorinating agents such as DAST, Deoxo-Fluor (bis(2-methoxyethyl)aminotrifluoride) or aminodifluorosulfinium tetrafluoroborates (e.g., in the presence of triethylamine trifluoride and TEA or DBU). In a suitable solvent (such as DCM or ACN), compound 25 can be further converted to compound 26 via a deoxyfluorination reaction. Step d ).

[0573] The protecting group in intermediate 26 is removed by the method described in step c of method or scheme 3 reported in the literature to provide intermediate E ( Step e ).

[0574] In another embodiment, intermediate 2 is an F-type intermediate. The F-type intermediate can be prepared according to methods well-known in the art, and the overall synthesis process is as follows: Option 9 The overview includes A, m, n, and R. 2 and R 3 As described in this article. Suppose R3 If the group is a hydroxyl group, then a suitable protecting group strategy known to those skilled in the art can be adopted.

[0575]

[0576] Option 9

[0577] The carboxylic acid functional group in intermediate 29, which is commercially available or prepared by methods known in the art, wherein PG represents a suitable protecting group, such as a Boc, Cbz, or Bn protecting group, is converted to, for example, an acyl chloride (LG = Cl) or a Weinreb amide (LG = NMeOMe) by methods widely described in the literature, to obtain intermediate 30. Step a ).

[0578] Intermediate 30 can react with compound type 31, which is commercially available or synthesized by methods known in the art, and is described below to produce intermediate 32 ( Step b ).

[0579] If compound 31 is not commercially available, it can be prepared according to literature methods. For example, the optionally substituted aryl or heteroaryl ring 33 is deprotonated in a suitable solvent (such as THF, n-hexane, or mixtures thereof) with a suitable base (such as n-butyllithium, sec-butyllithium, tert-butyllithium, LiHMDS, NaH, KH) in a temperature range of -78°C to room temperature to give intermediate 31 (where MX = Li, Na, or K depending on the base used). Step c ).

[0580] Compound 31, in which MX = MgHal (Hal is Cl, Br, or I (Grignard reagent)), can be prepared by reacting a corresponding optionally substituted aryl or heteroaryl halide 34, i.e., in a suitable solvent (e.g., diethyl ether or THF) at a temperature range from 0°C to the solvent boiling point, by directly inserting magnesium (e.g., magnesium chips optionally in the presence of iodine, powder in the presence of LiCl or Rieke magnesium, or an organohalide) or by treating 34 with an alkyl magnesium halide such as iPrMgCl (optionally in the presence of LiCl) via halogen-magnesium exchange (where Hal is preferably bromine or iodine). Step d ).

[0581] Use suitable fluorinating agents such as DAST, Deoxo-Fluor (bis(2-methoxyethyl)aminotrifluoride) or aminodifluorosulfinium tetrafluoroborates (e.g., in the presence of triethylamine trifluoride and TEA or DBU). In a suitable solvent (such as DCM or ACN), compound 32 can be further converted to compound 35 via a deoxyfluorination reaction. Step e ).

[0582] The protecting group in intermediate 35 is removed by the method described in step c of method or scheme 3 reported in the literature to provide F-type intermediate ( Step f ).

[0583] In some embodiments, intermediate 2 is a G-type intermediate. The G-type intermediate can be prepared according to methods well known in the art, and the overall synthesis process is as follows: Option 10 The overview includes A, m, n, and R. 2 As described in this article, and R 3 For hydrogen, C 1-6 -alkoxy group, C 1-6 -alkyl and halogenated-C 1-6 -alkyl.

[0584]

[0585] Option 10

[0586] Intermediate 38 can be prepared from alcohol 36, wherein PG is a suitable protecting group such as Cbz, Boc, or Bn, and can be alkylated by compound 37, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2-aryl (e.g., p-toluenesulfonate), using a suitable base such as sodium hydride or potassium tert-butoxide in a suitable solvent (e.g., DMF or THF) at a temperature between 0°C and the boiling temperature of the solvent. Step a ).

[0587] The protecting group in intermediate 38 is removed by the method described in step c of method or scheme 4 reported in the literature to provide intermediate G ( Step b ).

[0588] In some embodiments, intermediate 2 is an H-type intermediate. The H-type intermediate can be prepared according to methods well known in the art, and the overall synthesis process is as follows: Option 11 The overview includes A, m, n, and R. 2 and R 3 As described in this article.

[0589]

[0590] Option 11

[0591] Type 17 alcohols can undergo photoelectrophoresis with intermediate 39, where PG is a suitable protecting group, such as Cbz, Boc, or Bn, in a suitable solvent (such as THF) with a suitable phosphine (such as triphenylphosphine) and a dialkyl azodicarboxylic acid ester (such as DEAD or DIAD) to give intermediate 41. Step a That type of photoelongation reaction is widely described in the literature (e.g., Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109(6), 2551).

[0592] The method described in step c of method or scheme 4 reported in the literature is used to remove the protecting group in intermediate 41 to provide intermediate H ( Step b ).

[0593] Alternatively, intermediate 41 can be prepared from alcohol 17, which can be alkylated with compound 40, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2-aryl (e.g., p-toluenesulfonate), reacted with a suitable base such as Cs2CO3 or NaH in a suitable solvent (e.g., DMF) at a temperature between 0°C and the boiling point of the solvent. Step c ).

[0594] The reaction of intermediate H with intermediate 1, for example under the conditions described in step a of scheme 1, yields an If-type compound, wherein A and R... 1 R 2 R 3 m and n are as defined in this article.

[0595]

[0596] Alternatively, according to Option 12 If-type compounds can be prepared.

[0597]

[0598] Option 12

[0599] Type 17 alcohols can undergo photoelectrophoresis with intermediate 42, reacting in a suitable solvent (such as THF) with a suitable phosphine (such as triphenylphosphine) and a dialkyl azodicarboxylic acid ester (such as DEAD or DIAD) to give compound ID. Step a That type of photoelongation reaction is widely described in the literature (e.g., Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109(6), 2551).

[0600] Alternatively, compound ID can be prepared directly from alcohol 17 and alkylated with compound 43, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2-aryl (e.g., p-toluenesulfonate), reacted with a suitable base such as Cs2CO3 or NaH in a suitable solvent (e.g., DMF) at a temperature between 0°C and the boiling point of the solvent. Step b ).

[0601] In some embodiments, intermediate 2 is a J-type intermediate. The J-type intermediate can be prepared according to methods well known in the art, and the overall synthesis process is as follows: Option 13 The overview includes A, m, n, and R. 2 and R 3 As described in this article.

[0602]

[0603] Option 13

[0604] Intermediate 46 can be prepared from heterocyclic alkyl or heteroaryl 45, and can be alkylated by compound 44, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2-aryl (e.g., p-toluenesulfonate), reacted with a suitable base such as Cs2CO3, K2CO3, or NaH in a suitable solvent (e.g., DMF) at a temperature between 0°C and the boiling temperature of the solvent. Step a ).

[0605] The protecting group in intermediate 46 is removed by the method described in step c of method or scheme 4 reported in the literature to provide intermediate J ( Step b ).

[0606] Intermediate J reacts with intermediate 1 to give an Ig-type compound, wherein A and R 1 R 2 R 3 m and n are as defined in this article.

[0607]

[0608] Alternatively, Ig-type compounds can be prepared directly from heterocyclic alkyl or heteroaryl groups 45, which can be alkylated with compound 47, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2-aryl (e.g., p-toluenesulfonate), reacted with a suitable base such as Cs2CO3, K2CO3, or NaH in a suitable solvent (e.g., DMF) at a temperature between 0°C and the boiling point of the solvent. Option 14 ).

[0609]

[0610] Option 14

[0611] In some embodiments, intermediate 2 is a K-type intermediate. The K-type intermediate can be prepared according to methods well known in the art, and the overall synthetic process is as follows: Option 15 The overview includes A, m, n, and R. 2 and R 3 As described in this article.

[0612]

[0613] Option 15

[0614] Type 48 alcohols can undergo photoelectrophoresis with intermediate 39, where PG is a suitable protecting group, such as Cbz, Boc, or Bn, in a suitable solvent (such as THF) with a suitable phosphine (such as triphenylphosphine) and a dialkyl azodicarboxylic acid ester (such as DEAD or DIAD) to give intermediate 49. Step a That type of photoelongation reaction is widely described in the literature (e.g., Org. Chem. Front. 2015, 2, 739; Chem. Rev. 2009, 109(6), 2551).

[0615] The protecting group in intermediate 49 is removed by the method described in step c of method or scheme 4 reported in the literature to provide intermediate K ( Step b ).

[0616] Alternatively, intermediate 49 can be prepared from alcohol 48, which can be alkylated with compound 40, wherein LG is a suitable leaving group such as chlorine, bromine, iodine, OSO2 alkyl (e.g., methanesulfonate), OSO2 fluoroalkyl (e.g., trifluoromethanesulfonate), or OSO2-aryl (e.g., p-toluenesulfonate), reacted with a suitable base such as Cs2CO3 or NaH in a suitable solvent (e.g., DMF) at a temperature between 0°C and the boiling point of the solvent. Step c ).

[0617] In some embodiments, intermediate 2 is an L-type intermediate. The L-type intermediate can be prepared according to methods well known to those skilled in the art, and the overall synthesis process is as follows: Option 16 The overview includes A, m, n, and R. 2 and R 3 As described in this article.

[0618]

[0619] Option 16

[0620] Intermediate 51 can be prepared, for example, from aldehyde 50, which is commercially available or prepared by methods known in the art, using a Wittig reaction or a Horner-Wadsworth-Emmons (HWE) reaction, with alkyltriphenylphosphine type 8a and phosphonate 8b, respectively, as described in step a of scheme 4 ( Step a ).

[0621] The double bond in intermediate 51, obtained by applying the conditional reduction method described in step b of scheme 4, yields compound 52. Step b ).

[0622] The protecting group is removed from intermediate 52 using methods known in the art, and intermediate L is provided as described in step c of scheme 4. Step c ).

[0623] The protecting group is removed from intermediate 51 using methods known in the art, and intermediate M is provided as described in step c of scheme 4. Step d ).

[0624] In one aspect, the present invention provides a method for producing urea compounds of formula (I) as described herein, the method comprising:

[0625] Make the first amine of formula 1

[0626]

[0627] The second amine of Formula 2 reacts with a base and a urea forming agent in the presence of a base to form the compound of Formula (I);

[0628]

[0629] Where R 1 As described herein, preferably R 1 It is hydrogen, where A, L, m, n, X and R 2 As described in this article.

[0630] In one embodiment, a method according to the present invention is provided, wherein the base is sodium bicarbonate.

[0631] In one embodiment, a method according to the present invention is provided, wherein the urea forming agent is selected from bis(trichloromethyl) carbonate, phosgene, trichloroformate, (4-nitrophenyl) carbonate and 1,1′-carbonyldiimidazole, preferably wherein the urea forming agent is bis(trichloromethyl) carbonate.

[0632] In one aspect, the present invention provides a compound of formula (I) as described herein, which is produced according to any of the methods described herein.

[0633] MAGL inhibitory activity

[0634] The compounds of the present invention are MAGL inhibitors. Therefore, in one aspect, the present invention provides the use of compounds of formula (I) as described herein for inhibiting MAGL in mammals.

[0635] In another aspect, the present invention provides a method for using compounds of formula (I) as described herein to inhibit MAGL in mammals.

[0636] In another aspect, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for inhibiting MAGL in mammals.

[0637] In another aspect, the present invention provides a method for inhibiting MAGL in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0638] The enzymatic activity of MAGL was measured after hydrolysis of 4-nitrophenyl acetate to obtain 4-nitrophenol (absorption wavelength range 405-412 nm), and the inhibitory activity of the compound on MAGL was analyzed (G. G. Muccioli, G. Labar, D. D. Lambert, Chem. Bio. Chem. 2008, 9, 2704-2710). This assay is referred to below as the "4-NPA assay".

[0639] 4-NPA assays were performed in 384-well plates (black, with a clear bottom and a non-binding surface treatment, Corning Ref. 3655) in a total volume of 40 μL. Compound dilutions were prepared in 100% DMSO (VWRC Chemicals 23500.297) using a 3-fold dilution step in the polypropylene plate to achieve a final concentration range of 25 μM to 1.7 nM. 1 μL of the compound dilution (100% DMSO) was added to 19 μL of MAGL (recombinant wild-type) assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100 mL)). The plate was shaken at 2000 rpm for 1 min (Variomag Teleshake) and then incubated at room temperature for 15 min. Add 20 μL of assay buffer solution (Sigma N-8130) containing 6% EtOH to initiate the reaction. The final concentrations in this assay are 1 nM MAGL and 300 μM 4-nitrophenylacetate. After shaking (1 min, 2000 rpm) and incubating at room temperature for 5 min, the absorbance at 405 nm was measured for the first time (Molecular Devices, SpectraMax Paradigm). A second measurement was then performed after incubating at room temperature for 80 min. The slope was calculated by subtracting the first measurement from the second measurement.

[0640] Alternatively, the enzymatic activity can be determined by hydrolyzing the natural substrate 2-arachidonoylglycerol to obtain arachidonic acid, followed by analysis of the compound's inhibitory activity against MAGL, and then mass spectrometry analysis can be performed. This assay is referred to below as the "2-AG assay".

[0641] 2-AG assays were performed in 384-well plates (PP, Greiner catalog number 784201) with a total volume of 20 μL. Compound dilutions were prepared in 100% DMSO (VWR Chemicals 23500.297) using a 3-fold dilution step in the polypropylene plate to achieve a final concentration range of 12.5 μM to 0.8 pM. 0.25 μL of the compound dilution (100% DMSO) was added to 9 μL of MAGL assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100 mL), and 0.01% (v / v) Tween). After shaking, the plate was incubated at room temperature for 15 min. 10 μL of 2-arachidonicylglycerol assay buffer was added to initiate the reaction. The final concentrations used in this assay were 50 pM MAGL and 8 μM 2-arachidonic acid glycerol. After shaking and incubation at room temperature for 30 min, the reaction was quenched by adding 40 μL of acetonitrile containing 4 μM d8-arachidonic acid. The arachidonic acid concentration was monitored using an online SPE system (Agilent Rapidfire) coupled with a triple quadrupole mass spectrometer (Agilent 6460). A C18 SPE column (G9205A) was used in the acetonitrile / water liquid phase. The mass spectrometer was operated in negative electrospray ionization mode, with the mass ion pair of arachidonic acid ranging from 303.1 to 259.1 and that of d8-arachidonic acid from 311.1 to 267.0. The activity of the compounds was calculated based on the intensity ratio of [arachidonic acid / d8-arachidonic acid].

[0642] Table 1

[0643]

[0644]

[0645]

[0646]

[0647] [a]: Unless otherwise specified (see [b]), activity is determined by the 4-NPA assay; [b]: Activity is determined by the 2-AG assay.

[0648] In one aspect, the present invention provides compounds of formula (I) as described herein, and pharmaceutical salts or esters thereof, wherein the compounds of formula (I) and pharmaceutical salts or esters thereof have MAGL inhibitory IC50 values ​​of less than 25 μM, preferably less than 10 μM, more preferably less than 5 μM. 50 The IC 50 The value was measured in the MAGL measurement described in this article.

[0649] In one embodiment, the IC of a compound of formula (I) as described herein and its pharmaceutical salt or ester 50 (MAGL inhibition) values ​​ranged from 0.000001 μM to 25 μM, with specific compounds exhibiting IC50 values ​​between 0.000005 μM and 10 μM. 50 Values, more specific compounds have IC50 values ​​between 0.00005 μM and 5 μM. 50 Value, this IC 50 The value was measured in the MAGL measurement described in this article.

[0650] In one embodiment, the present invention provides a compound of formula (I) as described herein, and a pharmaceutical salt or ester thereof, wherein the compound of formula (I) and the pharmaceutical salt or ester thereof have an IC50 concentration of less than 25 μM, preferably less than 10 μM, more preferably less than 5 μM. 50 (MAGL suppression) value, this IC 50 The value was obtained in a determination that included the following steps:

[0651] a) Provide a solution of compound (I) or its pharmaceutical salt or ester in DMSO;

[0652] b) Provide a solution of the MAGL (recombinant wild-type) assay buffer (50 mM tris(hydroxymethyl)aminomethane; 1 mM ethylenediaminetetraacetic acid);

[0653] c) Add 1 μL of the compound solution obtained in step a) to 19 μL of the MAGL solution obtained in step b);

[0654] d) Shake the mixture at 2000 rpm for 1 min;

[0655] e) Incubate at room temperature for 15 minutes;

[0656] f) Add 20 μL of 4-nitrophenylacetic acid ester solution to the assay buffer (50 mM tris(hydroxymethyl)aminomethane; 1 mM ethylenediaminetetraacetic acid, 6% EtOH);

[0657] g) Shake the mixture at 2000 rpm for 1 min;

[0658] h) Incubate at room temperature for 5 min;

[0659] i) First measurement of absorbance at 405 nm;

[0660] j) Continue incubation at room temperature for 80 minutes;

[0661] k) Second measurement of absorbance at 405 nm;

[0662] l) Subtract the absorbance measured in i) from the absorbance measured in k), and calculate the slope of the absorbance.

[0663] in:

[0664] i) In this determination, the concentration of the compound of formula (I) or its pharmaceutical salt or ester after step f) is in the range of 25 μM to 1.7 nM;

[0665] ii) In this determination, the MAGL concentration after step f) is 1 nM;

[0666] iii) In this determination, the concentration of 4-nitrophenylacetic acid ester after step f) is 300 μM; and

[0667] iv) Repeat steps a) to 1) at least 3 times, each time using a different concentration of the compound of formula (I) or its pharmaceutical salt or ester.

[0668] Using the compounds of the present invention

[0669] In one aspect, the present invention provides compounds of formula (I) as described herein for use as therapeutically active substances.

[0670] In another aspect, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

[0671] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of neuroinflammatory and / or neurodegenerative diseases in mammals.

[0672] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of neurodegenerative diseases in mammals.

[0673] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of cancer in mammals.

[0674] In one aspect, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms in mammals.

[0675] In a preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of multiple sclerosis, Alzheimer's disease, and Parkinson's disease in mammals.

[0676] In a particularly preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein for the treatment or prevention of multiple sclerosis in mammals.

[0677] In one aspect, the present invention provides compounds of formula (I) as described herein for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, and / or mental disorders in mammals.

[0678] In one embodiment, the present invention provides a compound of formula (I) as described herein for the treatment or prevention of neuroinflammatory and / or neurodegenerative diseases in mammals.

[0679] In one embodiment, the present invention provides a compound of formula (I) as described herein for the treatment or prevention of cancer in mammals.

[0680] In one embodiment, the present invention provides a compound of formula (I) as described herein for the treatment or prevention of neurodegenerative diseases in mammals.

[0681] In one aspect, the present invention provides compounds of formula (I) as described herein for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasms in mammals.

[0682] In a preferred embodiment, the present invention provides compounds of formula (I) as described herein for the treatment or prevention of multiple sclerosis, Alzheimer's disease, and / or Parkinson's disease in mammals.

[0683] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein for the treatment or prevention of multiple sclerosis in mammals.

[0684] In one aspect, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

[0685] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of neuroinflammatory and / or neurodegenerative diseases in mammals.

[0686] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of neurodegenerative diseases in mammals.

[0687] In one embodiment, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of cancer in mammals.

[0688] In another aspect, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms in mammals.

[0689] In a preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of multiple sclerosis, Alzheimer's disease and / or Parkinson's disease in mammals.

[0690] In a particularly preferred embodiment, the present invention provides the use of compounds of formula (I) as described herein in the preparation of medicaments for the treatment or prevention of multiple sclerosis in mammals.

[0691] In one aspect, the present invention provides a method for treating or preventing neuroinflammation, neurodegenerative diseases, pain, cancer, and / or mental disorders in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0692] In one embodiment, the present invention provides a method for treating or preventing neuroinflammatory and / or neurodegenerative diseases in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0693] In one embodiment, the present invention provides a method for treating or preventing neurodegenerative diseases in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0694] In one aspect, the present invention provides a method for treating or preventing multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression and / or pain in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0695] In a preferred embodiment, the present invention provides a method for treating or preventing multiple sclerosis, Alzheimer's disease, and / or Parkinson's disease in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0696] In a particularly preferred embodiment, the present invention provides a method for treating or preventing multiple sclerosis in mammals, the method comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) as described herein.

[0697] Pharmaceutical composition and administration

[0698] In one aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.

[0699] Compounds of formula (I) and their pharmaceutical salts and esters may be used as pharmaceuticals (e.g., in the form of pharmaceutical formulations). Pharmaceutical formulations may be administered orally, such as orally (e.g., in the form of tablets, coated tablets, sugar-coated pills, hard and soft gelatin capsules, solutions, emulsions, or suspensions), nasally (e.g., in the form of nasal sprays), or rectally (e.g., in the form of suppositories). However, they may also be administered parenterally, such as intramuscularly or intravenously (e.g., in the form of injections).

[0700] Compounds of formula (I) and their pharmaceutical salts and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants into tablets, coated tablets, sugar-coated pills and hard gelatin capsules. For example, lactose, corn starch or derivatives thereof (talc, stearic acid or its salts, etc.) can be used as such adjuvants for tablets, sugar-coated pills and hard gelatin capsules.

[0701] Suitable adjuvants for soft gelatin capsules include, for example, vegetable oils, waxes, fats, semi-solid substances, and liquid polyols.

[0702] Suitable additives for preparing solutions and syrups include, for example, water, polyols, sucrose, invert sugar, glucose, etc.

[0703] Suitable adjuvants for injection solutions include, for example, water, alcohol, polyol, glycerin, and vegetable oil.

[0704] Suitable adjuvants for suppositories include, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols.

[0705] In addition, pharmaceutical preparations may contain preservatives, solubilizers, thickeners, stabilizers, humectants, emulsifiers, sweeteners, colorants, flavorings, salts that alter osmotic pressure, buffers, masking agents, or antioxidants. They may also contain other substances with therapeutic value.

[0706] Dosage can vary over a wide range, and of course, it should be adapted to individual requirements in each specific situation. Generally, a daily oral dose of about 0.1 mg to 20 mg per kg of body weight, preferably about 0.5 mg to 4 mg per kg of body weight (e.g., about 300 mg per person), should be appropriate, preferably divided into 1-3 individual doses (which may consist of, for example, the same amount). However, it will be apparent that, when indicated, the upper limits given herein may be exceeded.

[0707] According to the present invention, the compound of formula (I) or its pharmaceutical salts and esters may be used to treat or prevent microvascular complications associated with type 2 diabetes (such as, but not limited to, diabetic retinopathy, diabetic neuropathy and diabetic nephropathy), coronary artery disease, obesity and underlying inflammatory diseases, chronic inflammatory diseases and autoimmune / inflammatory diseases.

[0708] Example

[0709] The invention will be more fully understood by referring to the following examples. However, the claims should not be construed as limiting the scope to the examples.

[0710] If the preparation example is obtained in the form of an enantiomer mixture, the pure enantiomers can be separated by the methods described herein or by methods known to those skilled in the art, such as chiral chromatography (e.g., chiral SFC) or crystallization.

[0711] Unless otherwise stated, all reaction examples and intermediates were prepared under an argon atmosphere.

[0712] Method A1

[0713] Example 11

[0714] Racemic-(4aR,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0715]

[0716] To a DMF (1.5 mL) solution of 4-(4-(trifluoromethyl)benzyl)piperidin-1-carboxylic acid 4-nitrobenzene ester (100 mg, 245 μmol, BB2), racemic-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one dihydrochloride (45.9 mg, 294 μmol, ChemBridge Corporation, BB1) and TEA (49.6 mg, 68.3 μL, 490 μmol) were added. The resulting reaction mixture was heated at 80 °C for 18 h. The reaction mixture was diluted with EtOAc and then washed three times with H2O and NaHCO3. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. The crude product was purified by rapid chromatography (silica gel, eluted with a 0-10% gradient of MeOH / EtOAc) to give the title compound as a grayish-white oil (0.045 g; 43.2%). MS (ESI): m / z = 426.4 [M+H] + .

[0717] Method A2

[0718] Example 3

[0719] Racemic-(4aR,8aS)-6-[4-[(4-tert-butylthiazolyl-2-yl)methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0720]

[0721] A portion of 4-tert-butyl-2-(4-piperidinylmethyl)thiazole hydrochloride (60 mg, 218 μmol, Enamine Ltd) was added to a chilled DCM (2 mL) suspension of bis(trichloromethyl) carbonate (45.3 mg, 153 μmol, CAS RN 32315-10-9) and NaHCO3 (73.3 mg, 873 μmol), and the mixture was stirred overnight at room temperature. The suspension was filtered, and the filtrate was evaporated. The residue was diluted with DCM (1 mL) and then added dropwise to a chilled DCM (1 mL) solution of racemic-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-ketodihydrochloride (50 mg, 218 μmol, ChemBridge Corporation, BB1) and DIPEA (152 μL, 870 μmol). The suspension was stirred at room temperature for 19 h to form a solution. The reaction mixture was poured onto H₂O and DCM, and the layers were separated. The aqueous layer was extracted three times with DCM. The organic layer was washed twice with water, dried with MgSO₄, filtered, treated with silica gel, and evaporated. The compound was purified by silica gel chromatography, wherein separation was performed on a 4 g column using an MPLC system, and elution was performed using a gradient of DCM:MeOH (100:0 to 90:10) to give the desired compound as a colorless foam (0.039 g; 42.5%). MS (ESI): m / z = 421.2 [M+H] + .

[0722] Method A3

[0723] Example 34

[0724] (+)- or (-)-4-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidinyl]methyl]benzonitrile

[0725]

[0726] To an ice-cold DCM solution of bis(trichloromethyl) carbonate (39.9 mg, 134 μmol, CAS RN 32315-10-9), NaHCO3 (64.5 mg, 768 μmol) and (+)-cis-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (30 mg, 192 μmol, BB1a) were added, and the mixture was stirred overnight at room temperature. 4-(piperidin-4-ylmethyl)benzonitrile (38.5 mg, 192 μmol, CAS RN 333987-57-8) and DIPEA (99.3 mg, 134 μL, 768 μmol) were added to the suspension. The suspension was stirred at room temperature for 4.5 h. The reaction mixture was poured onto H2O and DCM to separate the layers. The aqueous layer was extracted three times with DCM. The organic layer was washed twice with H₂O, dried with MgSO₄, filtered, treated with silica gel, and then evaporated. The compound was purified by silica gel chromatography, using an MPLC system on a 4 g column with elution using a DCM:MeOH gradient (100:0 to 90:10) to give the desired compound as a colorless gel (0.023 g; 31.3%). MS (ESI): m / z = 383.2 [M+H] + .

[0727] Method A4

[0728] Example 79

[0729] (4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0730]

[0731] To a solution of (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid 4-nitrobenzene ester (25 mg, 77.8 μmol, BB7a) in NMP (1 mL), DIPEA (25.1 mg, 34 μL, 195 μmol) and 4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidine hydrochloride (19.5 mg, 66.1 μmol, BB12) were added. The reaction flask was stirred at 140 °C for 45 min. The crude product was purified by reversed-phase HPLC to obtain 23.2 mg of the desired product. MS (ESI): m / z = 440.2 [M+H] + .

[0732] Method A5

[0733] Example 64

[0734] (4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0735]

[0736] The microwave vial was dried with a hot air gun, and then filled with bis(trichloromethyl) carbonate (26.6 mg, 89.6 μmol) and sodium bicarbonate (32.3 mg, 384 μmol). The flask was placed under argon atmosphere, and DCM (1 mL) was added to form a suspension. The suspension was cooled in an ice bath, and 4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine hydrochloride (36.1 mg, 121 μmol, BB15) was added. The mixture was stirred at 0 °C for 15 min, and then stirred overnight at room temperature. The reaction mixture was cooled in an ice bath, and then DCM (500 μL), DIPEA (49.7 mg, 67.1 μL, 384 μmol), and (4aR, 8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (21.1 mg, 47.5 μmol, BB1a) were added sequentially. The resulting off-white suspension was stirred at room temperature for 7 h. The reaction mixture was poured into water, and DCM was added to separate the layers. The aqueous layer was extracted twice with DCM. The combined organic layers were washed with brine, dried over MgSO4, filtered, and evaporated to give a yellow oil (58 mg). The crude product was purified by reversed-phase HPLC and lyophilized to give the title compound as a white solid (21.1 mg, 37.1% yield). MS(ESI): m / z = 444.2[M+H] + .

[0737] Method A6

[0738] Example 39

[0739] (4aR,8aS)-6-[4-[(2-fluoro-4-methoxyphenoxy)methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0740]

[0741] DIAD (25.8 mg, 24.8 μL, 128 μmol) was added dropwise to a solution of 2-fluoro-4-methoxyphenol (16.5 mg, 13 μL, 116 μmol), (4aR, 8aS)-6-[4-(hydroxymethyl)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (34.5 mg, 116 μmol, BB16) and triphenylphosphine (33.5 mg, 128 μmol) in DCM (580 μL), and the reaction mixture was stirred at room temperature for 22 h. The reaction mixture was diluted with DCM and washed with 1 M NaOH aqueous solution. The phases were separated, and the aqueous phase was extracted twice with DCM. The combined organic layers were dried over sodium sulfate, filtered, and concentrated to dryness to give a red oil (99 mg). The crude product was purified by reversed-phase HPLC and then lyophilized to obtain the desired compound (20 mg, yield 40.9%) as a white solid. MS (ESI): m / z = 422.3 [M+H] + .

[0742] Method A7

[0743] Examples 42 and 43

[0744] (4aS, 8aR)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (Example 42)

[0745] and

[0746] (4aR,8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (Example 43)

[0747]

[0748] Step a) Racemic-(4aR,8aS)-6-(4-(chloromethyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0749]

[0750] DIPEA (52.2 mg, 70.5 μL, 404 μmol), DMAP (1.64 mg, 13.5 μmol), and methanesulfonyl chloride (46.2 mg, 404 μmol) were added to an anhydrous DMF (2 mL) solution of racemic-(4aR, 8aS)-6-(4-(hydroxymethyl)piperidin-1-carbonyl)hexahydrogen-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (80 mg, 269 μmol, BB16), and the reaction mixture was stirred at room temperature for 2 h. Then, 4,4-difluoropiperidine hydrochloride (84.8 mg, 538 μmol) and DIPEA (139 mg, 188 μL, 1.08 mmol) were added, and the reaction mixture was stirred at room temperature for 2 h. Finally, the reaction mixture was stirred at 70 °C for 14 h. The crude reaction product was purified by reversed-phase HPLC to obtain the title compound, which was a byproduct (35 mg). MS (ESI): m / z = 315.1 [M+H] + .

[0751] Step b) (4aS, 8aR)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (Example 42) and (4aR, 8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (Example 43)

[0752]

[0753] A solution of racemic-(4aR,8aS)-6-(4-(chloromethyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (70 mg, 222 μmol) in anhydrous DMF (1 mL) was mixed with 6-(trifluoromethyl)pyridin-3-ol (54.2 mg, 332 μmol) and Cs₂CO₃ (108 mg, 332 μmol). The reaction mixture was stirred at 95 °C for 18 h. Insoluble matter was removed by diatomaceous earth filtration, and the filtrate was concentrated to dryness under vacuum. The crude residue was then purified and enantiomers were separated by chiral SFC to give Examples 42 (33.8 mg) and 43 (32.5 mg). In both examples, MS (ESI): m / z = 443.2 [M+H] + .

[0754] Method A8

[0755] Example 26

[0756] (4aS, 8aR)-6-(4-((4-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0757]

[0758] DIPEA (39.1 mg, 52.9 μL, 303 μmol), DMAP (3.08 mg, 25.2 μmol), and methanesulfonyl chloride (30.3 mg, 265 μmol) were added to an anhydrous DMF (2 mL) solution of racemic-(4aR, 8aS)-6-(4-(hydroxymethyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (75 mg, 252 μmol, BB16), and the reaction mixture was stirred at room temperature for 2 h. Then, 4-(trifluoromethyl)-1H-pyrazole (68.6 mg, 504 μmol) and K2CO3 (87.1 mg, 631 μmol) were added, and the reaction mixture was stirred at 90 °C for 18 h. Insoluble matter was removed by diatomaceous earth filtration. The filtrate was concentrated to dryness under vacuum, and the crude residue was then directly purified by rapid chromatography (using a mixture of eluents of DCM and MeOH (0% to 10%)) to obtain 90 mg of the desired product, which was a racemic mixture. This product was subjected to SFC chiral separation to obtain Example 26 (25 mg) as a colorless oil and its enantiomer (31 mg) as a colorless oil. MS (ESI): m / z = 416.2 [M+H] + .

[0759] Method A9

[0760] Example 37

[0761] (4aR,8aS)-6-(4-((4,4-difluoropiperidin-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0762]

[0763] To an anhydrous DMF (2 mL) solution of (4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (40 mg, 256 μmol, BB1a) cooled to 0 °C, DIPEA (39.7 mg, 53.7 μL, 307 μmol) and 4-nitrophenyl chloroformate (61.9 mg, 307 μmol) were added. The reaction mixture was stirred at 0 °C for 20 min. LCMS control showed the formation of the intermediate carbamate. DIPEA (116 mg, 157 μL, 896 μmol) and 4,4-difluoro-1-(piperidin-4-ylmethyl)piperidine dihydrochloride (89.5 mg, 307 μmol, BB17) were added, and the reaction mixture was stirred at room temperature for 30 min, followed by stirring at 100 °C for 14 h. Volatile substances were removed under vacuum, and the crude residue was directly purified by SFC to obtain the desired compound (9.5 mg), which was a pale orange oil. MS (ESI): m / z = 401.3 [M+H] + .

[0764] Method A10

[0765] Example 125

[0766] (+)-(4aR,8aS)-6-[4-[2-(2-chlorophenyl)ethynyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0767]

[0768] In a sealed tube, 4-[2-(2-chlorophenyl)ethynyl]piperidine (BB18, 0.02 g, 0.078 mmol) and (4aR, 8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid 4-nitrobenzene ester (BB7a, 0.025 g, 0.078 mmol) were mixed in ACN (0.6 mL). Huenig's base (0.041 mL, 0.234 mmol) and DMAP (0.005 g, 0.039 mmol) were then added sequentially, and the reaction mixture was heated overnight at 90 °C. The mixture was evaporated to dryness, and the crude residue was purified by reversed-phase HPLC to give the title compound (0.013 g, 41%) as a colorless solid. MS (ESI): m / z = 402.2 [M+H] + .

[0769] Method B1

[0770] Example 1

[0771] (+)-(4aR,8aS)-6-(4-((4-(tert-butyl)thiazolyl-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0772]

[0773] The enantiomers of Example 3 were separated using preparative chiral HPLC (Chiralcel OD column) with EtOH (containing 0.05% NH4OAc):n-heptane (20:80). The fraction was evaporated to provide the desired compound as a colorless solid (0.012 g; 34.3%). MS (ESI): m / z = 421.2 [M+H] + .

[0774] Method B2

[0775] Example 12

[0776] (+)- or (-)-(4aR,8aS)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0777]

[0778] The enantiomers of Example 13 were separated using preparative chiral HPLC (Chiralpak AD column) with EtOH (containing 0.05% NH4OAc):n-heptane (40:60). The fraction was evaporated to provide the desired compound as a light brown oil (0.013 g; 28.4%). MS (ESI): m / z = 428.2 [M+H] + .

[0779] Method B3

[0780] Examples 103, 104 and 105

[0781] (4aR,8aS)-6-[2-methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (isomer A+B, isomer C, isomer D)

[0782]

[0783] The stereoisomers of Example 117 were separated using preparative chiral HPLC (Reprosil Chiral NR column) with an isocratic mixture of EtOH (containing 0.05% NH4OAc): n-heptane (40:60) to provide Examples 103 and 104 as single isomers and Example 105 as a mixture of two stereoisomers. The fractions were evaporated to provide the desired compound as a colorless solid.

[0784] Method C

[0785] Example 21

[0786] Racemic-(4aR,8aS)-6-(4-(4-(trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0787]

[0788] A mixture of racemic-cis-6-(piperazin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (35 mg, 130 μmol, BB3), 4-(trifluoromethyl)benzaldehyde (22.7 mg, 17.4 μL, 130 μmol), and sodium triacetoxyborohydride (27.6 mg, 130 μmol) in DCM (1 mL) was stirred at room temperature for 15 h. The reaction mixture was concentrated, and the residue was purified by preparative HPLC to give the desired compound as a white solid (8 mg, 14.4%). MS (ESI): m / z = 427.4 [M+H] + .

[0789] Unless otherwise specified, the following examples were synthesized from racemic-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-ketodihydrochloride (ChemBridge Corporation) and suitable building blocks according to a reaction method similar to that described herein.

[0790]

[0791]

[0792]

[0793]

[0794]

[0795]

[0796]

[0797]

[0798]

[0799]

[0800]

[0801]

[0802]

[0803]

[0804]

[0805]

[0806]

[0807]

[0808]

[0809]

[0810]

[0811]

[0812]

[0813]

[0814]

[0815]

[0816]

[0817]

[0818]

[0819]

[0820]

[0821]

[0822]

[0823]

[0824]

[0825]

[0826]

[0827]

[0828]

[0829]

[0830]

[0831]

[0832]

[0833]

[0834]

[0835]

[0836]

[0837]

[0838]

[0839]

[0840]

[0841]

[0842]

[0843]

[0844]

[0845]

[0846]

[0847]

[0848]

[0849]

[0850]

[0851]

[0852]

[0853]

[0854]

[0855]

[0856] Example 222

[0857] (4aR,8aS)-6-[3-[[6-fluoro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0858]

[0859] Step a) 3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[0860] To a THF (60 mL) solution of tert-butyl 3-(hydroxymethyl)azacyclobutane-1-carboxylic acid (CAS No. 142253-56-3) (2.60 g, 13.9 mmol) and 2,6-dichloro-4-(trifluoromethyl)pyridine (CAS No. 39890-98-7) (3.00 g, 13.9 mmol), NaH (60%, 1.11 g, 27.8 mmol) was added, and the mixture was stirred at 25 °C for 3 h. The solution was poured into a saturated aqueous solution of NH4Cl (50 mL) and then extracted with EtOAc (2 × 50 mL). The combined organic layers were concentrated under vacuum to give crude tert-butyl 3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carboxylic acid (3.00 g, 59%), which was a colorless oil and was used directly for the next step. LC-MS (ESI): m / z = 367.1 [M+H] + .

[0861] Step b) 2-(azacyclobutane-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine

[0862] A solution of trifluoroacetic acid (6.3 mL, 81.8 mmol, 10 eq) and 3-[[6-chloro-4-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carboxylic acid tert-butyl ester (3.00 g, 8.18 mmol) in DCM (30 mL) was stirred at 25 °C for 4 h. The solution was concentrated under vacuum to obtain a residue, which was then purified by preparative HPLC (HCl conditions) to give 2-(azacyclobutane-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine (1.00 g, 46%) as a white solid. LC-MS (ESI): m / z = 267.0 [M+H] + .

[0863] Step c)(4aR,8aS)-6-[3-[[[6-chloro-4-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one]

[0864] A solution of 2-(azacyclobutane-3-ylmethoxy)-6-chloro-4-(trifluoromethyl)pyridine (150 mg, 0.560 mmol), N,N-diisopropylethylamine (0.29 mL, 1.69 mmol), and (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid 4-nitrobenzene ester (BB7a) (199 mg, 0.620 mmol) in ACN (5 mL) was stirred at 25 °C for 16 h. The solution was concentrated under vacuum to obtain a residue, which was then purified by preparative HPLC (TFA conditions) to give (4aR,8aS)-6-[3-[[[6-chloro-4-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (100 mg, 40%), as a colorless oil. LC-MS (ESI): m / z = 449.2 [M+H] + .

[0865] Step d)(4aR,8aS)-6-[3-[[[6-fluoro-4-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one]

[0866] A solution of (4aR,8aS)-6-[3-[[[6-chloro-4-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (75 mg, 0.17 mmol) and cesium fluoride (101 mg, 0.670 mmol) in DMSO (3 mL) was stirred at 80 °C for 16 h. The solution was filtered and then purified by preparative HPLC (TFA conditions) to provide (4aR,8aS)-6-[3-[[[6-fluoro-4-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (22 mg, 28%), a white solid. LC-MS (ESI): m / z = 433.0 [M+H] + .

[0867] Example 223

[0868] (4aR,8aS)-6-[3-[[6-fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0869]

[0870] Step a) 3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[0871] To a THF (50 mL) solution of tert-butyl 3-(hydroxymethyl)azacyclobutane-1-carboxylic acid (CAS No. 142253-56-3) (1.56 g, 8.33 mmol), NaH (60%, 741 mg, 18.5 mmol) and 2,6-dichloro-3-(trifluoromethyl)pyridine (CAS No. 55304-75-1) (2.00 g, 9.26 mmol) were added sequentially. The resulting mixture was stirred at 25 °C for 3 h. The solution was then poured into a saturated NH4Cl aqueous solution (50 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were concentrated under vacuum to obtain a residue, which was then purified by rapid column chromatography (petroleum ether: EtOAc = 5:1) to give 3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carboxylic acid tert-butyl ester (1.10 g, 32%), as a colorless oil. LC-MS (ESI): m / z = 311.0 [M-56+H] + .

[0872] Step b) 6-(azacyclobutane-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine

[0873] A solution of trifluoroacetic acid (0.37 mL, 4.8 mmol) and 3-[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carboxylic acid tert-butyl ester (1.1 g, 3.0 mmol) in DCM (30 mL) was stirred at 25 °C for 4 h. The solution was concentrated under vacuum to obtain a residue, which was then analyzed by preparative HPLC (HCl conditions) to give 6-(azacyclobutane-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine (600 mg, 75%) as a white solid. LC-MS (ESI): m / z = 267.0 [M+H] + .

[0874] Step c)(4aR,8aS)-6-[3-[[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one]

[0875] While stirring, N,N-diisopropylethylamine (0.13 mL, 0.75 mmol) was added to a solution of 6-(azacyclobutane-3-ylmethoxy)-2-chloro-3-(trifluoromethyl)pyridine (100 mg, 0.380 mmol) and (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid 4-nitrobenzene ester (BB7a) (120 mg, 0.380 mmol) in ACN (5 mL) at 25 °C. The solution was stirred at 25 °C for 16 h. The solution was concentrated under vacuum to obtain a residue, which was then subjected to preparative HPLC (TFA conditions) to yield (4aR,8aS)-6-[3-[[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (76 mg, 45%), a white solid. LC-MS (ESI): m / z = 449.1 [M+H] + .

[0876] Step d)(4aR,8aS)-6-[3-[[6-fluoro-5-(trifluoromethyl)-2-pyridyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0877] A solution of (4aR,8aS)-6-[3-[[[6-chloro-5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (70 mg, 0.16 mmol) and cesium fluoride (95 mg, 0.62 mmol) in DMSO (3 mL) was stirred at 60 °C for 24 h. The mixture was filtered and then purified by preparative HPLC (TFA conditions) to provide (4aR,8aS)-6-[3-[[[6-fluoro-5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (38 mg, 49%), a white solid. LC-MS (ESI): m / z = 433.3 [M+H] + .

[0878] Component synthesis

[0879] BB1a and BB1b

[0880] (+)-cis-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one

[0881] and

[0882] (-)-cis-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one

[0883] The enantiomeric form of racemic-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one dihydrochloride (BB1, 500 mg, 2.18 mmol, ChemBridge Corporation) was separated by preparative chiral HPLC (ReprosilChiral NR column) using EtOH (containing 0.05% NH4OAc): n-heptane (30:70).

[0884] First eluted enantiomeric compound: (+)-cis-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one (BB1a). Yellow solid (0.150 g; 44.0%). MS (ESI): m / z = 157.1 [M+H] + .

[0885] The second eluted enantiomer: (-)-cis-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one. (BB1b). Yellow solid (0.152 g; 44.6%). MS (ESI): m / z = 157.1 [M+H] + .

[0886] BB2

[0887] (4-Nitrophenyl)4-[[4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid ester

[0888] TEA (83.2 mg, 115 μL, 822 μmol) was added to a DCM (1 mL) solution of 4-(4-(trifluoromethyl)benzyl)piperidine (100 mg, 411 μmol, CAS RN 192990-03-7). After cooling to 0 °C, 4-nitrophenyl chloroformate (91.1 mg, 452 μmol, CAS RN 7693-46-1) was added, and the reaction mixture was warmed to room temperature and stirred for 18 h. The reaction mixture was diluted with DCM and then washed with H2O and a saturated aqueous solution of NaHCO3. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. The crude product was purified by rapid chromatography (10 g silica gel, eluted with 0-50% EtOAc / heptane) to give the title compound as a pale yellow solid (0.165 g; 98.3%). MS(ESI): m / z = 409.3 [M+H] + .

[0889] BB3

[0890] Racemic-(4aR,8aS)-6-(piperazin-1-carbonyl)-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[0891] TFA (155 mg, 105 μL, 1.36 mmol) was added to a DCM (3 mL) solution of a racemic mixture of tert-butyl-4-((4aR, 8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperazine-1-carboxylic acid (100 mg, 271 μmol), and the mixture was stirred at room temperature for 15 h under an argon atmosphere. The reaction mixture was washed with a saturated aqueous solution of NaHCO3. The H2O layer was concentrated under vacuum to give a white solid, which was then prepared with DCM for 30 min and filtered. The filtrate was concentrated to give a pale yellow gel (70 mg, 96.1%). MS (ESI): m / z = 269.3 [M+H] + .

[0892] Step a) Racemic-4-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperazine-1-carboxylic acid tert-butyl ester

[0893] A 90 mL solution of piperazine-1-carboxylic acid tert-butyl ester (1.16 g, 6.23 mmol, CAS RN 57260-71-6) in THF was added dropwise to a 3 mL solution of a mixture of triphosgene (1.29 g, 4.36 mmol) and Na₂CO₃ (1.98 g, 18.7 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min, then warmed to room temperature and stirred for another 5 h at room temperature. The suspension was filtered off, and the filtrate was concentrated under vacuum. The residue was dissolved in THF (40 mL) and added dropwise to a continuously stirred suspension of racemic-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one hydrochloride (1200 mg, 6.23 mmol, Chembridge Corporation) and DIPEA (4.83 g, 6.53 mL, 37.4 mmol) in THF (40 mL). After maintaining at 0 °C for 30 min, the reaction mixture was warmed to room temperature and stirred at room temperature for 15 h. The mixture was filtered, and the filtrate was concentrated under vacuum. The residue was diluted with DCM and then washed with water, aqueous NaHCO3 solution, and brine. The organic layer was dried over Na2SO4, filtered, and concentrated to give a white solid (1.13 g, 58.6%). MS (ESI): m / z = 313.3 [M+H] + .

[0894] BB4

[0895] (4-Nitrophenyl)4-(phenoxymethyl)piperidine-1-carboxylic acid ester

[0896] The preparation method of this compound is similar to that of BB2, using 4-(phenoxymethyl)piperidine (CAS N63614-86-8) to obtain the title compound as a white solid, which can be used directly in the next step without further purification.

[0897] BB5

[0898] 2-(4-piperidinylmethyl)-5-(trifluoromethyl)pyridine; hydrochloride

[0899] 320 mg (0.930 mmol) of 4-[[5-(trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carboxylic acid tert-butyl ester was dissolved in 10.0 mL (40 mmol) of EtOAc in 4 M HCl, and the solution was stirred at 20 °C for 2 h. The mixture was concentrated to give the desired compound as a pale yellow solid (0.25 g, 94.8%). MS (ESI): m / z = 245.0 [M-HCl+H] + .

[0900] Step a) 4-[[5-(trifluoromethyl)-2-pyridyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[0901] 2-Bromo-5-(trifluoromethyl)pyridine (500.0 mg, 2.21 mmol, CAS RN 1000773-62-5) was degassed, and then 0.5 M 9-BBN in THF solution (4.87 mL, 2.43 mmol, CAS RN 280-64-8) was added. The resulting solution was refluxed for 1 h. After cooling to room temperature, the solution was added to a solution of 4-methylenepiperidin-1-carboxylic acid tert-butyl ester (480.1 mg, 2.43 mmol, CAS RN159635-49-1), [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) chloride (161.89 mg, 0.220 mmol, CAS RN72287-26-4), and K2CO3 (611.56 mg, 4.42 mmol) in DMF (5 mL) and water (0.5 mL). The resulting mixture was heated at 80 °C for 4 h. The mixture was cooled to room temperature and poured into water. The pH was adjusted to 11 with a 10% NaOH aqueous solution, and the mixture was then extracted with EtOAc. The combined organic extracts were washed with brine, dried over Na2SO4, filtered, and evaporated to obtain a crude oil, which was then purified by column chromatography (silica gel adsorbent, with PE:EtOAc gradients of 10:1 and 5:1 sequentially) to obtain the desired compound as a pale yellow oil (320 mg, 0.930 mmol, 42%). MS (ESI): m / z = 289.0 [M-C4H8+H] + .

[0902] BB6

[0903] Racemic-(4aS,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0904] Racemic benzyl(4aS,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid ester (125 mg, 431 μmol) was dissolved in MeOH (5 mL). The reaction solution was degassed under vacuum and then backfilled with argon. Pd-C (20 mg, 188 μmol) was added under an argon atmosphere. Argon was removed from the reaction mixture and backfilled with hydrogen. The reaction mixture was stirred at room temperature for 15 h under a hydrogen atmosphere. The reaction mixture was filtered through an injection filter and concentrated under vacuum to give the desired product as a white solid (62 mg, 92.2%). MS (ESI): m / z = 157.098 [M+H] + .

[0905] Step a) Racemic 3S,4S)-3-(2-chloroacetamido)-4-hydroxypiperidine-1-carboxylic acid benzyl ester

[0906] To a stirred mixture of racemic benzyl(3S,4S)-3-amino-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (317 mg, 1.27 mmol, synthesized according to patent US 2011 / 59118 A1) and sodium acetate (208 mg, 2.53 mmol, CAS RN 127-09-3) in acetone (4 mL) / H₂O (0.5 mL), a solution of chloroacetyl chloride (150 mg, 107 μL, 1.33 mmol, CAS RN 79-04-9) in acetone (3 mL) at 0–5 °C was added dropwise. After the addition was complete, the reaction mixture was stirred at room temperature for 1 h, and then evaporated to dryness to give a yellow gel. The crude product was purified by silica gel chromatography to give the desired product as a yellow solid (385 mg, 93%). MS (ESI): m / z = 325.2 [MH] - .

[0907] Step b) Racemic-(4aS,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid benzyl ester

[0908] To a stirred solution of racemic benzyl(3S,4S)-3-(2-chloroacetamido)-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (385 mg, 1.18 mmol) in wastewater THF (4 mL), NaH (67.9 mg, 1.7 mmol) was added at 0 °C. The mixture was warmed to room temperature and then stirred for 90 min under an argon atmosphere. H2O (5 mL) was added, and stirring was continued for 10 min at room temperature. THF was removed from the reaction mixture under vacuum. The residue was treated with DCM, and the organic phase was washed with H2O and brine, dried with Na2SO4, filtered, and then concentrated under vacuum. The residue was purified by rapid chromatography (12 g reversed-phase column, gradient 0-100% ACN (0.1% FA) in aqueous solution (0.1% FA)) to give the desired product as a white solid (133 mg, 38.9%). MS(ESI): m / z = 291.3[M+H] + .

[0909] BB7a and BB7b

[0910] (4aR,8aS)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid 4-nitrobenzene ester

[0911] (BB7a)

[0912] and

[0913] (4aS,8aR)-3-oxohexahydro-2H-pyrido[4,3-b][1,4]oxazine-6(5H)-carboxylic acid 4-nitrobenzene ester

[0914] (BB7b)

[0915] To a suspension of racemic-(4aR,8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-ketodihydrochloride (4.5 g, 19.6 mmol, BB1) in DCM (125 mL), DIPEA (6.35 g, 8.58 mL, 49.1 mmol) and 4-nitrophenyl chloroformate (4.35 g, 21.6 mmol) were added sequentially. The reaction mixture was stirred at 0 °C for 10 min and then at room temperature for 2 h. The crude product was diluted with DCM and then transferred to a separatory funnel for extraction using a saturated aqueous solution of Na2CO3. The organic phase was collected, and the aqueous phase was then back-extracted with DCM. The combined organic phases were dried over Na2SO4 and then evaporated to dryness to give 6.62 g of crude racemic product (BB7) as a yellow solid. The crude product was directly separated by chiral SFC to obtain enantiomer BB7b (2.72 g, the second eluted enantiomer, a yellow solid) and enantiomer BB7a (3.25 g, the first eluted enantiomer, a light beige solid contaminated with BB7b). Further chiral SFC separation was performed to obtain 2.71 g of BB7a. For both enantiomers, MS (ESI): m / z = 322.2 [M+H] + .

[0916] BB8

[0917] 5-tert-butyl-2-(4-piperidinylmethyl)oxazole; hydrochloride

[0918] A solution of 167 mg (518 μmol) of 4-[(5-tert-butyloxazol-2-yl)methyl]piperidine-1-carboxylic acid tert-butyl ester (2.59 mL, 5.18 mmol) in 2 M HCl diethyl ether was stirred at room temperature for 5 h. Then, another 1.29 mL (2.59 mmol) of the 2 M HCl diethyl ether solution was added. The white suspension was stirred overnight at room temperature. The mixture was cooled in an ice bath, filtered, and washed with diethyl ether to give the desired compound as a colorless solid (0.126 g, 94.0%). MS (ESI): m / z = 223.2 [M+H] + .

[0919] Step a) (5-tert-butyloxazol-2-yl)methyl-triphenylphosphonium bromide

[0920] Triphenylphosphine (722 mg, 2.75 mmol, CAS RN 603-35-0) was added to a 5 mL solution of 2-(bromomethyl)-5-(tert-butyl)oxazole (600 mg, 2.75 mmol, CAS RN 1334492-54-4) in diethyl ether, and the mixture was stirred at room temperature for 64 h. The suspension was cooled in an ice bath and then filtered. The filter cake was washed with a small amount of cold diethyl ether to give the desired compound as a pale yellow solid (0.864 g, 65.4%). MS (ESI): m / z = 400.2 [M-Br+H] + .

[0921] Step b) 4-[(5-tert-butyloxazol-2-yl)methylene]piperidine-1-carboxylic acid tert-butyl ester

[0922] A 1M potassium tert-butoxide solution of 738 μL (738 μmol) in THF was added to a chilled solution of (5-tert-butyloxazol-2-yl)methyl-triphenylphosphonium bromide (355 mg, 739 μmol) in THF, and the reaction mixture was stirred at this temperature for 15 min. Then, 4-oxopiperidinium-1-carboxylic acid tert-butyl ester (162 mg, 813 μmol, CAS RN 79099-07-3) was added to the turbid orange solution, and stirring was continued at 0 °C for 15 min, followed by incubation at room temperature for 42 h. The reaction mixture was poured into a semi-saturated aqueous solution of NH4Cl and EtOAc, and the layers were separated. The aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over MgSO4, filtered, treated with silica gel, and evaporated. The compound was purified by silica gel chromatography, wherein separation was performed on a 12 g column using an MPLC system, and elution was carried out using a gradient of n-heptane:EtOAc (100:0 to 50:50) to give the desired compound as a colorless solid (0.180 mg; 76.0%). MS (ESI): m / z = 321.3 [M+H] + .

[0923] Step c) 4-[(5-tert-butyloxazol-2-yl)methyl]piperidine-1-carboxylic acid tert-butyl ester

[0924] To a solution of 180 mg (562 μmol) of 4-[(5-tert-butyloxazol-2-yl)methylene]piperidine-1-carboxylic acid tert-butyl ester (180 mg, 16.9 μmol) in MeOH (1 mL) and EtOAc (1 mL), 10% Pd / C (17.9 mg, 16.9 μmol) was added, and the suspension was stirred at 1.3 bar for 2 h under a hydrogen atmosphere. The suspension was filtered through a microporous filter, and the filtrate was evaporated to give the desired compound as a colorless oil (0.167 g; 92.2%). MS (ESI): m / z = 323.3 [M+H] + .

[0925] BB12

[0926] 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-methylpiperidine; hydrochloride

[0927] A solution of HCl in EtOAc (4M, 1.5mL) was added to a solution of tert-butyl 4-[(2-chloro-4-fluorophenoxy)methyl]-4-methylpiperidin-1-carboxylic acid (186 mg, 0.520 mmol) in EtOAc (1.5 mL) at 0 °C. The solution was stirred at 15 °C for 3 h. The solution was concentrated under vacuum and then lyophilized to give the desired product as a white solid (64.0 mg, 0.220 mmol, yield 40.3%). MS (ESI): m / z = 258 [M+H] + .

[0928] Step a) 4-Methyl-4-(methylsulfonyloxymethyl)piperidine-1-carboxylic acid tert-butyl ester

[0929] NET3 (0.45 mL, 3.22 mmol) and methanesulfonyl chloride (0.23 mL, 3.0 mmol) were added to a DCM (5 mL) solution of 4-(hydroxymethyl)-4-methylpiperidin-1-carboxylic acid tert-butyl ester (500 mg, 2.14 mmol, CAS RN: 614730-97-1) at 0 °C. The mixture was stirred at 0 °C for 2 h. The mixture was washed twice with 3 mL of water at 0 °C and dried over Na2SO4. The organic layer was concentrated under vacuum to give the desired compound as a colorless oil (766 mg, 2.46 mmol, 98.5%), which was used directly for the next step without further purification. MS (ESI): m / z = 256 [M-56+H] + .

[0930] Step b) 4-[(2-chloro-4-fluorophenoxy)methyl]-4-methyl-piperidine-1-carboxylic acid tert-butyl ester

[0931] To a DMF (5 mL) solution of 4-methyl-4-(methanesulfonyloxymethyl)piperidine-1-carboxylic acid tert-butyl ester (450 mg, 1.46 mmol), 620 mg (1.9 mol) of Cs₂CO₃ and 2-chloro-4-fluorophenol (0.14 mL, 1.46 mmol) were added at 15 °C. The mixture was heated to 90 °C and stirred for 16 h. The reaction solution was diluted with EtOAc (10 mL), washed twice with brine (10 mL each), and dried over Na₂SO₄. The organic layer was concentrated under vacuum to give a crude product (0.7 g) as a pale yellow oil. The crude product was purified by preparative HPLC and lyophilized to give the desired compound as a colorless solid (186 mg, 0.520 mmol, yield 35.5%). MS (ESI): m / z = 302 [M⁻⁶⁺H] + .

[0932] BB15

[0933] 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine; hydrochloride

[0934] HCl / EtOAc (0.4 mL, 3.6 mmol) was added to a solution of tert-butyl 4-[(2-chloro-4-fluorophenoxy)methyl]-4-fluoro-piperidine-1-carboxylic acid (220 mg, 0.610 mmol) in EtOAc (2 mL) at 0 °C. The solution was stirred at 15 °C for 2.5 h. The solution was concentrated under vacuum and then lyophilized to give the desired product as a white solid (136.7 mg, 75.4%).

[0935] Step a) 4-Fluoro-4-(Methylsulfonyloxymethyl)piperidine-1-carboxylic acid tert-butyl ester

[0936] NET3 (0.45 mL, 3.22 mmol) and methanesulfonyl chloride (0.23 mL, 3 mmol) were added to a DCM (5 mL) solution of tert-butyl 4-fluoro-4-(hydroxymethyl)piperidine-1-carboxylic acid (500 mg, 2.14 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h. The mixture was washed twice with H2O (3 mL each) at 0 °C and dried over Na2SO4. The organic layer was concentrated to give the desired colorless oily compound (766 mg, 98.5%), which was used directly for the next step without further purification. MS (ESI): m / z = 256 [M-56+H] + .

[0937] Step b) 4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-fluoro-piperidine-1-carboxylic acid tert-butyl ester

[0938] To a DMF (4 mL) solution of tert-butyl 4-fluoro-4-(methanesulfonyloxymethyl)piperidine-1-carboxylic acid (383 mg, 1.23 mmol), Cs₂CO₃ (601 mg, 1.85 mmol), 2-chloro-4-fluorophenol (0.13 mL, 1.35 mmol), and 2-chloro-4-fluorophenol (0.13 mL, 1.35 mmol) were added at 15 °C. The mixture was heated to 85 °C and stirred for 16 h. The mixture was extracted three times with EtOAc (5 mL each) at 15 °C. The combined organic layers were washed three times with brine (5 mL each), dried over Na₂SO₄, filtered, and evaporated. The crude product was purified by preparative HPLC and lyophilized to give the desired compound as a pale yellow oil (275 mg, 0.760 mmol, 61.5%). MS (ESI): m / z = 306 [M⁻⁶ + H] + .

[0939] BB16

[0940] Racemic-(4aR,8aS)-6-(4-(hydroxymethyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0941] DIPEA (787 mg, 1.06 mL, 6.09 mmol) and 4-nitrophenyl chloroformate (475 mg, 2.36 mmol) were added to an anhydrous DMF (9 mL) suspension of racemic-(4aR, 8aS)-hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one dihydrochloride (450 mg, 1.96 mmol, BB1) cooled to 0 °C under an inert atmosphere. The reaction mixture was stirred at 0 °C for 30 min. Piperidin-4-ylmethanol (271 mg, 2.36 mmol, CAS RN 6457-49-4) and DIPEA (381 mg, 515 μL, 2.95 mmol) were added, and the reaction mixture was stirred at 100 °C for 14 h. Volatile substances were removed under vacuum, and the crude residue was purified by rapid chromatography using a 24 g SiO2 column and an eluent mixture of DCM and MeOH (5% to 25%). The crude product was purified by SFC to obtain the desired compound as a pale yellow oil (338 mg). MS (ESI): m / z = 298.3 [M+H] + .

[0942] BB17

[0943] 4,4-Difluoro-1-(piperidin-4-ylmethyl)piperidine; dihydrochloride

[0944] To a solution of 4-((4,4-difluoropiperidin-1-yl)methyl)piperidin-1-carboxylic acid tert-butyl ester (453 mg, 1.07 mmol) in dioxane (2.5 mL), HCl (4.0 M dioxane solution) (2.67 mL, 10.7 mmol) was added, and the reaction mixture was stirred at room temperature for 14 h. Volatile substances were removed under vacuum to obtain the desired compound as a white solid (286 mg) which could be used directly for the next step without further purification. MS (ESI): m / z = 219.3 [M+H] + .

[0945] Step a) 4-((4,4-difluoropiperidin-1-yl)methyl)piperidin-1-carboxylic acid tert-butyl ester

[0946] To an anhydrous DMF (4 mL) solution of 4-(bromomethyl)piperidine-1-carboxylic acid tert-butyl ester (0.5 g, 1.8 mmol, CAS RN: 158407-04-6), 4,4-difluoropiperidine dihydrochloride (425 mg, 2.7 mmol) and Cs₂CO₃ (1.17 g, 3.59 mmol) were added. The reaction mixture was then stirred at 80 °C under microwave irradiation for 60 min. Insoluble matter was removed by filtration, and the filtrate was concentrated under vacuum. The obtained crude residue was suspended in DCM and filtered through a diatomaceous earth pad to give a crude yellow oil, which was purified by rapid chromatography on a SiO₂ column using a mixture of n-heptane and EtOAc (10% to 60%) as eluent to give the desired product, a colorless oil (453 mg). This compound could be used directly for the next step without further purification. MS(ESI): m / z = 319.3 [M+H] + .

[0947] BB19

[0948] N-(azacyclobutane-3-ylmethyl)-2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl-1-amine; bis(trifluoroacetate) salt

[0949] TFA (5.53 g, 3.74 mL, 48.5 mmol) was added to a solution of tert-butyl 3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid (1 g, 2.42 mmol) in DCM (10 mL). The resulting reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under vacuum to give the desired compound as a colorless oil (1.29 g). MS (ESI): m / z = 313.5 [M+H] + .

[0950] Step a) 3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[0951] To a septated, dry flask, under nitrogen atmosphere, add tert-butyl 3-(aminomethyl)azacyclobutane-1-carboxylate (0.852 g, 4.57 mmol), triethylamine (1.39 g, 1.91 mL, 13.7 mmol), 2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl-1-one (1.11 g, 780 μL, 4.57 mmol), and anhydrous DCM (28 mL). Using a syringe, add a 1 M titanium tetrachloride solution of DCM (2.29 mL, 2.29 mmol) to the ice-cold flask (exothermic). Stir the reaction mixture overnight at room temperature, then carefully quench it with a solution of NaCNBH3 (862 mg, 13.7 mmol) in MeOH (8.79 g, 11.1 mL, 274 mmol) and stir overnight. Basic the reaction mixture with saturated NaHCO3 solution. Filter the obtained insoluble material with diatomaceous earth. The filtrate was extracted with DCM, the organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated. The crude product was purified by rapid chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane solution) to give 3-(((2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester, which was used directly in the next step without further purification.

[0952] BB26

[0953] 3-Chloro-4-(4-piperidinylmethoxy)benzonitrile; hydrochloride

[0954] A solution of HCl in EtOAc (4 M, 2.0 mL) was added to a solution of 300 mg (0.860 mmol) of 4-[(2-chloro-4-cyanophenoxy)methyl]piperidine-1-carboxylic acid tert-butyl ester (EtOAc) in 3 mL at 0 °C. The solution was stirred at 15 °C for 3 h. The solution was concentrated under vacuum and then lyophilized to give the desired product as a white solid (238 mg, 0.830 mmol, yield 96%). MS (ESI): m / z = 251 [M+H] + .

[0955] Step a) 4-(((methanesulfonyl)oxy)methyl)piperidine-1-carboxylic acid tert-butyl ester

[0956] Neptyl ether (7.04 g, 69.7 mmol) was added to a solution of N-Boc-4-piperidinemethanol (10.0 g, 46.5 mmol, 1 eq) in DCM (200 mL), followed by the addition of methanesulfonyl chloride (3.95 mL, 51.1 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h. The mixture was poured into ice water, and the aqueous phase was extracted twice with DCM (50 mL each). The combined organic layers were washed with brine (50 mL) and then concentrated under vacuum. The residue was used directly without any purification. MS (ESI): m / z = 238.1 [M+H] + .

[0957] Step b) 4-[(2-chloro-4-cyano-phenoxy)methyl]piperidine-1-carboxylic acid tert-butyl ester

[0958] To a DMF (7 mL) solution of 4-(methanesulfonyloxymethyl)piperidine-1-carboxylic acid tert-butyl ester (700 mg, 2.39 mmol), 855 mg (2.62 mmol) of Cs₂CO₃ and 0.25 mL (2.39 mmol) of 3-chloro-4-hydroxybenzonitrile were added at 15 °C. The mixture was heated to 85 °C and stirred for 16 h. The reaction mixture was diluted with 8 mL of EtOAc at 15 °C, washed three times with brine (8 mL each), and the combined organic layers were dried over Na₂SO₄ and then evaporated. The colorless residue (0.75 g) was purified by preparative HPLC and lyophilized to give the desired product as a white solid (531 mg, 1.51 mmol, 53.4%). MS (ESI): m / z = 295 [M⁻⁶⁺H] + .

[0959] BB27

[0960] 4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine; hydrochloride

[0961] To a solution of 4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidin-1-carboxylic acid tert-butyl ester (430 mg, 1.29 mmol) in dioxane (3 mL), HCl (4 M dioxane solution; 3.22 mL, 12.9 mmol) was added, and the reaction mixture was stirred at room temperature for 14 h. Volatile substances were removed under vacuum to give a crude product (362 mg), which was used directly for the next step without further purification. MS (ESI): m / z = 234.2 [M+H] + .

[0962] Step a) 4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidine-1-carboxylic acid tert-butyl ester

[0963] To an anhydrous DMF (4 mL) solution of 4-(bromomethyl)piperidine-1-carboxylic acid tert-butyl ester (0.5 g, 1.8 mmol, CAS RN: 158407-04-6), 4-(trifluoromethyl)-1H-imidazole (293 mg, 2.16 mmol) and Cs₂CO₃ (1.17 g, 3.59 mmol) were added. The reaction mixture was then stirred at 80 °C for 14 h. Insoluble matter was removed by filtration, and the filtrate was concentrated under vacuum. The crude residue was suspended in DCM and filtered through a diatomaceous earth pad to give a yellow oil, which was purified by rapid chromatography using a SiO₂ column and an eluent mixture of n-heptane and EtOAc (10% to 90%). This yielded a first fraction (301 mg) of the desired product as a colorless oil, and a second fraction (261 mg) of a mixture of the desired product and impurities. The second fraction was purified by SFC, and then the purified product was combined with the first fraction to obtain 430 mg of the desired product, which was a colorless oil. MS (ESI): m / z = 334.2 [M+H] + .

[0964] BB29

[0965] 3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane

[0966] Trifluoroacetic acid (2 g, 1.35 mL, 17.5 mmol) was added to a solution of tert-butyl 3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carboxylic acid (320 mg, 875 μmol) in DCM (4.37 mL), and the solution was stirred at room temperature for 2 h. The solvent was removed under reduced pressure, and the resulting light-colored oil (470 mg) was diluted with EtOAc and then with an aqueous solution of Na₂CO₃. The aqueous phase was extracted three times with EtOAc, and the combined organic layers were washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure to give a yellow oil (259 mg, 877 μmol). MS (ESI): m / z = 266.1 [M+H] + .

[0967] Step a) 3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[0968] DIAD (594 mg, 571 μL, 2.94 mmol) was added dropwise to a solution of 2-chloro-4-(trifluoromethyl)phenol (525 mg, 357 μL, 2.67 mmol), 3-(hydroxymethyl)azacyclobutane-1-carboxylic acid tert-butyl ester (500 mg, 2.67 mmol, CAS RN: 142253-56-3), and triphenylphosphine (770 mg, 2.94 mmol) in DCM (13.4 mL). The reaction mixture was then stirred at room temperature for 17 h. The reaction mixture was quenched by adding 20 mL of saturated NaHCO3 aqueous solution. The phases were separated, and the aqueous phase was extracted twice with DCM. The combined organic layers were dried over Na2SO4 and concentrated to dryness. The residue was dissolved in EtOH (7 mL), and a homogeneous solution of zinc chloride (218 mg, 1.6 mmol) in EtOH (2 mL, 0.5 M) was added. The mixture was stirred for 30 min, during which a white solid precipitate formed. The white solid was filtered off and then washed with EtOH. The filtrate was concentrated to give a yellow oily substance with a white precipitate. The crude product was fixed onto an Isolute column and purified by column chromatography (40 g, 0 to 30% heptane solution of EtOAc) to give the title compound as a white solid (764.6 mg, 1.99 mmol, 74.4%). MS (ESI): m / z = 310.1 [M-56+H] + .

[0969] BB30

[0970] N-Benzyl-N-(2-hydroxyethyl)piperidine-4-carboxamide hydrochloride

[0971] A solution of 2M HCl in diethyl ether (1.1 mL, 2.21 mmol) was added to a DCM solution of 0.080 g (221 μmol) of tert-butyl piperidine-1-carboxylic acid. The resulting reaction mixture was stirred at room temperature for 1 h and then concentrated under vacuum at 22 °C to give the desired compound as a colorless oil (63 mg) (BB30). MS (ESI): m / z = 263.18 [M+H] + .

[0972] Step a) 4-(benzyl(2-hydroxyethyl)carbamoyl)piperidine-1-carboxylic acid tert-butyl ester

[0973] In a 10 mL glass tube, 2-(benzylamino)ethanol-1-ol (72.5 mg, 480 μmol), DIPEA (169 mg, 229 μL, 1.31 mmol), and HATU (182 mg, 480 μmol) were added to a DMF (2 mL) solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.1 g, 436 μmol). The mixture was stirred at room temperature for 1 h and then extracted with H2O / DCM. The crude product was purified by rapid chromatography (silica gel, 20 g, 50% to 100% EtOAc in n-heptane) to give a pale yellow oily compound (156 mg).

[0974] BB31

[0975] N-Benzylpiperidine-4-carboxamide hydrochloride

[0976] 4-(benzylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester (0.138 g, 433 μmol) was dissolved in DCM (1 mL), and a solution of 2 M HCl in diethyl ether (2.17 mL, 4.33 mmol) was added. The reaction mixture was stirred for 2 h. The residue was concentrated under vacuum to give a colorless oily compound (108 mg). MS (ESI): m / z = 219.15 [M+H] + .

[0977] Step a) 4-(benzylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester

[0978] In a 10 mL glass tube, benzylamine (51.4 mg, 52.4 μL, 480 μmol), DIPEA (169 mg, 229 μL, 1.31 mmol), and HATU (182 mg, 480 μmol) were added to a DMF (2 mL) solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (0.1 g, 436 μmol). The mixture was stirred at room temperature for 2 h and then extracted with H2O / DCM. The crude product was purified by rapid chromatography (silica gel, 20 g, 50% to 100% EtOAc in n-heptane) to give a colorless oily compound (0.138 g).

[0979] BB32

[0980] 4-((4-(tert-butyl)-1H-pyrazol-1-yl)methyl)piperidine; hydrochloride

[0981] To a solution of 100 mg (311 μmol) of tert-butyl piperidin-1-carboxylic acid in dioxane (1 mL), HCl (4.0 M dioxane solution; 1.17 mL, 4.67 mmol) was added, and the reaction mixture was stirred at room temperature for 14 h. Volatile substances were removed under vacuum to give 84 mg of crude product, which was used directly for the next step without further purification. MS (ESI): m / z = 222.3 [M+H] + .

[0982] Step a) 4-((4-(tert-butyl)-1H-pyrazole-1-yl)methyl)piperidin-1-carboxylic acid tert-butyl ester

[0983] To an anhydrous DMF (4 mL) solution of 4-(bromomethyl)piperidin-1-carboxylic acid tert-butyl ester (0.5 g, 1.8 mmol, CAS RN 158407-04-6), 4-(tert-butyl)-1H-pyrazole (268 mg, 2.16 mmol) and NaH (86.3 mg, 2.16 mmol) were added. The reaction mixture was stirred at 80 °C for 14 h. The reaction was quenched by adding a few drops of saturated NH4Cl aqueous solution, and then transferred to a separatory funnel for partitioning between DCM and saturated NaHCO3 aqueous solution. The organic phase was collected, and the aqueous phase was then back-extracted with DCM. The combined organic phases were dried over Na2SO4 and evaporated to dryness. The crude product was purified by rapid chromatography using a SiO2 column, eluting with a mixture of n-heptane and EtOAc (5% to 60%), to give the desired compound as a colorless oil (102 mg). MS(ESI): m / z = 322.3[M+H] + .

[0984] BB33

[0985] (2R,4aR,8aS)-2-methyl-4a,5,6,7,8,8a-hexahydro-4H-pyrido[4,3-b][1,4]oxazin-3-one

[0986] Under argon atmosphere, Pd-C (227 mg, 213 μmol) was added to a solution of 6-benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (isomer A, 1.10 g, 4.26 mmol) in EtOAc (16 mL) and MeOH (16 mL). The suspension was then stirred at 1 bar for 24 h under a hydrogen atmosphere (balloon). The suspension was filtered through a microglass filter and then washed with 20 mL of EtOAc in an inert gas atmosphere. The filtrate was evaporated to give BB33, a colorless solid (715 mg). MS (ESI): m / z = 170.8 [M+H] + Note: During the reduction process, only a single enantiomer is formed.

[0987] Step a) 2-Methyl-4H-pyrido[4,3-b]1[,4]oxazin-3-one

[0988] 2-Chloropropionyl chloride (3.03 g, 2.31 mL, 23.8 mmol) was added dropwise to a DMF (100 mL) solution of 3-aminopyridin-4-ol (2.5 g, 22.7 mmol), and the mixture was stirred at room temperature for 30 min. After adding K₂CO₃ (7.84 g, 56.8 mmol), the suspension was heated to 100 °C (oil bath) for 20 h. DMF was removed under vacuum, and then 100 mL of EtOAc was added. The mixture was stirred at room temperature for 10 min, washed with 50 mL of H₂O, and extracted three times with EtOAc. The organic phases were combined, dried with MgSO₄, and concentrated under vacuum to give 3.72 g of 2-methyl-4H-pyrido[4,3-b][1,4]oxazin-3-one, which was used directly for the next step without further purification.

[0989] Step b) 6-Benzyl-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine-6-onium bromide

[0990] A suspension of 2-methyl-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (3.72 g, 22.7 mmol) in DCM (32 mL) and MeOH (8 mL) was treated with (bromomethyl)benzene (4.65 g, 3.23 mL, 27.2 mmol) and the mixture was stirred at room temperature for 60 h. The resulting suspension was cooled to 0 °C, and 20 mL of n-hexane was added. The precipitate was then filtered. The residue was washed with 15 mL of ice-cold DCM / n-hexane to give a grayish-white solid compound (5.2 g). MS (ESI): m / z = 255 [M+H] + .

[0991] Step c) 6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0992] NaBH4 (763 mg, 20.2 mmol) was added fractionally to a suspension of 6-benzyl-2-methyl-3-oxo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine-6-onium bromide (5.2 g, 15.5 mmol) in EtOH (38 mL) (exothermic, 22 °C to 30 °C, yellow suspension). After the exothermic reaction gradually subsided, the mixture was stirred at room temperature for 3 h, then at 60 °C for 1 h, and finally at 22 °C for 1 h. The reaction mixture was evaporated and partitioned between H2O and EtOAc, and the layers were then separated. The aqueous layer was extracted once with EtOAc. The organic layer was washed twice with H2O, dried with MgSO4, filtered, treated with silica gel, and evaporated. The compound was purified by silica gel chromatography, wherein separation was performed on a 120 g column using an MPLC system with n-heptane:EtOAc (50:100, over 30 min) to give a pale yellow solid compound (2.48 g), which was used directly in subsequent steps without further purification.

[0993] Step d) 6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[0994] Enantiomers were separated using preparative chiral HPLC (Chiralcel OD column) with EtOH (containing 0.05% NH4OAc): n-heptane (10:90). The fraction was evaporated to provide the desired compounds as pale yellow solids (1.17 g of isomer A and 1.10 g of isomer B).

[0995] BB34

[0996] N-(azacyclobutane-3-ylmethyl)-2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl-1-amine

[0997] In a 100 mL two-necked flask, 0.913 g (2.05 mmol) of 3-(((2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester was dissolved in a mixture of THF (5 mL) and MeOH (5 mL). 10% Pd / C (109 mg, 102 μmol) was added under argon. The flask was purged and backfilled with H2 gas (3 times). The reaction mixture was then stirred at 25 °C for 4 h. The suspension was filtered through diatomaceous earth, concentrated, and the resulting title compound (611 mg, colorless oil) was used directly for the next step. MS (ESI): m / z = 313.4 [M+H] + .

[0998] Step a) 3-(((2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester

[0999] Add benzyl 3-(aminomethyl)azacyclobutane-1-carboxylate (0.5 g, 2.27 mmol), NEt3 (689 mg, 949 μL, 6.81 mmol), 2,2,2-trifluoro-1-(3-(trifluoromethyl)phenyl)ethyl-1-one (554 mg, 391 μL, 2.27 mmol), and anhydrous DCM (15 mL) to a septate-equipped dry flask. Add a 1 M titanium tetrachloride solution of DCM (1.13 mL, 1.13 mmol) using a syringe, and then cool the flask in an ice bath (exothermic). Stir the reaction mixture overnight at room temperature, then carefully quench it with a solution of NaCNBH3 (428 mg, 6.81 mmol) in MeOH (4.36 g, 5.51 mL, 136 mmol) and acetic acid (0.1 mL), and stir overnight at room temperature. The reaction mixture was alkalized with a saturated aqueous solution of NaHCO3, and the obtained insoluble substances were filtered off through diatomaceous earth. The filtrate was extracted with DCM. The organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated under vacuum. The crude product was purified by rapid chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane solution) to give the desired compound as a colorless oil (913 mg). MS (ESI): m / z = 447.2 [M+H] + .

[1000] BB35

[1001] In a 100 mL two-necked flask, 3-(((1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester (0.660 g, 1.48 mmol) was dissolved in EtOAc (20 mL) to give a colorless solution. 10% Pd / C (78.5 mg, 73.8 μmol) was added under argon atmosphere. The flask was purged and backfilled with H2 gas (3 times). The reaction mixture was stirred at 25 °C for 4 h. LC-MS showed the title product N-(azacyclobutane-3-ylmethyl)-1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl-1-amine with the dehalogenation byproducts N-(azacyclobutane-3-ylmethyl)-1-(2-chlorophenyl)-2,2,2-trifluoroethyl-1-amine and N-(azacyclobutane-3-ylmethyl)-1-phenyl-2,2,2-trifluoroethyl-1-amine. The reaction mixture was filtered through diatomaceous earth, concentrated under vacuum, and used directly in the next step.

[1002] Step a) 3-[[[1-(2,4-dichlorophenyl)-2,2,2-trifluoro-ethylene]amino]methyl]azacyclobutane-1-carboxylic acid benzyl ester

[1003] To a septated, dry flask, under nitrogen atmosphere, added benzyl 3-(aminomethyl)azacyclobutane-1-carboxylate (0.500 g, 2.27 mmol, CAS RN 1016731-24-0), NET3 (689 mg, 949 μL, 6.81 mmol), 1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl-1-one (556 mg, 2.27 mmol), and anhydrous DCM (16.4 mL). Titanium tetrachloride (1 M DCM solution; 1.13 mL, 1.13 mmol) was added exothermally to the chilled flask using a syringe. The reaction mixture was stirred overnight at room temperature, then carefully quenched with a solution of NaCNBH3 (428 mg, 6.81 mmol) in MeOH (4.36 g, 5.51 mL, 136 mmol) and stirred for 6 h. LC-MS indicated that the reaction terminated at an imine.

[1004] The reaction mixture was alkalized with saturated NaHCO3. The obtained insoluble substance was filtered through diatomaceous earth, and the filtrate was extracted with DCM. The organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated. The crude product was purified by rapid chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane solution) to give the desired compound as a colorless oil (1 g).

[1005] Step b) 3-(((1-(2,4-dichlorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester

[1006] In a 25 mL two-necked flask, 3-[[[1-(2,4-dichlorophenyl)-2,2,2-trifluoro-ethylene]amino]methyl]azacyclobutane-1-carboxylic acid benzyl ester (1 g, 2.25 mmol) was dissolved in THF (10 mL) and MeOH (1 mL) to give a colorless solution. Acetic acid (135 mg, 129 μL, 2.25 mmol) and NaCNBH3 (423 mg, 6.74 mmol) were added. The reaction mixture was stirred at 25 °C for 6 h. The reaction mixture was alkalized with saturated NaHCO3. The obtained insoluble substance was filtered through diatomaceous earth, and the filtrate was extracted with DCM. The organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated. The crude product was purified by rapid chromatography (silica gel, 50 g, 0% to 50% heptane solution of EtOAc) to obtain the title compound as a colorless oil (660 mg) which was used directly for the next step without further purification.

[1007] BB36

[1008] cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine; hydrochloride

[1009] 115 mg (321 μmol) of cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidin-1-carboxylic acid tert-butyl ester was dissolved in DCM (2 mL), and a solution of 2 M HCl in ether (161 μL, 321 μmol) was added. The reaction mixture was stirred at room temperature for 6 h, and then the solvent was removed under vacuum. The crude product (94 mg, colorless foam) was used directly in the next step without purification. MS (ESI): m / z = 258.2 [M+H] + .

[1010] Step a) cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carboxylic acid tert-butyl ester

[1011] Mitsunobu reaction: In a 50 mL four-necked sulfonated flask under argon atmosphere, 840 mg (3.66 mmol) of cis-4-(hydroxymethyl)-3-methylpiperidin-1-carboxylic acid tert-butyl ester was dissolved in 15 mL of THF, followed by the addition of 2-chloro-4-fluorophenol (590 mg, 439 μL, 4.03 mmol) and triphenylphosphine (1.06 g, 4.03 mmol). The clear solution was stirred at room temperature for 5 min, then cooled to 0–2 °C, and DEAD (702 mg, 638 μL, 4.03 mmol) was added over 10 min. The reaction mixture was stirred at 2–4 °C for 1 h, then stirred overnight at room temperature. 50 mL of diethyl ether was added, and the mixture was washed with 2 x 25 mL of water, 3 x 20 mL of 1N NaOH, and 1 x 20 mL of brine. The organic phase was dried over Mg2SO4, and after solvent removal under vacuum, 2.7 g of a yellow oil was obtained. To remove triphenylphosphine oxide, the residue was stirred in n-heptane / diethyl ether for 30 min, the solid was filtered off, and the filtrate was concentrated under vacuum to obtain 1.8 g of crude product. It was purified by rapid chromatography (silica gel, 50 g, 0% to 30% EtOAc in heptane solution, 40 min) to give 1.21 g of cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidin-1-carboxylic acid tert-butyl ester, which was a white solid.

[1012] BB39

[1013] 3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane; trifluoroacetate

[1014] TFA (1.3 g, 875 μL, 11.4 mmol) was added to a DCM (5 mL) solution of 415 mg (1.14 mmol) of tert-butyl 3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carboxylic acid (tert-butyl ester) and the reaction mixture was stirred at room temperature for 3 h. Volatile substances were removed under vacuum to give 455 mg of a pale yellow oil, which was used directly in the next step without further purification. MS (ESI): m / z = 266.1 [M+H] + .

[1015] Step a) 3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carboxylic acid tert-butyl ester

[1016] Potassium tert-butoxide (1.65 M THF solution, 735 μL, 1.21 mmol) was added to an anhydrous THF solution of 200 mg (1.15 mmol) of tert-butyl 3-hydroxyazacyclobutane-1-carboxylic acid (5 mL), and the reaction mixture was stirred at room temperature for 15 min. Then, 1-(bromomethyl)-2-fluoro-4-(trifluoromethoxy)benzene (315 mg, 1.15 mmol) was added. The reaction mixture was then stirred at room temperature for 14 h. The crude product was diluted with EtOAc and extracted with 1 M NaHCO3 aqueous solution. The organic phase was collected, and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over NaSO4 and evaporated to dryness to give 418 mg of crude product, which was used directly for the next step without further purification. MS (ESI): m / z = 310.1 [M-56+H] + .

[1017] BB40

[1018] N-(azacyclobutan-3-yl)-2-chloro-4-fluorobenzamide; trifluoroacetate

[1019] TFA (0.7 mL) was added to a DCM (3.5 mL) solution of 3-[(2-chloro-4-fluorobenzoyl)amino]azacyclobutane-1-carboxylic acid tert-butyl ester (346 mg, 1.05 mmol) at 0 °C. The solution was stirred at 0 °C for 2 h. The reaction product was concentrated under vacuum to give a crude product (600 mg) as a pale yellow oil. The crude product was purified by preparative HPLC (0.1% TFA in H₂O and MeCN solution) and lyophilized to give the desired compound as a colorless solid (223 mg, 0.650 mmol, yield 59.2%). MS (ESI): m / z = 229 [M+H] + .

[1020] Step a) 3-[(2-chloro-4-fluoro-benzoyl)amino]azacyclobutane-1-carboxylic acid tert-butyl ester

[1021] 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (714 mg, 3.72 mmol) was added to a THF (10 mL) solution of 2-chloro-4-fluorobenzoic acid (500 mg, 2.86 mmol), 1-Boc-3-(amino)azacyclobutane (493 mg, 2.86 mmol), and DMAP (35.0 mg, 0.290 mmol) at 0 °C. The mixture was heated to 30 °C and stirred for 16 h. The reaction product was diluted with EtOAc (5 mL), washed three times with brine (10 mL each), and dried over Na2SO4. The organic layer was concentrated under vacuum to give a crude product (0.72 g) as a yellow oil. The crude product was purified by preparative HPLC and lyophilized to give the desired compound as a colorless solid (546 mg, 1.66 mmol, yield 57.9%). MS(ESI): m / z = 273[M-56+H] + .

[1022] BB41

[1023] N-(azacyclobutane-3-ylmethyl)-2,2,2-trifluoro-N-methyl-1-[4-(trifluoromethyl)phenyl]ethylamine; trifluoroacetate

[1024] TFA (1.37 g, 925 μL, 12 mmol) was added to a DCM (5 mL) solution of 0.256 g (600 μmol) of tert-butyl 3-((methyl(2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester. The resulting reaction mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under vacuum to give the desired compound as a colorless oil (268 mg). MS (ESI): m / z = 327.4 [M+H] + .

[1025] Step a) 3-((methyl(2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl)amino)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[1026] Towards with padding and In a dry flask containing molecular sieves, tert-butyl 3-((methylamino)methyl)azacyclobutane-1-carboxylic acid (0.300 g, 293 μL, 1.5 mmol), TEA (455 mg, 626 μL, 4.49 mmol), 2,2,2-trifluoro-1-(4-(trifluoromethyl)phenyl)ethyl-1-one (363 mg, 255 μL, 1.5 mmol), and anhydrous DCM (9.86 mL) were added under nitrogen atmosphere. A 1 M titanium tetrachloride solution of DCM (749 μL, 749 μmol) was added to the ice-cold flask (exothermic) using a syringe. The reaction mixture was stirred overnight at room temperature, then carefully quenched with a solution of NaCNBH3 (282 mg, 4.49 mmol) in MeOH (3.64 mL, 89.9 mmol) and stirred at room temperature for 2 h. The reaction mixture was alkalized with NaHCO3 solution. The insoluble substance obtained by filtration with diatomaceous earth was extracted with DCM. The organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated. The crude product was purified by rapid chromatography (silica gel, 50 g, 0% to 50% EtOAc in n-heptane solution) and used directly in the next step.

[1027] BB42

[1028] N-Methyl-N-(piperidin-4-yl)-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamide hydrochloride

[1029] A solution of tert-butyl 4-(N-methyl-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamido)piperidine-1-carboxylic acid (tert-butyl ester, 0.301 g, 706 μmol) in diethyl ether (3.53 mL, 7.06 mmol) was added. The resulting reaction mixture was stirred overnight at room temperature and then concentrated under vacuum at 22 °C to give 256 mg of BB42 as a grayish-white solid, MS (ESI): m / z = 327.2 [M+H]. +

[1030] Step a) 4-(N-methyl-1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxamido)piperidine-1-carboxylic acid tert-butyl ester

[1031] In a 20 mL glass tube, HATU (293 mg, 770 μmol) and DIPEA (271 mg, 367 μL, 2.1 mmol) were added to a DMF (5 mL) solution of 1-(3-(trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid (177 mg, 770 μmol). The reaction mixture was stirred for 15 min, and then tert-butyl 4-(methylamino)piperidine-1-carboxylic acid (0.15 g, 700 μmol) was added. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was extracted with water / DCM. The crude product was purified by rapid chromatography (silica gel, 20 g, 0% to 100% heptane solution of EtOAc) to give the desired compound as a pale yellow oil (301 mg). MS (ESI): m / z = 371.2 [M-56+H] +

[1032] BB43

[1033] 2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methyl-N-(piperidin-4-yl)acetamide; hydrochloride

[1034] To a solution of 0.301 g (692 μmol) of tert-butyl piperidine-1-carboxylic acid in 2 mL of DCM, HCl (3.46 mL, 6.92 mmol) was added. The resulting reaction mixture was stirred at room temperature for 2 days, and then concentrated under vacuum at 22 °C to give 252 mg of BB43 as a grayish-white solid. MS (ESI): m / z = 335.1 [M+H] + .

[1035] Step a) 4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidine-1-carboxylic acid tert-butyl ester

[1036] In a 20 mL glass tube, HATU (293 mg, 770 μmol) and DIPEA (271 mg, 367 μL, 2.1 mmol) were added to a DMF (5 mL) solution of 2-(2-chloro-3-(trifluoromethyl)phenyl)acetic acid (184 mg, 770 μmol). The reaction mixture was stirred for 15 min, and then tert-butyl 4-(methylamino)piperidin-1-carboxylic acid (0.150 g, 700 μmol) was added. The reaction mixture was stirred at room temperature for 2 h, and then extracted with water / DCM. The crude product was purified by rapid chromatography (silica gel, 20 g, 0% to 100% heptane solution of EtOAc) to give 301 mg of tert-butyl 4-(2-(2-chloro-3-(trifluoromethyl)phenyl)-N-methylacetamido)piperidin-1-carboxylic acid as a pale yellow oil, MS (ESI): m / z = 379.1 [M-56+H]. +

[1037] BB44

[1038] 2-(2-chloro-5-(trifluoromethyl)phenyl)-N-methyl-N-(piperidin-4-yl)acetamide; hydrochloride

[1039] Synthesized from 2-(2-chloro-5-(trifluoromethyl)phenyl)acetic acid and tert-butyl 4-(methylamino)piperidine-1-carboxylic acid. See the synthesis of BB43 for details. MS (ESI): m / z = 335.1 [M+H] + .

[1040] BB46

[1041] 3-Methyl-5-(piperidin-4-ylmethoxy)-2-(trifluoromethyl)pyridine; dihydrochloride

[1042] In a 25 mL tube, 87 mg (232 μmol) of 4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carboxylic acid tert-butyl ester was dissolved in DCM (2 mL), followed by the addition of 697 μL (1.39 mmol) of 2 M HCl ether solution. The reaction mixture was stirred at room temperature for 12 h. The mixture was concentrated under vacuum to give 80 mg of BB46 as a white solid. MS (ESI): m / z = 275.2 [M+H] + .

[1043] Step a) 4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carboxylic acid tert-butyl ester

[1044] In a 5 mL tube, tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylic acid (80.7 mg, 375 μmol) was dissolved in DMF (1.5 mL), followed by the addition of a 60% NaH oil solution (18 mg, 450 μmol) at room temperature. The mixture was stirred for 20 min, and then 5-bromo-3-methyl-2-(trifluoromethyl)pyridine (90 mg, 60 μL, 375 μmol) was added and stirred at room temperature for 2 h to obtain a brown solution. 10 mL of saturated NH4Cl was added, and the solution was extracted with water / ethyl acetate, dried over MgSO4, and the solvent was removed at 40 °C / 150 mbar. The crude product was purified by rapid chromatography (silica gel, 20 g, 0 to 40% EtOAc in n-heptane solution, eluting over 35 min) to give 87 mg of tert-butyl 4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carboxylic acid. MS(ESI): m / z = 319.2[M-56+H] +

[1045] BB58

[1046] N-(azacyclobutane-3-ylmethyl)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl-1-amine

[1047] In a 100 mL two-necked flask, 3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester (707 mg, 1.64 mmol) was combined with THF (5 mL) and MeOH (5 mL) to give a colorless solution. 10% Pd / C (87.3 mg, 82.1 μmol) was added under argon atmosphere. The flask was purged and backfilled with H2 (3 times). The reaction mixture was stirred at 25 °C for 1 h. The reaction mixture was filtered through diatomaceous earth, concentrated, and used directly for the next step. A colorless oil (472 mg) was obtained. MS (ESI): m / z = 263.2 [M+H] + (Loss of ortho-chlorine during hydrogenation).

[1048] Step a: 3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester

[1049] Under a nitrogen stream, 3-(aminomethyl)azacyclobutane-1-carboxylic acid benzyl ester (0.5 g, 2.27 mmol), triethylamine (689 mg, 949 μL, 6.81 mmol), 1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoro-ethyl ketone (519 mg, 2.27 mmol), and anhydrous DCM (15 mL) were added to a dry flask. A 1 M solution of titanium tetrachloride in DCM (1.13 mL, 1.13 mmol) was added to the ice-cold flask (exothermic) using a syringe. The reaction mixture was stirred overnight at room temperature, then carefully quenched with a solution of sodium cyanoborohydride (428 mg, 6.81 mmol) in methanol (4.36 g, 5.51 mL, 136 mmol) + acetic acid (0.1 mL), and stirred overnight at room temperature. The reaction mixture was alkalized with saturated NaHCO3. The obtained insoluble substances were filtered off with diatomaceous earth. The filtrate was extracted with DCM, the organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated. Purification: The crude product was purified by rapid chromatography (silica gel, 50 g, 0% to 50% heptane solution of EtOAc) to give 707 mg of 3-(((1-(2-chloro-4-fluorophenyl)-2,2,2-trifluoroethyl)amino)methyl)azacyclobutane-1-carboxylic acid benzyl ester, which was a colorless oil. MS (ESI): m / z = 431.2 [M+H] + .

[1050] BB59

[1051] 2,2,2-Trifluoro-1-(piperidin-4-yl)-N-(3-(trifluoromethyl)benzyl)ethyl-1-amine; hydrochloride

[1052] To a solution of 0.140 g (318 μmol) of tert-butyl piperidine-1-carboxylic acid in DCM (2 mL), 1.59 mL (3.18 mmol) of 2 M HCl in diethyl ether was added. The resulting reaction mixture was stirred overnight at room temperature and then concentrated under vacuum at 22 °C to give 119 mg of the title compound as a grayish-white solid. MS (ESI): m / z = 340.8 [M+H] + .

[1053] Step a) 4-(2,2,2-trifluoro-1-((3-(trifluoromethyl)benzyl)amino)ethyl)piperidine-1-carboxylic acid tert-butyl ester

[1054] A solution of 1,2-DCE (1 mL) of 4-(1-amino-2,2,2-trifluoroethyl)piperidine-1-carboxylic acid tert-butyl ester (0.150 g, 531 μmol) and 3-(trifluoromethyl)benzaldehyde (92.5 mg, 71.1 μL, 531 μmol) was stirred at room temperature for 1 hour. Then, sodium triacetoxyborohydride (225 mg, 1.06 mmol) was added at 0 °C, and the reaction mixture was stirred overnight at room temperature. The reaction mixture was poured onto saturated NaHCO3 and extracted with DCM. The organic layers were mixed, washed with brine, dried over Na2SO4, and concentrated under vacuum. The crude product was purified by rapid chromatography (silica gel, 20 g, 0% to 100% heptane solution of EtOAc) to give 145 mg of the desired compound as a colorless oil. MS (ESI): m / z = 383.1 [M-56+H] +

[1055] BB69

[1056] 2-Methyl-3-((4-(trifluoromethyl)benzyl)oxy)azacyclobutane; trifluoroacetate

[1057] Trifluoroacetic acid (1.19 g, 10.4 mmol) was added to a DCM (4 mL) solution of tert-butyl 2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carboxylic acid (0.36 g, 1.04 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under high vacuum to give 399 mg BB69 as a pale yellow oil, a mixture of all four stereoisomers. MS (ESI): m / z = 246.1 [M+H] + .

[1058] Step a) 2-Methyl-3-((4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carboxylic acid tert-butyl ester

[1059] In a 25 mL two-necked flask, tert-butyl 3-hydroxy-2-methylazacyclobutane-1-carboxylic acid (215 mg, 1.15 mmol) was dissolved in DMF (5 mL) to obtain a colorless solution. Sodium hydride (60%, dispersed in mineral oil) (41.8 mg, 1.05 mmol) was added at 0 °C. The reaction mixture was stirred at 0 °C for 15 min. Then, 1-(bromomethyl)-4-(trifluoromethyl)benzene (0.250 g, 1.05 mmol) was added at 0 °C. The reaction mixture was stirred overnight at room temperature. The reaction mixture was poured into 20 mL of saturated NH4Cl solution and extracted with EtOAc (2 × 50 mL). The organic layers were mixed, washed with brine, dried over Na2SO4, and then concentrated under vacuum. The crude product was purified by rapid chromatography (silica gel, 20 g, 0% to 70% heptane solution of EtOAc) to give 360 ​​mg of tert-butyl 2-methyl-3-((4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carboxylic acid, as a colorless oil. MS (ESI): m / z = 290.1 ​​[M-56+H] +

[1060] BB87

[1061] 3-Fluoro-5-(trifluoromethyl)benzyl ester of 4-toluenesulfonic acid

[1062] To a solution of (3-fluoro-5-(trifluoromethyl)phenyl)methanol (100 mg, 72.5 μL, 515 μmol, Eq: 1) in DCM (2.58 mL), p-toluenesulfonic anhydride (185 mg, 567 μmol), DIPEA (79.9 mg, 108 μL, 618 μmol), and DMAP (6.29 mg, 51.5 μmol) were added. The reaction mixture was stirred at 0 °C for 4 h and then stirred at room temperature for 2 days. The reaction mixture was then dissolved in EtOAc and washed with water and brine. The organic layer was dried over MgSO4 and concentrated under vacuum to give a yellow oil (178 mg), which was used directly without further purification.

[1063] Similar to BB39, unless otherwise stated, the intermediates shown in the table below are prepared from commercially available benzyl bromide or prepared toluenesulfonate intermediates and the corresponding tert-butyl 3-hydroxyazacyclobutane-1-carboxylic acid structural units.

[1064]

[1065]

[1066]

[1067] Similar to BB29, intermediates BB20, BB25, and BB61 in the table below are prepared from commercially available phenols. Where trifluoroacetate is specified, the crude product obtained by concentrating the reaction mixture is used directly without further neutralization or purification.

[1068]

[1069]

[1070] Similar to BB26, intermediates BB21 to BB24 and BB28 in the table below are prepared from commercially available phenols.

[1071]

[1072]

[1073] Method D1

[1074] BB9

[1075] 4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidine; trifluoroacetate

[1076] A solution of tert-butyl piperidine-1-carboxylic acid (750.0 mg, 1.97 mmol) in DCM (20 mL) and TFA (0.76 mL) was stirred at 20 °C for 12 h. The mixture was concentrated. The residue was dissolved in H₂O (20 mL) and washed with PE:EA = 10:1 (20 mL each). The aqueous layer was lyophilized to give the desired product as a pale yellow solid (716 mg, 1.82 mmol, 87.8%). MS (ESI): m / z = 280.1 [M+H] + .

[1077] Step a) 4-[2-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1078] A mixture of 2-chloro-4-(trifluoromethyl)phenol (500 mg, 2.54 mmol), 1-Boc-4-hydroxypiperidine (768 mg, 3.82 mmol), and triphenylphosphine (1334 mg, 5.09 mmol) was stirred in 10 mL of THF at 0 °C until completely dissolved. DIAD (1542 mg, 7.63 mmol) was slowly added dropwise at 0 °C. The mixture was stirred at 20 °C for 3 h, and then concentrated under vacuum. The residue was purified by preparative HPLC to give the desired compound as a pale yellow solid (760 mg, 2 mmol, yield 78.7%). MS (ESI): m / z = 324.0 [M-56+H] + .

[1079] BB57

[1080] 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azacyclobutane; trifluoroacetate

[1081] TFA (793 mg, 536 μL, 6.96 mmol) was added to a solution of tert-butyl 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azacyclobutane-1-carboxylic acid (158 mg, 435 μmol) in DCM (1.74 mL), and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was then concentrated to give 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azacyclobutane; trifluoroacetate (202 mg, 434 μmol, yield 99.7%), as a colorless oil. The crude product was used directly without further purification. MS (ESI): m / z = 264.1 [M+H] + .

[1082] Step a) 3-(((2-fluoro-4-(trifluoromethyl)benzyl)oxy)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[1083] A solution of 1.65 M potassium tert-butoxide in THF (340 μL, 561 μmol) was added to an anhydrous THF solution of 100 mg (534 μmol) of tert-butyl 3-(hydroxymethyl)azacyclobutane-1-carboxylic acid (2.67 mL). The turbid reaction mixture was stirred at room temperature for 15 min, and then 1-(bromomethyl)-2-fluoro-6-(trifluoromethyl)benzene (137 mg, 534 μmol) was added. The reaction mixture was then stirred at room temperature for 3 h. The crude product was diluted with ethyl acetate and extracted with a saturated aqueous solution of NaHCO3. The organic phase was collected, and the aqueous phase was back-extracted with ethyl acetate. The combined organic phases were dried over sodium sulfate and then evaporated to dryness to give a clear oil. The crude product was immobilized on an Isolute column and purified by column chromatography using a 0-30% heptane solution of EtOAc to give 3-(((2-fluoro-6-(trifluoromethyl)benzyl)oxy)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester (158 mg, 413 μmol, yield 77.3%), as a colorless oil. MS (ESI): m / z = 308.1 [M-56+H] +

[1084] Method D2

[1085] BB10

[1086] 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine; formate

[1087] At 20 °C, a mixture of 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester (440 mg, 0.610 mmol) and 5.0 mL of 4 M HCl in EtOAc solution was stirred in EtOAc (10 mL) for 12 h. The mixture was concentrated under vacuum. The residue was redissolved in H2O (5 mL), washed twice with PE:EA (3:1; 10 mL each), and the layers were separated. The aqueous layer was purified by preparative HPLC to give the desired compound as a pale yellow solid (124 mg, 0.350 mmol, yield 65.3%). MS (ESI): m / z = 312.2 [M+H] + .

[1088] Step a) 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester

[1089] A 20 mL solution of 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (500 mg, 1.19 mmol), bromocyclopentane (266 mg, 1.78 mmol), Ir(dF(CF3)ppy)2(dtbbpy)PF6 (13.4 mg, 0.010 mmol, CAS RN 870987-63-6), NiCl2.glycol dimethyl ether (0.77 mg, 0.060 mmol), dtbbpy (19.2 mg, 0.070 mmol, CAS RN 72914-19-3), TTMSS (296 mg, 1.19 mmol, CAS RN 1873-77-4), and Na2CO3 (252 mg, 2.38 mmol) was degassed for 20 min using a bubbling argon flow. The reaction mixture was irradiated with blue LEDs (4 × 1) for 16 h at 25 °C. The mixture was diluted with H₂O and then extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by preparative HPLC to give a colorless oily compound (460 mg, 1.12 mmol, 53.8%). MS (ESI): m / z = 354.1 [M⁻⁶ + H] + .

[1090] Step b) 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[1091] To a solution of 4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (460 mg, 0.640 mmol) in EtOAc (10 mL), wet Pd / C (40 mg) was added, and the mixture was stirred in H2 (1520 mmHg) at 20 °C for 12 h. The mixture was filtered, and the filtrate was concentrated to give a colorless oily compound (460 mg, 1.12 mmol, 99.5%). MS (ESI): m / z = 356.1 [M+H-56] + .

[1092] BB11

[1093] 2-(4-piperidinylmethyl)-1,3-benzoxazole; formate

[1094] A solution of 2-aminophenol (1.0 g, 9.16 mmol) and 1-Boc-4-piperidinylacetic acid (2.68 g, 11 mmol) in polyphosphoric acid (2.2 g) was stirred at 180 °C for 2 h. The mixture was diluted with a mixture of 12 M NH4OH aqueous solution and ice to pH > 7, and then extracted three times with EtOAc (10 mL each). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was then purified by preparative HPLC to obtain the desired compound as a brown oil (251 mg, 0.960 mmol, 9.7%). MS (ESI): m / z = 217.2 [M+H] + .

[1095] Method D3

[1096] BB13

[1097] 4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine; hydrochloride

[1098] 4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (1000 mg, 2.37 mmol) was stirred for 12 h in a 4 M HCl solution in dioxane (50 mL). The mixture was concentrated to give the title compound as a white solid (845 mg, 2.35 mmol, 96.2%). MS (ESI): m / z = 322.0 [M+H] + .

[1099] Step a) 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1100] 3-Bromo-4-chlorophenol (1000 mg, 4.82 mmol), 1-Boc-4-hydroxypiperidine (1164 mg, 5.78 mmol), and triphenylphosphine (2529 mg, 9.64 mmol) were stirred in 10 mL of THF until completely dissolved. Then, DIAD (1948 mg, 9.64 mmol) was slowly added dropwise at 0 °C. The mixture was stirred at 20 °C for 12 h, concentrated, and the residue was purified by reversed-phase rapid chromatography to give a yellow oily compound (1300 mg, 3.33 mmol, 69.0%). MS (ESI): m / z = 336.0 [M-56+H] + .

[1101] Step b) 4-[4-chloro-3-(4-chlorophenyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1102] Tetra(triphenylphosphine)palladium(O) (340 mg, 0.290 mmol, CAS RN 14221-01-3) was added to a solution of 4-(3-bromo-4-chlorophenoxy)piperidine-1-carboxylic acid tert-butyl ester (1150 mg, 2.94 mmol), 4-chlorophenylboronic acid (506 mg, 3.24 mmol), Na₂CO₃ (1248 mg, 11.8 mmol), 1,4-dioxane (20 mL), and H₂O (5 mL). The mixture was stirred at 110 °C for 12 h under a N₂ atmosphere. The mixture was filtered, the filtrate was concentrated, and the residue was purified by silica gel column chromatography using a 5–20% EtOAc-PE gradient to give the desired compound as a pale yellow oil (1100 mg, 2.6 mmol, 88.5%). MS (ESI): m / z = 366.1 [M⁻⁵⁶ + H⁺]. + .

[1103] BB14

[1104] 4-[[2-(1H-pyrazol-4-yl)-4-(trifluoromethyl)phenyl]methyl]piperidine; trifluoroacetate

[1105] TFA (1.0 mL) was added to a 5 mL solution of 4-[[2-(1-tert-butoxycarbonylpyrazole-4-yl)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester (150.0 mg, 0.290 mmol). The mixture was stirred at 20 °C for 15 h. The mixture was concentrated under vacuum and then lyophilized to give the title compound as a pale yellow gel (149 mg, 0.280 mmol, yield 85.1%). MS (ESI): m / z = 310.0 [M+H] + .

[1106] Step a) 4-[[2-(1-tert-butoxycarbonylpyrazole-4-yl)-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester

[1107] A solution of tert-butyl piperidine-1-carboxylate (600 mg, 1.43 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3-dioxolane-2-yl)pyrazole-1-carboxylate (846 mg, 2.86 mmol), and K₂CO₃ (592 mg, 4.28 mmol) in DMF (10 mL) and H₂O (0.5 mL) was stirred at 80 °C for 12 h. The mixture was poured into H₂O (30 mL) and extracted twice with EtOAc (50 mL each time). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum to give a pale yellow oily compound (520 mg, 1.02 mmol, yield 71.8%). MS (ESI): m / z = 308.1 [M+H] + .

[1108] Step b) 4-[[2-(1-tert-butoxycarbonylpyrazole-4-yl)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[1109] A mixture of 4-[[2-(1-tert-butoxycarbonylpyrazole-4-yl)-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (180 mg, 0.350 mmol) and wet Pd / C (18 mg) was stirred in EtOAc (10 mL) for 24 h at 30 °C under a H2 atmosphere (approximately 1520 mm Hg). The mixture was filtered and concentrated under vacuum to give a brown oily compound (150 mg, 0.290 mmol, 83%). MS (ESI): m / z = 354.1 [M - 56 - 100 + H] + .

[1110] BB18

[1111] 4-[2-(2-chlorophenyl)ethynyl]piperidine

[1112] To a suspension of 4-((2-chlorophenyl)ethynyl)piperidine-1-carboxylic acid tert-butyl ester (0.05 g, 0.156 mmol) in MeOH (3 mL), dioxane (0.391 mL, 1.56 mmol) in 4 M HCl was added, and the reaction mixture was stirred at room temperature for 2 h. The mixture was evaporated to dryness, and the residue was ground with diisopropyl ether, filtered off, and further dried under high vacuum to give the title compound as a white solid consisting of hydrochloride (0.02 g, 50%). MS (ESI): m / z = 220.1 [M+H] + .

[1113] Step a) 4-[2-(2-chlorophenyl)ethynyl]piperidine-1-carboxylic acid tert-butyl ester

[1114] In a sealed tube under argon atmosphere, tert-butyl 4-ethynylpiperidin-1-carboxylate (0.1 g, 0.478 mmol, CAS RN287192-97-6), 1-bromo-2-chlorobenzene (0.084 mL, 0.717 mmol), cuprous iodide (I) (0.002 g, 0.009 mmol), TEA (0.666 mL, 4.78 mmol), and bis(triphenylphosphine)palladium(II) chloride (0.027 g, 0.038 g) were degassed in THF (2.8 mL) for 5 min. The reaction mixture was then heated to 70 °C and stirred for 4 h. The mixture was filtered through a diatomaceous earth filter, washed with EtOAc, and the mother liquor was evaporated to dryness. The residue was purified by rapid silica gel chromatography, eluting with a gradient of 0–50% EtOAc / n-heptane, to give the title compound as a white solid (0.05 g, 33%). MS(ESI): m / z = 264.1 [M-56+H] + .

[1115] BB48a

[1116] 4-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[1117] The degassed tert-butyl 4-methylenepiperidin-1-carboxylate (4465 mg, 22.6 mmol, CAS RN159635-49-1) solution in 9-BBN (45.3 mL, 22.6 mmol) was refluxed for 1 h. After cooling to room temperature, the solution was added to a solution of 4-bromo-3-trifluorotoluene (5.0 g, 20.6 mmol, CAS RN 40161-54-4), Pd(dppf)Cl2 (1514 mg, 2.06 mmol), and K2CO3 (5687 mg, 41.1 mmol) in DMF (50 mL) and water (5 mL). The resulting mixture was heated at 80 °C for 5 h. After cooling to room temperature and pouring into water, the pH was adjusted to 11 with 10% NaOH aqueous solution, and then the mixture was extracted with EtOAc. The combined organic extracts were dried over brine and Na₂SO₄, filtered, and evaporated to obtain a residue, which was further purified by column chromatography (silica gel, PE:EtOAc = 10:1 to 5:1) to give a pale yellow solid compound (240 mg, 3.2%). MS (ESI): m / z = 306 [M + H - 56] + .

[1118] BB51a

[1119] A solution of 20 mL of EtOAc containing 1000 mg (2.62 mmol) of 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (1000 mg, 2.62 mmol) and PtO2 (100 mg, 0.440 mmol) was stirred at 20 °C for 12 h under a H2 atmosphere (1520 mmHg). The mixture was filtered, and the filtrate was concentrated to provide a pale yellow solid compound (940 mg, 93.5%). MS (ESI): m / z = 328.2 [M+H] + .

[1120] Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene

[1121] A mixture of 2-bromo-1-methyl-4-(trifluoromethyl)benzene (5.5 g, 23.0 mmol, CAS RN 128-08-5), benzoyl peroxide (835 mg, 3.45 mmol), and NBS (4.07 g, 23.01 mmol) was stirred in CCl4 (50.0 mL, 23.0 mmol) for 5 h at 70 °C. The mixture was poured into water (20 mL) and extracted twice with DCM (20 mL each time). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give the desired compound as a pale yellow oil, which was used directly for the next step without further purification (7.1 g, 97%).

[1122] Step b) 2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene

[1123] A mixture of 2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (7.1 g, 22.3 mmol) and triethyl phosphite (30 mL) was stirred at 155 °C for 5 h. The mixture was concentrated under vacuum to remove triethyl phosphite, and the residue was diluted with water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography (PE:EtOAc = 100:1 to 10:1) to give a pale yellow oily compound, which was used directly in the next step without further purification (8 g, 95.5%).

[1124] Step c) 4-(2-bromo-4-(trifluoromethyl)benzylmethyl)piperidine-1-carboxylic acid tert-butyl ester

[1125] Sodium hydride (2.21 g, 55.2 mmol) was added to a THF (100 mL) solution of 2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene (6.9 g, 18.4 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h, then 1-Boc-4-piperidinone (7.33 g, 36.79 mmol, CAS RN 79099-07-3) was added, and the mixture was stirred at 20 °C for 12 h. The mixture was poured into water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by column chromatography (PE:EA = 100:1 to 50:1) to give the desired compound as a grayish-white solid (4 g, 51.7%). MS(ESI): m / z = 365.9 [M-56+H] + .

[1126] Step d)-4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester

[1127] A mixture of tert-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidin-1-carboxylic acid (2.0 g, 4.76 mmol), cyclopropylboronic acid (818 mg, 9.52 mmol, CAS RN 411235-57-9), and potassium carbonate (1973 mg, 14.3 mmol) was stirred for 12 h in DMF (10 mL) and water (0.5 mL) at 80 °C under a nitrogen atmosphere. The mixture was poured into water (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by preparative HPLC to give a pale yellow oily compound (1020 mg, yield 56.2%). MS (ESI): m / z = 326.0 [M⁻⁶⁺H] + .

[1128] BB53a

[1129] 3-[(4-chlorophenyl)methoxy]pyrrolidine-1-carboxylic acid tert-butyl ester

[1130] Potassium carbonate (1.48 g, 10.68 mmol) was added to a solution of N-Boc-3-hydroxypyrrolidine (1.0 g, 5.34 mmol) and 4-chlorobenzyl bromide (1.32 g, 6.41 mmol) in ACN (10 mL). The mixture was stirred at 80 °C for 15 h. The mixture was then concentrated, diluted with water, and extracted three times with EtOAc (10 mL each). The combined organic layers were concentrated to give the desired compound as a colorless oil (326 mg, yield 19.6%). MS (ESI): m / z = 256.0 [M-56+H] + .

[1131] Method D4

[1132] BB70

[1133] 3-[4-(trifluoromethyl)phenoxy]azacyclobutane

[1134] TFA (1.0 mL, 0.950 mmol) was added to a DCM (3 mL) solution of tert-butyl 3-[4-(trifluoromethyl)phenoxy]azacyclobutane-1-carboxylic acid (500 mg, 1.58 mmol, BB70a), and the reaction mixture was stirred at 25 °C for 12 h. The mixture was concentrated, and the residue was purified by preparative HPLC to provide a colorless solid compound (150 mg, 0.690 mmol, 43.8%). MS (ESI): m / z = 218.1 [M+H] + .

[1135] BB72a

[1136] 4-(4-chloro-3-cyclopropyl-phenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1137] To a solution of tert-butyl 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylic acid (500 mg, 1.28 mmol, BB90), potassium carbonate (354 mg, 2.56 mmol), and cyclopropylboronic acid (121 mg, 1.41 mmol) in 1,4-dioxane (5 mL) and water (1 mL), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (187.28 mg, 0.260 mmol) was added. The mixture was stirred at 100 °C for 12 h under a nitrogen atmosphere. The reaction mixture was filtered, and the filtrate was diluted with EtOAc (30 mL), washed successively with water and brine, and the organic phase was dried over Na₂SO₄ and then concentrated. The residue was purified by silica gel column chromatography (eluting with a gradient of 5%–10% EtOAc-PE) to give a pale yellow oily compound (220 mg, 48.9%). MS(ESI): m / z = 296.1 [M-56+H]+ .

[1138] BB73a

[1139] 4-(4-chloro-3-morpholino-phenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1140] Tris(dibenzylacetone)dipalladium(O) (187 mg, 0.260 mmol) was added to a DMF (10 mL) solution of 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylic acid tert-butyl ester (500 mg, 1.28 mmol, BB90), cesium carbonate (834 mg, 2.56 mmol), (R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-bidinaphthalene (159 mg, 0.260 mmol), and morpholine (112 mg, 1.28 mmol). The mixture was stirred at 110 °C for 12 h under a nitrogen atmosphere. The reaction mixture was filtered, the filtrate was diluted with EtOAc (30 mL), washed successively with water and brine, the organic phase was dried over Na2SO4, and then concentrated. The residue was purified by silica gel column chromatography (eluting with a 5%–10% EtOAc-PE gradient) to give the desired compound (360 mg, yield 70.9%) as a pale yellow oil. MS (ESI): m / z = 397.1 [M+H] + .

[1141] BB74a

[1142] 4-[2-methyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1143] Methyllithium (11.8 mL, 18.9 mmol) was added dropwise to a THF (40 mL) solution of 2.0 g (4.71 mmol, BB74b) of 4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (BB74b) at -70 °C. The mixture was stirred at -70 °C for 1 h, and then at 20 °C for 12 h. The mixture was poured into ice water (100 mL) and extracted three times (50 mL each) with EtOAc. The combined organic layers were washed with brine (100 mL), dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum to give a pale yellow solid compound (780 mg, 46%). MS (ESI): m / z = 260.1 [M-100+H] + .

[1144] BB75a

[1145] 4-[2-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1146] At 20 °C, dppf (627 mg, 1.13 mmol), N,N-diisopropylethylamine (1.97 mL, 11.3 mmol), zinc powder (245 mg, 3.77 mmol), and Pd2(dba)3 (1036 mg, 1.13 mmol) were added to a DMA (30 mL) solution of zinc cyanide (2214 mg, 18.9 mmol) and 4-[2-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (1600 mg, 3.77 mmol, BB74b). The mixture was then stirred at 140 °C for 4 h under a nitrogen atmosphere. The mixture was filtered. The filtrate was poured into water (100 mL) and extracted three times with EtOAc (50 mL each time). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum to give the title compound as a light brown solid (2.3 g, crude product). MS (ESI): m / z = 315.0 [M-56+H] + .

[1147] BB76a

[1148] 4-(oxazolo[5,4-c]pyridin-2-ylmethyl)piperidin-1-carboxylic acid tert-butyl ester

[1149] Triphenylphosphine (3.28 g, 12.5 mmol) and NEt3 (4.65 mL, 33.4 mmol) were added to a solution of hexachloroethane (2.47 g, 10.4 mmol) in toluene (20 mL). The mixture was stirred at 80 °C for 5 min, and then 4-[2-[(3-hydroxy-4-pyridinyl)amino]-2-oxo-ethyl]piperidine-1-carboxylic acid tert-butyl ester (1.4 g, 4.17 mmol) was added and stirred at 80 °C for 12 h. The mixture was concentrated to remove toluene, then diluted with water (100 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and then concentrated. The crude product was purified by silica gel chromatography (PE:EtOAc = 10:1 to 1:0) to give a yellow oily compound (814 mg, yield 21%). MS(ESI): m / z = 318.1 [M+H] + .

[1150] Step a) 4-[2-[(3-hydroxy-4-pyridyl)amino]-2-oxo-ethyl]piperidine-1-carboxylic acid tert-butyl ester

[1151] To a DMF (30 mL) solution of 4-aminopyridin-3-ol (3.0 g, 27.3 mmol) and 1-Boc-4-piperidinylacetic acid (7.95 g, 32.7 mmol), HOBt (6.26 g, 40.9 mmol), EDCI (6.34 g, 40.87 mmol), and NEt3 (11.39 mL, 81.74 mmol) were added. The mixture was stirred at 20 °C for 15 h. The mixture was then concentrated, and the residue was dissolved in water (100 mL) and extracted three times with EtOAc (20 mL each). The organic layer was washed with brine, dried over Na2SO4, and then concentrated. The residue was purified by reversed-phase chromatography and lyophilized to obtain two batches of the desired compound. Batch 1 was a colorless solid (1.2 g, purity 85%, 11.1%), and batch 2 was a colorless solid (520 mg, purity 76.7%, yield 4.4%). For both batches, MS (ESI): m / z = 336.1 [M+H] + .

[1152] BB77

[1153] 4-Chloro-3-(2-piperidin-4-ylethynyl)pyridine

[1154] Intermediate BB77 was prepared using a method similar to BB18, but with the use of 3-bromo-4-chloro-pyridine in step a) to give the title compound, which is an orange solid. MS (ESI): m / z = 221.1 [M+H] + .

[1155] BB78

[1156] 3-Chloro-2-(2-piperidin-4-ylethynyl)pyridine

[1157] Intermediate BB78 was prepared similarly to BB18, but with the use of 2-bromo-3-chloro-pyridine in step a) to give the title compound, a yellow solid. MS (ESI): m / z = 221.1 [M+H] + .

[1158] BB79

[1159] 4-[2-(2-chloro-4-fluorophenyl)ethynyl]piperidine

[1160] Intermediate BB79 was prepared similarly to BB18, but with the use of 1-bromo-2-chloro-4-fluorobenzene in step a) to give the title compound, a white solid. MS (ESI): m / z = 238.1 [M+H] + .

[1161] BB80

[1162] 4-[2-(3-chlorophenyl)ethynyl]piperidine

[1163] Intermediate BB80 was prepared similarly to BB18, but with the use of 1-bromo-3-chlorobenzene in step a) to give the title compound, a colorless amorphous solid. MS (ESI): m / z = 220.2 [M+H] + .

[1164] BB81

[1165] 4-[2-(4-chlorophenyl)ethynyl]piperidine

[1166] Intermediate BB81 was prepared similarly to BB18, but with the use of 1-bromo-4-chlorobenzene in step a) to give the title compound, a yellow amorphous solid. MS (ESI): m / z = 220.2 [M+H] + .

[1167] BB82

[1168] 4-[2-(2-chloro-4-chlorophenyl)ethynyl]piperidine

[1169] Intermediate BB82 was prepared similarly to BB18, but with the use of 1-bromo-2,4-dichlorobenzene in step a) to give the title compound, a pale yellow amorphous solid. MS (ESI): m / z = 254.1 [M+H] + .

[1170] BB83

[1171] 4-[2-(2-chlorophenyl)ethynyl]piperidin-4-ol

[1172] Intermediate BB83 was prepared similarly to BB18, but with the use of tert-butyl 4-ethynyl-4-hydroxypiperidine-1-carboxylic acid (CAS RN 275387-83-2) in step a) to obtain the title compound, which is a yellow amorphous solid. MS (ESI): m / z = 218.1 [M-H2O+H] + .

[1173] BB84

[1174] 3-[2-(2-chlorophenyl)ethynyl]azacyclobutane

[1175] TFA (0.9-2.4 mL, 1.2 mmol) was added to a DCM (0.6 mL) solution of 3-[2-(2-chlorophenyl)ethynyl]azacyclobutane-1-carboxylic acid tert-butyl ester (0.035 g, 0.120 mmol), and the reaction mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM, poured into a saturated aqueous solution of NaHCO3, and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, evaporated, and further dried under high vacuum to give the crude title compound (0.02 g, 87%) as a pale yellow oil. MS (ESI): m / z = 192.0 [M+H] + .

[1176] Step a) 3-[2-(2-chlorophenyl)ethynyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1177] This compound was prepared using a method similar to that for intermediate BB18, but with the use of tert-butyl 3-ethynylazetane-1-carboxylate (CAS RN 287193-01-5) in step a) to give the title compound, which is a white solid. MS (ESI): m / z = 236.1 [M-56+H] + .

[1178] BB85

[1179] 3-[2-(2,4-dichlorophenyl)ethynyl]azacyclobutane

[1180] Intermediate BB85 was prepared in a manner similar to that of intermediate BB84, but with the use of 1-bromo-2,4-dichlorobenzene in step a) to obtain the title compound, which is a pale yellow oil. MS (ESI): m / z = 226.1 [M+H] + .

[1181] BB86

[1182] 3-[2-(2-chloro-4-fluoro-phenyl)ethynyl]azacyclobutane

[1183] Intermediate BB86 was prepared in a similar manner to intermediate BB84, but with the use of 1-bromo-2-chloro-4-fluorobenzene in step a) to obtain the title compound, which is a yellow oil. MS (ESI): m / z = 210.1 [M+H] + .

[1184] Similar to BB9a, the following components are made from the corresponding components.

[1185]

[1186] Similar to BB15a, the following components are made from the corresponding components.

[1187]

[1188] Similar to step a of BB9, the following components are prepared from the corresponding starting materials.

[1189]

[1190]

[1191] Method D5

[1192] BB51

[1193] 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidinecarboxylate

[1194] TFA (2.0 mL, 2.45 mmol) was added to a DCM (10 mL) solution of tert-butyl piperidine-1-carboxylate (940 mg, 2.45 mmol, BB51a). The reaction mixture was stirred at 20 °C for 12 h. The mixture was concentrated under vacuum. The residue was purified twice by preparative HPLC to provide the desired compound as a pale yellow gel (111 mg, 12.4%). MS (ESI): m / z = 284.2 [M+H] + .

[1195] Step a) 2-Bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene

[1196] A mixture of 2-bromo-1-methyl-4-(trifluoromethyl)benzene (5.5 g, 23.0 mmol, CAS RN 128-08-5), benzoyl peroxide (835 mg, 3.45 mmol), and NBS (4.07 g, 23.0 mmol) was stirred in CCl4 (50.0 mL, 23.0 mmol) for 5 h at 70 °C. The mixture was poured into water (20 mL) and extracted twice with DCM (20 mL each time). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated under vacuum to give a pale yellow oily compound (7.1 g, 97%), which was used directly in the next step without further purification.

[1197] Step b) 2-Bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene

[1198] A mixture of 2-bromo-1-(bromomethyl)-4-(trifluoromethyl)benzene (7.1 g, 22.3 mmol) and triethyl phosphite (30.0 mL) was stirred at 155 °C for 5 h. The mixture was concentrated under vacuum to remove triethyl phosphite. The residue was diluted with water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated. The residue was purified by column chromatography (PE:EA = 100:1 to 10:1) to give the title compound as a pale yellow oil (8 g, 21.3 mmol, 95.5%), which was used directly in subsequent steps without further purification.

[1199] Step c) 4-(2-bromo-4-(trifluoromethyl)benzylmethyl)piperidine-1-carboxylic acid tert-butyl ester

[1200] To a mixture of 2-bromo-1-(diethoxyphosphorylmethyl)-4-(trifluoromethyl)benzene (6.9 g, 18.4 mmol) and THF (100 mL), 2.21 g (55.2 mmol) of NaH (0 °C) was added. The mixture was stirred at 0 °C for 1 h, then 1-Boc-4-piperidinone (7.33 g, 36.8 mmol, CAS RN 79099-07-3) was added, and the mixture was stirred at 20 °C for 12 h. The mixture was poured into water (100 mL) and extracted three times with EtOAc (100 mL each). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by column chromatography (PE:EA = 100:1 to 50:1) to give the desired compound as a grayish-white solid (4 g, 9.52 mmol, 51.7%). MS(ESI): m / z = 365.9 [M-56+H] + .

[1201] Step d) 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester

[1202] A mixture of tert-butyl 4-[[2-bromo-4-(trifluoromethyl)phenyl]methylene]piperidin-1-carboxylic acid (2.0 g, 4.76 mmol), cyclopropylboronic acid (818 mg, 9.52 mmol, CAS RN 411235-57-9), and potassium carbonate (1973 mg, 14.3 mmol) was stirred for 12 h in DMF (10 mL) and water (0.5 mL) at 80 °C under a nitrogen atmosphere. The mixture was poured into water (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, and concentrated under vacuum. The residue was purified by preparative HPLC to give a pale yellow oily compound (1020 mg, yield 56.2%). MS (ESI): m / z = 326.0 [M-56+H] + .

[1203] Step e) 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[1204] A mixture of 4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (1000 mg, 2.62 mmol) and PtO2 (100 mg, 0.440 mmol) was stirred in EtOAc (20 mL) for 12 h at 20 °C under a hydrogen atmosphere (1520 mm Hg). The mixture was then filtered, and the filtrate was concentrated to give a pale yellow solid compound (940 mg, yield 93.5%). MS (ESI): m / z = 328.2 [M+H] + .

[1205] Method D6

[1206] BB92

[1207] N-Methyl-N-[4-(trifluoromethyl)phenyl]piperidine-4-amine; trifluoroacetate

[1208] TFA (0.1 mL) was added to a DCM (1 mL) solution of 150 mg (0.420 mmol) of 4-[N-methyl-4-(trifluoromethyl)aniline]piperidine-1-carboxylic acid tert-butyl ester (DCM) at 0 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under vacuum. The residue was purified by preparative HPLC (in the presence of TFA) to obtain the desired product as a yellow solid (120 mg, 77.0%). MS (ESI): m / z = 259.2 [M+H] + .

[1209] Step a) 4-[4-(trifluoromethyl)aniline]piperidine-1-carboxylic acid tert-butyl ester

[1210] To a DCM (30 mL) solution of p-trifluoromethylaniline (1.17 mL, 9.31 mmol, CAS RN 455-14-1), AcOH (0.560 g, 9.31 mmol) and 1-BOC-4-piperidinone (2.78 g, 14.0 mmol, CAS RN 79099-07-3) were added. Then, under a nitrogen atmosphere at 0 °C, a 1 M BH3 / THF solution (27.9 mL, 27.9 mmol) was carefully added. The reaction mixture was stirred at 25 °C for 12 h. The mixture was poured into a saturated NH4Cl aqueous solution (30 mL) and extracted three times with EtOAc. The combined organic layers were washed twice successively with H₂O and brine, dried over Na₂SO₄, and concentrated under vacuum to obtain a yellow residue. This residue was purified by silica gel column chromatography (eluting with a PE:EtOAc gradient of 20:1 to 5:1) to obtain the desired product as a white solid (2.0 g, 62.4%). MS (ESI): m / z = 289.1 [M⁻⁶⁺H] + .

[1211] Step b) 4-[N-methyl-4-(trifluoromethyl)aniline]piperidine-1-carboxylic acid tert-butyl ester

[1212] Under a nitrogen atmosphere at 0 °C, tert-butyl 4-[4-(trifluoromethyl)aniline]piperidine-1-carboxylic acid was added to a solution of NaH (52.3 mg, 60.0% wt%, 1.31 mmol) in DMF (5 mL). The mixture was stirred at 0 °C for 15 min, and then methyl iodoform (371 mg, 2.61 mmol) was added. The reaction mixture was stirred at 80 °C for 12 h. The reaction mixture was poured into water (20 mL) and extracted three times with EtOAc. The combined organic layers were washed twice with water and brine, dried over sodium sulfate, and concentrated under vacuum to give a pale yellow residue, which was purified by silica gel column chromatography (eluting with a PE:EtOAc gradient of 20:1 to 5:1) to give the desired product as a white solid (160 mg, 51.3%). MS (ESI): m / z = 303.1 [M-56+H] + .

[1213] BB93

[1214] N-Methyl-N-(4-(trifluoromethyl)phenyl)azacyclobutane-3-amine (trifluoroacetate)

[1215] The title compound was prepared by a method similar to D6 from tert-butyl 3-[N-methyl-4-(trifluoromethyl)aniline]azacyclobutane-1-carboxylic acid (48%). MS (ESI): m / z = 231.1 [M+H] + .

[1216] Step a) 3-[4-(trifluoromethyl)aniline]azacyclobutane-1-carboxylic acid tert-butyl ester

[1217] At 25°C, NaBH3CN (1.95 g, 31.0 mmol) was added to a solution of p-trifluoromethylaniline (0.780 mL, 6.21 mmol, CAS RN 455-14-1), AcOH (1.86 g, 31.0 mmol), and 1-BOC-3-azacyclobutanone (2.13 g, 12.4 mmol, CAS RN 398489-26-4) in EtOH (10 mL). The mixture was stirred at 25°C for 12 h. The reaction mixture was then poured into a saturated aqueous solution of NH4Cl (20 mL) and extracted twice with EtOAc. The combined organic layers were washed twice with H₂O and brine, dried over sodium sulfate, and concentrated under vacuum to give a yellow residue, which was purified by silica gel column chromatography (eluting with a gradient of PE:EtOAc (10:1 to 5:1)) to give the desired product as a white solid (340 mg, 17.3%). MS (ESI): m / z = 261.1 [M⁻⁶ + H⁺] + .

[1218] Step b) 3-[N-methyl-4-(trifluoromethyl)aniline]azacyclobutane-1-carboxylic acid tert-butyl ester

[1219] To a DMF (5 mL) solution of 3-[4-(trifluoromethyl)anilino]azacyclobutane-1-carboxylic acid tert-butyl ester (300 mg, 0.950 mmol), 0 °C NaH (45.5 mg, 60% wt%, 1.14 mmol) was added. The mixture was stirred for 15 min, and then iodomethane (404 mg, 2.85 mmol) was added. The reaction mixture was stirred at 25 °C for 12 h. The mixture was poured into H2O (20 mL) and extracted twice with EtOAc. The combined organic layers were washed three times with H2O and brine, dried over Na2SO4, and concentrated under vacuum to give a yellow residue. The residue was purified by silica gel column chromatography (eluting with a gradient of PE:EtOAc (10:1 to 5:1)) to give the desired product as a white solid (310 mg, 98.9%). MS (ESI): m / z = 275.2 [M-56+H] + .

[1220] Method D7

[1221] BB94

[1222] N-Methyl-N-(piperidin-4-yl)-2-(3-(trifluoromethyl)phenyl)acetamide hydrochloride

[1223] To a solution of tert-butyl 4-[methyl-[2-[3-(trifluoromethyl)phenyl]acetyl]amino]piperidine-1-carboxylic acid (0.080 g, 200 μmol) in DCM (1 mL), 999 μL (2 mmol) of diethyl ether solution of 2 M HCl was added. The reaction mixture was stirred overnight at room temperature and then concentrated under vacuum to give the title compound (67 mg, 199 μmol) as a grayish-white solid. MS (ESI): m / z = 301.2 [M+H] + .

[1224] Step a) 4-[methyl-[2-[3-(trifluoromethyl)phenyl]acetyl]amino]piperidine-1-carboxylic acid tert-butyl ester

[1225] HATU (195 mg, 513 μmol) and DIPEA (181 mg, 244 μL, 1.4 mmol) were added to a DMF (5 mL) solution of 2-(3-(trifluoromethyl)phenyl)acetic acid (105 mg, 513 μmol, CAS RN 351-35-9) under constant stirring. After stirring for 15 min, tert-butyl 4-(methylamino)piperidin-1-carboxylic acid (0.100 g, 467 μmol, CAS RN 147539-41-1) was added, and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was washed with DCM and then with H2O. The organic phase was concentrated to give a crude product, which was purified by rapid chromatography on a 20 g SiO2 column (using an elution mixture of n-heptane and EtOAc (0% to 100%)) to give the desired compound as a pale yellow oil (85 mg, 213 μmol). MS(ESI): m / z=459.259[M+CH3CN+NH4] + .

[1226] Method D8

[1227] BB194

[1228] 3-(4-chloro-3-cyclopropylphenoxy)azacyclobutane

[1229] TFA (0.088 mL, 1.14 mmol) was added to a DCM (1 mL) solution of 0.023 g (0.057 mmol) of tert-butyl 3-(4-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carboxylic acid, and the reaction mixture was stirred at room temperature for 18 hours. The mixture was diluted with DCM, poured into a saturated aqueous solution of NaHCO3, and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and evaporated to dryness to give the crude title compound (0.007 g, 35%) as a colorless oil. MS (ESI): m / z = 224.1 [M+H] + .

[1230] Step a) 3-(3-bromo-4-chlorophenoxy)azacyclobutane-1-carboxylic acid tert-butyl ester

[1231] In a sealed tube, 3-bromo-4-chlorophenol (0.1 mg, 0.482 mmol) and tert-butyl 3-hydroxyazacyclobutane-1-carboxylic acid (0.083 g, 0.482 mmol) were dissolved in toluene (1.5 mL). The sample vial was degassed with argon, and then cyanomethylenetri-n-butylphosphine (CAS RN 157141-27-0, 0.195 mL, 0.723 mmol) was added. The reaction mixture was heated at 100 °C for 30 minutes. The mixture was diluted with EtOAc, poured into a saturated aqueous solution of NaHCO3, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by rapid silica gel chromatography, eluting with a 0–20% EtOAc / heptane gradient to give the title compound (0.116 g, 53%) as a yellow oil. MS (ESI): m / z = 308.1 [M-56+H] + .

[1232] Step b) 3-(4-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carboxylic acid tert-butyl ester

[1233] In a microwave-safe vial, tert-butyl 3-(3-bromo-4-chlorophenoxy)azacyclobutane-1-carboxylic acid (0.075 g, 0.165 mmol), cyclopropylboronic acid (0.021 g, 0.248 mmol), and K₂CO₃ (0.046 g, 0.331 mmol) were mixed in dioxane (1.6 mL). Water (0.4 mL) and bis(triphenylphosphine)palladium(II) chloride (0.012 g, 0.016 mmol) were then added sequentially, and the reaction mixture was heated at 130 °C for 1 hour under microwave irradiation. The reaction mixture was diluted with EtOAc, poured into water, and extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by rapid silica gel chromatography, eluting with a 0–10% EtOAc / heptane gradient to give the title compound (0.023 g, 43%) as a colorless oil. MS (ESI): m / z = 268.2 [M-56+H] + .

[1234] Method D9

[1235] BB197

[1236] 3-(2-chloro-3-cyclopropylphenoxy)azacyclobutane, trifluoroacetate

[1237] TFA (0.25 mL) was added to a 2.5 mL solution of 0.1 g (0.310 mmol) of tert-butyl 3-(2-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carboxylic acid in DCM, and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated under vacuum to give the crude title compound (0.083 g, 80% yield) as a dark brown oil. MS (ESI): m / z = 224.6 [M+H] + .

[1238] Step a) 3-(3-bromo-2-chloro-phenoxy)azacyclobutane-1-carboxylic acid tert-butyl ester

[1239] To a THF (10 mL) solution of tert-butyl 3-hydroxyazacyclobutane-1-carboxylate (0.5 g, 2.89 mmol) and 3-bromo-2-chlorophenol (0.5 g, 2.41 mmol), PPh3 (0.948 g, 3.62 mmol) and diethyl azodicarboxylate (0.47 mL, 3.62 mmol) were added sequentially, and the reaction mixture was stirred at room temperature for 12 hours. The mixture was purified by reversed-phase HPLC to give the title product (0.4 g, 46%) as a pale yellow oil. MS (ESI): m / z = 308.3 [M-56+H] + .

[1240] Step b) 3-(2-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carboxylic acid tert-butyl ester

[1241] In a sealed tube, cyclopropylboronic acid (0.071 g, 0.830 mmol), tert-butyl 3-(3-bromo-2-chloro-phenoxy)azacyclobutane-1-carboxylic acid (0.2 g, 0.550 mmol), and Na₂CO₃ (0.117 g, 1.1 mmol) were mixed in 1,4-dioxane (5 mL) and water (1 mL). Pd(dppf)Cl₂ (0.040 g, 0.060 mmol) was then added, and the mixture was stirred at 110 °C for 12 hours. The mixture was purified by reversed-phase HPLC to give the title compound (0.12 g, 67%) as a pale yellow oil. MS (ESI): m / z = 268.1 [M-56+H] + .

[1242] Method D10

[1243] BB202

[1244] 5-(4-piperidinoxy)-2-(trifluoromethyl)benzonitrile, trifluoroacetate

[1245] TFA (0.2 mL) was added to a DCM (1.5 mL) solution of 0.05 g (0.140 mmol) of tert-butyl piperidine-1-carboxylic acid, and the reaction mixture was stirred at room temperature for 12 hours. The mixture was concentrated under vacuum to give crude title compound (0.051 g, 98%) as a light brown oil. MS (ESI): m / z = 271.6 [M+H] + .

[1246] Step a) 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1247] To a solution of 3-bromo-4-(trifluoromethyl)phenol (0.5 g, 2.54 mmol) and 1-Boc-4-hydroxypiperidine (0.512 g, 2.54 mmol) in THF (8.5 mL), PPh3 (1 g, 3.82 mmol) and diethyl azodicarboxylate (0.665 g, 3.82 mmol) were added sequentially, and the reaction mixture was stirred at room temperature for 12 hours. The mixture was purified by rapid silica gel chromatography, eluting with PE:EtOAc 5:1, to give the title compound (0.5 g, 47%) as a pale yellow oil. MS (ESI): m / z = 370.2 [M-56+H] + .

[1248] Step b) 4-[3-cyano-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1249] In a sealed tube, tert-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid (0.2 g, 0.470 mmol), Zn(CN)₂ (0.111 g, 0.940 mmol), and CuI (0.09 g, 0.470 mmol) were mixed in DMF (10 mL). Then, Pd(PPh₃)₄ (0.109 g, 0.090 mmol) was added, and the reaction mixture was stirred at 130 °C for 16 hours. The mixture was purified by reversed-phase HPLC to give the title product (0.05 g, 29%) as a colorless oil. MS (ESI): m / z = 315.5 [M-56+H] + .

[1250] Method E

[1251] Example 263

[1252] (+)-5-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azacyclobutane-3-yl]oxy-2-(trifluoromethyl)benzonitrile

[1253]

[1254] In a sealed tube, (+)-(4aR,8aS)-6-[3-[3-bromo-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (BB 205, 0.2 g, 0.420 mmol), Zn(CN)2 (0.098 g, 0.840 mmol), Zn (0.027 g, 0.420 mmol), dppf (0.232 g, 0.420 mmol), and Hünig base (0.108 g, 0.840 mmol) were mixed in DMA (10 mL) and the mixture was degassed. Then Pd2(dba)3 (76.59 mg, 0.080 mmol) was added, and the reaction mixture was stirred at 130 °C for 16 h. The mixture was purified by reversed-phase HPLC to give the title compound (0.055 g, 30%) as a pale yellow solid. MS (ESI): m / z = 425.3 [M+H] + .

[1255] Method F

[1256] Example 265

[1257] (+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one

[1258]

[1259] In a sealed tube, (+)-(4aR,8aS)-6-[3-[3-bromo-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one (BB203, 0.2 g, 0.420 mmol), 2-azaspiro[3,3]heptane (CAS RN 665-04-03, 0.117 g, 0.630 mmol), BINAP (0.052 g, 0.080 mmol), and K2CO3 (0.173 g, 1.25 mmol) were mixed in DMF (10 mL) and the mixture was degassed. Then Pd2(dba)3 (76.59 mg, 0.080 mmol) was added, and the reaction mixture was stirred at 110 °C for 16 hours. The reaction mixture was filtered off, and the filtrate was diluted with water (50 mL) and then extracted with EtOAc (3 × 20 mL). The combined organic compounds were washed with brine, dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by reversed-phase HPLC to give the title compound (0.06 g, 29%) as a white solid. MS (ESI): m / z = 495.1 [M + H] + .

[1260] Method G

[1261] Example 293

[1262] (4aR,8aS)-6-(3-(4-hydroxy-2-(trifluoromethyl)phenethyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one

[1263]

[1264] Boron tribromide (11.3 mg, 4.29 μL, 45.3 μmol) was added to an ice-cold DCM (0.5 mL) solution of (4aR, 8aS)-6-(3-(4-methoxy-2-(trifluoromethyl)phenethyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one (Example 216, 20 mg, 45.3 μmol). The reaction mixture was stirred at room temperature for 3 h. A saturated aqueous solution of NaHCO3 was added, and the mixture was extracted with AcOEt. The layers were separated, the organic layer was dried over Na2SO4, filtered, and the solvent was removed under reduced pressure. The crude product was purified by preparative HPLC to give the title compound (19%) as a colorless solid. MS (ESI): m / z = 427.2 [M+H] + .

[1265] The following examples listed in the table below were prepared by steps similar to those described for the preparation of Example 265, using the intermediates shown and / or commercially available compounds and the purification methods described above, such as reversed-phase HPLC or silica gel rapid chromatography.

[1266]

[1267]

[1268]

[1269]

[1270]

[1271] Similar to the methods described above, the following components are prepared from the corresponding starting materials shown in the table below.

[1272]

[1273]

[1274]

[1275] BB91

[1276] 4-[[2-pyrrolidone-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine; formate

[1277] 4-[[2-pyrrolidone-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester (500 mg, 1.21 mmol) was stirred for 1 h in 10.0 mL of 6 M HCl MeOH solution at 20 °C. The mixture was concentrated under vacuum and purified by reverse-phase column chromatography to give the title compound as an orange oil (84.4 mg, yield 21.8%). MS (ESI): m / z = 313.2 [M+H] + .

[1278] Step a) 4-[[2-pyrrolidone-1-yl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester

[1279] To a solution of tert-butyl piperidine-1-carboxylic acid (800 mg, 1.90 mmol; BB51, step c), pyrrolidine (163 mg, 2.28 mmol), Ruphos (4.25 mg, 0.010 mmol), and potassium tert-butoxide (320 mg, 2.86 mmol) in toluene (15 mL), palladium(II) acetate (1.28 mg, 0.010 mmol) was added. The mixture was stirred at 80 °C for 15 h under a nitrogen atmosphere. The mixture was filtered and concentrated under vacuum to remove toluene. The mixture was diluted with H2O (40 mL) and extracted three times with EtOAc (40 mL each). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography (PE / EtOAc = 1:0 to 8:1) to give a pale yellow oily compound (552 mg, 1.34 mmol, 36.7%). MS (ESI): m / z = 411.1 [M+H] + .

[1280] Step b) 4-[[2-pyrrolidone-1-yl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[1281] To a 20 mL MeOH methanol solution of 4-[[2-pyrrolidone-1-yl-4-(trifluoromethyl)phenyl]methylene]piperidine-1-carboxylic acid tert-butyl ester (525 mg, 0.660 mmol), wet Pd / C (approximately 52 mg) was added, and the mixture was stirred for 1 h at 20 °C under a H2 atmosphere (balloon). The mixture was filtered and concentrated under vacuum to give the desired colorless oily compound (500 mg), which was used directly for the next step without further purification.

[1282] BB95

[1283] 3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane 4-toluenesulfonate

[1284] To a solution of 3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carboxylic acid tert-butyl ester (50 mg, 144 μmol, Eq: 1) in EtOAc (0.8 mL), 4-toluenesulfonic acid monohydrate (29.7 mg, 173 μmol, Eq: 1.2) was added, and the mixture was heated under reflux for 1.5 hours. The clear, colorless solution was cooled to room temperature. No precipitation occurred. The solution was evaporated to give the desired product, which was a colorless foam. MS (ESI): m / z = 248.1 [M-TsOH+H]+.

[1285] Step a) 3-[(E)-2-[2-fluoro-6-(trifluoromethyl)phenyl]vinyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1286] To a chilled THF (2 mL) solution of (300 mg, 955 μmol) 2-fluoro-4-(trifluoromethyl)benzyl)phosphonate, sodium hydride (55%, dispersed in mineral oil) (41.7 mg, 955 μmol) was added, and the mixture was stirred at this temperature for 30 minutes. A THF (1 mL) solution of 177 mg, 955 μmol) 3-formylazetane-1-carboxylic acid tert-butyl ester was added dropwise to the light brown mixture. This caused an immediate color change in the reaction mixture. Stirring was continued for 1 hour at an ice bath temperature, followed by stirring at room temperature for 1.5 hours. The mixture was poured into water and ethyl acetate, and the layers were separated. The aqueous layer was extracted twice with ethyl acetate. The organic layer was washed once with brine, dried over MgSO4, filtered, treated with silica gel, and evaporated. The compound was purified by silica gel chromatography, wherein separation was performed on a 12 g column using an MPLC system and a mixture of n-heptane:ethyl acetate (100:0 to 25:75) was used to give the desired compound as a colorless solid (0.108 g; 32.8%). MS (ESI): m / z = 290.2 [M-56+H]+.

[1287] Step b) 3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1288] Pd / C 10% (11 mg, 304 μmol) was added to a solution of (E)-3-(2-fluoro-4-(trifluoromethyl)styryl)azacyclobutane-1-carboxylic acid tert-butyl ester (105 mg, 304 μmol) in MeOH (1 mL) and ethyl acetate (1 mL), and the mixture was stirred for 30 min under a nitrogen atmosphere (1.7 bar) at room temperature. The suspension was filtered. The filtrate was evaporated to give the desired compound as a colorless oil (0.104 g; 98.5%). MS (ESI): m / z = 292.2 [M-56+H]+.

[1289] BB96

[1290] 4-((2-chloro-4-fluorophenoxy)methyl)azacycloheptane hydrochloride

[1291] To a solution of tert-butyl 4-((2-chloro-4-fluorophenoxy)methyl)azacycloheptan-1-carboxylic acid (620 mg, 1.73 mmol) in DCM (7.5 mL), a solution of 2 M HCl in ether (10 mL, 20 mmol) was added, and the reaction mixture was stirred overnight at room temperature. The mixture was concentrated under vacuum, and the crude product was collected as a white solid (490 mg, 1.67 mmol, 96.1%) and used directly in the next step. LC-MS (ESI): m / z = 258.2 [M+H]+

[1292] Step a) 4-((2-chloro-4-fluorophenoxy)methyl)azacycloheptan-1-carboxylic acid tert-butyl ester

[1293] In a 25 mL four-necked sulfonated flask under argon atmosphere, 4-(hydroxymethyl)azacycloheptan-1-carboxylic acid tert-butyl ester (480 mg, 2.09 mmol) was dissolved in THF (10 mL). Subsequently, 2-chloro-4-fluorophenol (337 mg, 251 μL, 2.3 mmol) and triphenylphosphine (604 mg, 2.3 mmol) were added, and the clear solution was stirred at room temperature for 5 min. The mixture was cooled to 0 °C, and DEAD (401 mg, 365 μL, 2.3 mmol) was added in portions over 10 min. The mixture was stirred at 0 °C for 1 h, then stirred overnight at room temperature. The mixture was dissolved in EtOAc (50 mL), washed with water (2 × 25 mL), and the organic phase was washed with 1 M NaOH (3 × 25 mL) and water (20 mL), dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was dissolved in n-heptane / diethyl ether, and the mixture was stirred for 30 min. The TPPO precipitate was filtered, and the crude product was concentrated under vacuum. The crude product was adsorbed onto... The sample was purified by rapid column chromatography (0-30% EtOAc / heptane) on silica gel (50 g) to obtain the desired product (630 mg, 1.76 mmol, 84.1%), which was a yellow oil. LC-MS (ESI): m / z = 302.1 [M-56+H]+

[1294] BB97

[1295] 4-[[4-(trifluoromethyl)phenyl]methyl]azacycloheptane hydrochloride

[1296] To a DCM solution (1.5 mL) of 4-(4-(trifluoromethyl)benzyl)azacycloheptan-1-carboxylic acid tert-butyl ester (88 mg, 246 μmol, Eq: 1), a 2 M HCl ether solution (3.08 mL, 6.16 mmol) was added, and the reaction mixture was stirred overnight at room temperature. The mixture was concentrated under vacuum, and the crude product was collected as a white solid (71 mg, 0.24 mmol, 98.2%) and used directly in the next step. LC-MS (ESI): m / z = 258.2 [M+H]+

[1297] Step a: Triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide

[1298] Triphenylphosphine (1.84 g, 7 mmol) and 1-(bromomethyl)-4-(trifluoromethyl)benzene (1.61 g, 6.74 mmol) were dissolved in xylene (35 mL). The reaction mixture was heated under reflux at 155 °C for 3.5 h and then cooled to room temperature. The precipitate was collected by filtration as a white crystalline solid, washed with diethyl ether, and dried under vacuum. The final compound (3.30 g, 6.58 mmol, yield 97.7%) was given as a white powder and used directly in the next step. LC-MS (ESI): m / z = 421.2 [M+H]+

[1299] Step b: (E)-4-(4-(trifluoromethyl)benzyl)azacycloheptan-1-carboxylic acid tert-butyl ester

[1300] A DMF (7.5 mL) suspension of sodium hydride (88.6 mg, 2.22 mmol) was cooled in an ice bath, and then triphenyl(4-(trifluoromethyl)benzyl)phosphonium bromide (1.11 g, 2.22 mmol) was added. The suspension was stirred at 0 °C for 5 min, and then at room temperature for 25 min. 4-oxozylidene-1-carboxylic acid tert-butyl ester (315 mg, 1.48 mmol) was added, and the resulting mixture was stirred at 80 °C for 28 h. The mixture was concentrated under vacuum, diluted with water (50 mL) and EtOAc (40 mL), and extracted with EtOAc (3 × 30 mL). The combined organic fractions were washed with water and 10% LiCl solution, dried with Na₂SO₄, and concentrated under vacuum. The remaining oily substance was treated with Et₂O to form a triphenylphosphine oxide precipitate, which was then filtered off. The solution was concentrated under vacuum and purified by rapid column chromatography (0-35% EtOAc / heptane) on silica gel (50 g) to obtain the desired product (92 mg, 259 μmol, yield 17.5%), which was a yellow oil. LC-MS (ESI): m / z = 300.2 [M-56+H]+

[1301] Step c: 4-(4-(trifluoromethyl)benzyl)azacycloheptan-1-carboxylic acid tert-butyl ester

[1302] A solution of (E)-4-(4-(trifluoromethyl)benzyl)azacycloheptan-1-carboxylic acid tert-butyl ester (90 mg, 253 μmol) was dissolved in MeOH (2.5 mL). The reaction vessel was evacuated and backfilled with argon five times. Pd-C (13.5 mg, 12.7 μmol) was added under argon atmosphere, and the atmosphere was replaced with hydrogen three times. The reaction mixture was stirred for 24 h under a hydrogen atmosphere (1 bar). The atmosphere was replaced with argon, and the reaction mixture was filtered through a diatomaceous earth pad. The filter cake was washed with methanol. The filtrate was concentrated under vacuum to give the desired product (89 mg, 249 μmol, yield 98.3%), which was a colorless oil and used directly without further purification. LC-MS (ESI): m / z = 302.2 [M-56+H]+

[1303] BB98

[1304] 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azacyclobutane 2,2,2-trifluoroacetate

[1305] 110 mg (299 μmol) of 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester was dissolved in DCM (2 mL), and TFA (273 mg, 184 μL, 2.39 mmol) was added. The reaction mixture was stirred at room temperature for 3 h. Volatile substances were removed under vacuum to give 110 mg of a pale yellow solid (96%). MS (ESI): m / z = 268.1 [M+H] + .

[1306] Step a) 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester

[1307] In a 20 mL glass tube, a 1 M potassium tert-butoxide solution (2.17 mL, 2.17 mmol) in THF was added to an anhydrous THF solution of 2-chloro-4-(trifluoromethyl)benzylthiol (440 mg, 2.07 mmol) in 6 mL of THF. The yellow reaction mixture was stirred at room temperature for 15 min, and then tert-butyl 3-bromoazacyclobutane-1-carboxylic acid (489 mg, 2.07 mmol) was added. The reaction mixture was then stirred at room temperature for 5 h and then overnight at 70 °C. The crude reaction product was diluted with EtOAc and extracted with H2O, the organic phase was collected, and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na2SO4 and evaporated to dryness. The residue was purified by chromatography (SiO2, n-heptane / EtOAc (0-40%) over 40 min) to give the product, which was a viscous oil (467 mg, 61%). MS(ESI): m / z = 312.1 [M-56] + .

[1308] BB99

[1309] 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azacyclobutane 2,2,2-trifluoroacetate

[1310] 100 mg (250 μmol) of tert-butyl 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azacyclobutane-1-carboxylic acid was dissolved in DCM, and TFA (228 mg, 154 μL, 2 mmol) was added. The reaction mixture was stirred at room temperature for 8 h. Volatile substances were removed under vacuum to give the desired compound as a pale yellow solid (102 mg, 98%). MS (ESI): m / z = 300.0 [M+H] + .

[1311] Step a) 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester

[1312] In a 20 mL glass tube, a 1 M potassium tert-butoxide solution (2.17 mL, 2.17 mmol) in THF was added to an anhydrous THF solution of 2-chloro-4-(trifluoromethyl)benzylthiol (440 mg, 2.07 mmol) in 6 mL of THF. The yellow reaction mixture was stirred at room temperature for 15 min, followed by the addition of tert-butyl 3-bromoazacyclobutane-1-carboxylic acid (489 mg, 2.07 mmol). The reaction mixture was then stirred at room temperature for 5 h and then overnight at 70 °C. The crude reaction product was diluted with EtOAc and extracted with H2O, the organic phase was collected, and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na2SO4 and evaporated to dryness. The residue was purified by column chromatography (SiO2, n-heptane / EtOAc (0-40%) over 40 min) to obtain the desired product, which was a viscous oil (467 mg, 61%). MS(ESI): m / z = 312.1 [M-56+H] + .

[1313] Step b) 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[1314] In an ice bath, one part of mCPBA (347 mg, 1.41 mmol) was added to a continuously stirred solution of 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester (345 mg, 938 μmol) in DCM (6 mL). The reaction mixture was stirred at room temperature for 20 min. The mixture was poured into 5 mL of saturated Na₂CO₃ solution and extracted twice with DCM (20 mL each time). The organic layers were mixed, washed with brine, dried with Na₂SO₄, and then concentrated under vacuum. The crude product (YMC-Triart C18, ACN / H₂O + 0.1% HCOOH) was purified by preparative HPLC to provide the product as a white powder (253 mg, 67.5%). MS (ESI): m / z = 344.0 [M-56+H] + .

[1315] BB100

[1316] 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azacyclobutane 2,2,2-trifluoroacetate

[1317] 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azacyclobutane-1-carboxylic acid tert-butyl ester (50 mg, 130 μmol) was dissolved in DCM (1.5 mL), and TFA (149 mg, 100 μL, 1.3 mmol) was added. The reaction mixture was stirred at room temperature for 8 h. Volatile substances were removed under vacuum to give a white solid compound (51 mg, 98%). MS (ESI): m / z = 284.1 [M+H] + .

[1318] Step a) 3-((2-chloro-4-(trifluoromethyl)phenyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester

[1319] The preparation method of this compound is similar to that of BB99, step a, and it is used directly in the next step without further purification.

[1320] Step b) 3-((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[1321] The sulfoxide intermediate was isolated from step b of the synthesis of the corresponding sulfone component BB99. The product was obtained as a white lyophilized powder (50 mg, 13.9%). MS (ESI): m / z = 328.1 [M-56+H] + .

[1322] BB101

[1323] 3-(((2-chloro-4-(trifluoromethyl)phenyl)thio)methyl)azacyclobutane 2,2,2-trifluoroacetate

[1324] TFA (478 mg, 323 μL, 4.19 mmol) was added to a DCM (3 mL) solution of 0.200 g (524 μmol) of tert-butyl 3-(chloro-4-(trifluoromethyl)phenyl)thio)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester (DCM), and the reaction mixture was stirred at room temperature for 3 h. Volatile substances were removed under vacuum to give a pale yellow oily compound, which was used directly in the next step (267 mg) without further purification. MS (ESI): m / z = 282.2 [M+H] + .

[1325] Step a) 3-[[2-chloro-4-(trifluoromethyl)phenyl]thioalkylmethyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1326] A 1M potassium tert-butoxide solution (1.98 mL, 1.98 mmol) in THF was added to an anhydrous THF solution of 2-chloro-4-(trifluoromethyl)benzylthiol (0.400 g, 1.88 mmol) in 6 mL of THF. The turbid reaction mixture was stirred at room temperature for 15 min, and then tert-butyl 3-(bromomethyl)azacyclobutane-1-carboxylic acid (471 mg, 1.88 mmol) was added. The reaction mixture was then stirred at room temperature for 19 h. The crude product was diluted with EtOAc and extracted with 1M NaHCO3 aqueous solution. The organic phase was collected, and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over Na2SO4 and evaporated to dryness to give the crude product (762 mg), which was used directly for the next step without further purification. MS (ESI): m / z = 326.1 [M-56+H] + .

[1327] BB102

[1328] 3-((2-fluoro-6-(trifluoromethyl)benzyl)sulfonyl)azacyclobutane 2,2,2-trifluoroacetate

[1329] 0.047 g (118 μmol) of 3-((2-fluoro-6-(trifluoromethyl)phenyl)methylsulfonyl)azacyclobutane-1-carboxylic acid tert-butyl ester was dissolved in DCM (0.5 mL), and TFA (108 mg, 72.9 μL, 946 μmol) was added. The reaction mixture was stirred at room temperature for 2 h. Volatile substances were removed under vacuum to give a yellow oily compound (56 mg), which was used directly in the next step without further purification. MS (ESI): m / z = 298.2 [M+H] + .

[1330] Step a) 3-((2-fluoro-6-(trifluoromethyl)benzyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester

[1331] A 1M potassium tert-butoxide THF solution (2.22 mL, 2.22 mmol) was added to an anhydrous THF solution of 0.400 g (2.11 mmol) of tert-butyl 3-mercaptoazacyclobutane-1-carboxylic acid. The reaction mixture was stirred at room temperature for 15 min, and then 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene (CAS RN 239087-08-2) was added. The reaction mixture was then stirred at room temperature for 14 h. The crude product was diluted with EtOAc and extracted with 1M NaHCO3 aqueous solution. The organic phase was collected, and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over NaSO4 and evaporated to dryness to give the crude product (805 mg), which was used directly for the next step without further purification. MS (ESI): m / z = 310.2 [M-56+H] + .

[1332] Step b) 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfonyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1333] In an ice bath, 3-chlorobenzoylperoxy acid (283 mg, 1.64 mmol) was added in portions to a continuously stirred solution of 3-((2-fluoro-6-(trifluoromethyl)benzyl)thio)azacyclobutane-1-carboxylic acid tert-butyl ester (0.300 g, 821 μmol) in 5 mL of DCM. The reaction mixture was stirred at room temperature for 15 min and then poured into 5 mL of saturated NaHCO3 aqueous solution, and extracted twice with DCM (10 mL each time). The organic layers were mixed, washed with brine, dried over Na2SO4, and then concentrated under vacuum. The crude product was purified by rapid column chromatography (silica gel, 20 g, 0% to 100% EtOAc in n-heptane solution) to give the desired compound as a colorless oil (47 mg, 15%). MS (ESI): m / z = 415.1 [M+NH4] + .

[1334] BB103

[1335] 3-((2-fluoro-6-(trifluoromethyl)benzyl)sulfinyl)azacyclobutane 2,2,2-trifluoroacetate

[1336] 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfinyl]azacyclobutane-1-carboxylic acid tert-butyl ester (0.086 g, 225 μmol) was dissolved in DCM (1 mL), and TFA (206 mg, 139 μL, 1.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. Volatile substances were removed under vacuum to give a yellow oily compound (93 mg), which was used directly in the next step without further purification. MS (ESI): m / z = 282.2 [M+H] + .

[1337] Step a) 3-[[2-fluoro-6-(trifluoromethyl)phenyl]methylsulfinyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1338] The sulfoxide intermediate was isolated from step b of the BB102 synthesis as a colorless oil (86 mg, 28%). MS (ESI): m / z = 404.1 [M + Na] + .

[1339] BB104

[1340] 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azacyclobutane 2,2,2-trifluoroacetate

[1341] 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester (0.145 g, 350 μmol) was dissolved in DCM (2 mL), and TFA (320 mg, 216 μL, 2.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. Volatile substances were removed under vacuum to give a yellow oily compound (181 mg), which was used directly in the next step without further purification. MS (ESI): m / z = 314.1 [M+H] + .

[1342] Step a) 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfonyl)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[1343] In an ice bath, 3-chlorobenzoylperoxy acid (352 mg, 1.57 mmol) was added in portions to a continuously stirred solution of tert-butyl 3-(((2-chloro-4-(trifluoromethyl)phenyl)thio)methyl)azacyclobutane-1-carboxylic acid (BB101, step a) (0.300 g, 786 μmol) in 5 mL of DCM. The reaction mixture was stirred at room temperature for 15 min and then poured into 5 mL of saturated NaHCO3 aqueous solution, and extracted twice with DCM (10 mL each time). The organic layers were mixed, washed with brine, dried with Na2SO4, and then concentrated under vacuum. The crude product was purified by rapid chromatography (silica gel, 20 g, 0% to 100% EtOAc in n-heptane solution) to give the desired compound as a colorless oil (145 mg, 45%). MS (ESI): m / z = 314.0 [M-56+H] + .

[1344] BB105

[1345] 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azacyclobutane 2,2,2-trifluoroacetate

[1346] 0.086 g (216 μmol) of 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester (DCM) was dissolved in 1 mL of DCM, and TFA (197 mg, 133 μL, 1.73 mmol) was added. The reaction mixture was stirred at room temperature for 2 h. Volatile substances were removed under vacuum to give a yellow oily compound (99 mg), which was used directly in the next step without further purification. MS (ESI): m / z = 298.1 [M+H] + .

[1347] Step a) 3-(((2-chloro-4-(trifluoromethyl)phenyl)sulfinyl)methyl)azacyclobutane-1-carboxylic acid tert-butyl ester

[1348] The sulfoxide intermediate was isolated from step a of the synthesis of BB104. The desired product was obtained as a yellow oil (80 mg, 25.6%). MS (ESI): m / z = 398.1 [M+H] + .

[1349] BB106

[1350] 3-((2-fluoro-4-(trifluoromethyl)benzyl)thio)azacyclobutane 2,2,2-trifluoroacetate

[1351] TFA (880 mg, 595 μL, 7.72 mmol) was added to a DCM (3 mL) solution of 0.282 g (772 μmol) of tert-butyl 3-((2-fluoro-4-(trifluoromethyl)benzyl)thio)azacyclobutane-1-carboxylic acid, and the reaction mixture was stirred at room temperature for 3 h. Volatile substances were removed under vacuum to obtain the desired compound as a colorless oil (302 mg), which was used directly for the next step without further purification. MS (ESI): m / z = 266.2 [M+H] + .

[1352] Step a) 3-[[2-fluoro-4-(trifluoromethyl)phenyl]methylthioalkyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1353] To a solution of tert-butyl 3-mercaptoazacyclobutane-1-carboxylic acid (0.200 g, 1.06 mmol) in anhydrous THF (2 mL), a solution of 1 M potassium tert-butoxide in THF (1.11 mL, 1.11 mmol) was added, and the reaction mixture was stirred at room temperature for 15 min. Then, 1-(bromomethyl)-2-fluoro-4-(trifluoromethyl)benzene (272 mg, 1.06 mmol, CAS RN 239087-07-1) was added. The reaction mixture was then stirred at room temperature for 14 h. The crude product was diluted with EtOAc and extracted with an aqueous solution of 1 M NaHCO3. The organic phase was collected, and the aqueous phase was back-extracted with EtOAc. The combined organic phases were dried over NaSO4 and evaporated to dryness. The purified organic phases were purified by rapid chromatography (silica gel, 20 g, 0% to 80% EtOAc in n-heptane solution) to provide the desired product as a colorless oil (288 mg, 75%). MS(ESI): m / z = 310.2[M-56+H] + .

[1354] Similar to BB84, the following intermediates are prepared from the corresponding commercially available starting materials.

[1355]

[1356]

[1357]

[1358] Similar to BB18, the following intermediates are prepared from the corresponding commercially available starting materials.

[1359]

[1360] BB149

[1361] 1-[2-(azacyclobutane-3-yl)ethynyl]cyclopentanol hydrochloride

[1362] A solution of 4M HCl in dioxane (0.5 mL) was added to a solution of tert-butyl 3-[2-(1-hydroxycyclopentyl)ethynyl]azacyclobutane-1-carboxylic acid (0.02 g, 0.075 mmol) in dioxane (0.5 mL), and the reaction mixture was stirred at room temperature for 18 h. The mixture was evaporated to dryness, and the residue was prepared with diisopropyl ether, filtered off, and further dried under high vacuum to give the title compound as a white solid consisting of hydrochloride (0.013 g, 87%). MS (ESI): m / z = 166.1 [M+H] + .

[1363] Step a) 3-[2-(1-hydroxycyclopentyl)ethynyl]azacyclobutane-1-carboxylic acid tert-butyl ester

[1364] At -78 °C, nBuLi (0.759 mL, 1.21 mmol) was added dropwise to a THF (6.5 mL) solution of 0.2 g (1.1 mmol) of 3-ethynylazycyclobutane-1-carboxylic acid tert-butyl ester (THF), and the reaction mixture was stirred at this temperature for 1 h. Then, a THF (3 mL) solution of cyclopentanone (0.107 mL, 1.21 mmol) was added dropwise to the mixture, and the mixture was stirred at -78 °C for 2 h. The mixture was warmed to 0 °C, poured into a saturated aqueous NH4OH solution, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and evaporated. The residue was purified by rapid silica gel chromatography, eluting with a gradient of EtOAc:n-heptane (0 to 100%), to give the title compound as a pale yellow oil (0.020 g, 7%). MS(ESI): m / z=192.2[M-56-18+H] + .

[1365] BB150

[1366] 4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine carboxylate

[1367] A mixture of 4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (400.0 mg, 0.970 mmol) and TFA (1.0 mL, 0.970 mmol) was stirred in DCM (10 mL) for 12 h at 20 °C. The mixture was purified by preparative HPLC (containing 0.225% v / v FA in ACN and an aqueous solution) to give the desired product (300 mg, 94.4%) as a colorless gel. MS (ESI): m / z = 312.1 [M+H] + .

[1368] Step a: 4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1369] To a solution of 3-bromo-5-(trifluoromethyl)phenol (2.0 g, 8.3 mmol), 1-BOC-4-hydroxypiperidine (1.84 g, 9.13 mmol, CAS RN 106-52-5), and PPh3 (2.61 g, 9.96 mmol) in THF (32.6 mL), diisopropyl azodicarboxylate (1.96 mL, 9.96 mmol) was added, and the reaction mixture was stirred at 20 °C for 15 h. The mixture was concentrated under vacuum. The residue (containing 0.225% v / v FA in ACN and aqueous solution) was purified by preparative HPLC and concentrated under vacuum to give the desired product (2.6 g, yield 73.9%) as a pale yellow oil. MS (ESI): m / z = 367.9 [M-56+H] + .

[1370] Step b) 4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1371] A mixture of tert-butyl 4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid (500.0 mg, 1.18 mmol), pyrazole (160.47 mg, 2.36 mmol), CuI (22.37 mg, 0.120 mmol), cesium carbonate (1152 mg, 3.54 mmol), and N,N′-dimethylethylenediamine (519.15 mg, 5.89 mmol) was stirred in DMF (5 mL) for 12 h at 110 °C. The mixture was poured into H2O (30 mL) and extracted three times (50 mL) with EtOAc. The combined organic layers were washed with ammonia (10 mL) and brine (50 mL), dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum to give the desired product (400 mg, yield 82.5%), which was a pale yellow oil. MS(ESI): m / z = 356.2[M-56+H]+ .

[1372] BB151

[1373] 4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine

[1374] A mixture of 4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methylene]piperidine (250.0 mg, 0.740 mmol) and Pd / C (50.0 mg, wt. 10%) was stirred in 10 mL of THF for 12 h at 20 °C under H2 (1520 mmHg). The mixture was filtered and concentrated under vacuum to give the desired compound (240 mg, 95.4%) as a light brown gel. MS (ESI): m / z = 342.1 [M+H] + .

[1375] Step a) 4-(p-Toluenesulfonylhydrazine)piperidine-1-carboxylic acid tert-butyl ester

[1376] To a MeOH (100 mL) solution of 4-toluenesulfonyl hydrazine (9.35 g, 50.19 mmol, CAS RN 1576-35-8), 1-BOC-4-piperidinone (10.0 g, 50.19 mmol, CAS RN 17502-28-8) was added, and the mixture was stirred at 25 °C for 12 h. The mixture was concentrated to give the desired product (18.4 g, 99.8%) as a grayish-white solid. MS (ESI): m / z = 368.2 [M+H] + .

[1377] Step b) 2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzaldehyde

[1378] At 0 °C, NaH (187.39 mg, 60%, dispersed in mineral oil, 4.68 mmol) was stirred in 2,2,2-trifluoroethanol (16.67 mL, 228.74 mmol, CAS RN75-89-8). The cooling bath was removed, and the mixture was stirred at 20 °C for 2 h. Then, 2-fluoro-4-(trifluoromethyl)benzaldehyde (1.0 g, 5.21 mmol, CAS RN 763-93-9) was added, and the mixture was stirred at 20 °C for 12 h. The mixture was poured into H₂O (30 mL) and extracted twice with EtOAc (30 mL each time). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum to give the desired product (1.2 g, 84.7%) as a pale yellow solid. 1H NMR (400MHz, DMSO-d6) δ10.44-10.34 (m, 1H), 7.93 (d, J=8.1Hz, 1H), 7.75 (s, 1H), 7.55 (d, J=8.1Hz, 1H), 5.11 (q, J=8.7Hz, 2H).

[1379] Step c) 4-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzoyl]piperidine-1-carboxylic acid tert-butyl ester

[1380] A mixture of 2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzaldehyde (1000.0 mg, 3.67 mmol), 4-(p-toluenesulfonylhydrazine)piperidine-1-carboxylic acid tert-butyl ester (1350.3 mg, 3.67 mmol), and cesium carbonate (1795.9 mg, 5.51 mmol) was stirred in 1,4-dioxane (30 mL) for 12 h at 110 °C under a nitrogen atmosphere. The mixture was poured into H₂O (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the residue (MeCN containing 0.225% v / v FA and aqueous solution) was purified by preparative HPLC to give the desired product (980 mg, 58.6%) as a pale yellow gel. MS(ESI): m / z = 400.1[M-56+H] + .

[1381] Step d) 4-[hydroxy-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester

[1382] To a solution of 4-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)benzoyl]piperidine-1-carboxylic acid tert-butyl ester (900.0 mg, 1.98 mmol) in MeOH (45 mL), 0 °C NaBH4 (149.54 mg, 3.95 mmol) was added, and the mixture was stirred at 20 °C for 12 h. The mixture (containing 0.225% v / v FA in MeCN and an aqueous solution) (650 mg, 71.9%) was purified by preparative HPLC as a pale yellow oil. MS (ESI): m / z = 384.0 [M-56-OH+H] + .

[1383] Step e) 4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methylene]piperidine

[1384] A mixture of 4-[hydroxy-[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carboxylic acid tert-butyl ester (400.0 mg, 0.870 mmol) and MsOH (840.43 mg, 8.74 mmol) was stirred in DCM (4 mL) for 24 h at 40 °C. The mixture was poured into a saturated aqueous solution of Na₂CO₃ (5 mL) and extracted three times with EtOAc (10 mL each). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum to give the desired compound as a pale yellow oil (260 mg, 76.2%). MS (ESI): m / z = 340.1 [M+H] + .

[1385] BB152

[1386] 4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine trifluoroacetate

[1387] TFA (1.0 mL) was added to a DCM (10 mL) solution of tert-butyl piperidine-1-carboxylic acid (240.0 mg, 0.580 mmol). The mixture was stirred at 20 °C for 12 h and then concentrated under vacuum to give 2,2,2-trifluoroacetate of 4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine (240 mg, 96.7%) as a pale yellow gel. MS (ESI): m / z = 313.1 [M+H] + .

[1388] Step a) 4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1389] A mixture of tert-butyl 4-[3-bromo-5-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid (500.0 mg, 1.18 mmol, BB98, intermediate a), 1,2,4-triazole (162.8 mg, 2.36 mmol), and CuI (22.37 mg, 0.120 mmol) was stirred in DMF (5 mL) for 12 h at 110 °C. The mixture was poured into H2O (20 mL) and extracted three times with EtOAc (30 mL each time). The combined organic layers were washed with ammonia (20 mL), brine (20 mL, three times), dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum, and the residue was purified by column chromatography (PE:EA = 50:1 to 3:1) to give the desired product (240 mg, 49.4%) as a pale yellow solid. MS(ESI): m / z = 357.1 [M-56+H] + .

[1390] BB153

[1391] 3-[4-chloro-3-(trifluoromethyl)phenoxy]azacyclobutane-trifluoroacetate

[1392] TFA (1.04 mL) was added to a 7.5 mL solution of 3-[4-chloro-3-(trifluoromethyl)phenoxy]azacyclobutane-1-carboxylic acid tert-butyl ester (300.0 mg, 0.530 mmol) in DCM, and the mixture was stirred at 20 °C for 2 h. The mixture was concentrated to give the title compound as a yellow oil (280 mg, 97%). MS (ESI): m / z = 252.0 [M+H] + .

[1393] Step a) 3-[4-chloro-3-(trifluoromethyl)phenoxy]azacyclobutane-1-carboxylic acid tert-butyl ester

[1394] To a solution of 2-chloro-5-hydroxytrifluorotoluene (1 g, 5.1 mmol, CAS RN 6294-93-5), tert-butyl 3-hydroxyazacyclobutane-1-carboxylate (0.97 g, 5.6 mmol, CAS RN 141699-55-0), and triphenylphosphine (1.6 g, 6.11 mmol) in THF (20 mL), diisopropyl azodiacarboxylate (1.2 mL, 6.11 mmol) was added, and the mixture was stirred at 20 °C for 15 h. The mixture was concentrated and purified by reversed-phase chromatography (MeCN and aqueous solution containing 0.225% v / v FA) to give the title compound (820 mg, 28.7%) as a brown solid. MS (ESI): m / z = 295.9 [M-56+H] + .

[1395] BB154

[1396] 4-(4-chloro-3-pyrazol-1-ylphenoxy)piperidine trifluoroacetate

[1397] TFA (1.34 mL, 17.46 mmol) was added to a solution of 260.0 mg (0.690 mmol) of tert-butyl 4-(4-chloro-3-pyrazol-1-ylphenoxy)piperidine-1-carboxylic acid in DCM (5.38 mL) at 0 °C, and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give the title compound as an orange oil (250 mg, yield 92.7%). MS (ESI): m / z = 278.1 [M+H] + .

[1398] Step a) 4-(3-bromo-4-chloro-phenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1399] To a THF (50 mL) solution of 1-BOC-4-hydroxypiperidine (2.04 g, 10.12 mmol, CAS RN 106-52-5), 3-bromo-4-chlorophenol (2.0 g, 9.64 mmol, CAS RN 2402-82-6), and triphenylphosphine (3.03 g, 11.57 mmol), diisopropyl azodicarboxylate (2.28 mL, 11.57 mmol) was added, and the mixture was stirred at 20 °C for 15 h. The mixture was then concentrated, and the residue (MeCN and aqueous solution containing 0.1% v / v FA) was purified by reversed-phase rapid chromatography to give the desired product (2.8 g, 74.3%) as a pale yellow oil. MS (ESI): m / z = 335.9 [M-56+H] + .

[1400] Step b) 4-(4-chloro-3-pyrazol-1-ylphenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1401] CuI (48.59 mg, 0.260 mmol) was added to a DMF (20 mL) solution of 4-(3-bromo-4-chlorophenoxy)piperidine-1-carboxylic acid tert-butyl ester (1.0 g, 2.56 mmol), pyrazole (139.4 mg, 2.05 mmol), cesium carbonate (2501.8 mg, 7.68 mmol), and 1,10-phenanthroline (225.49 mg, 2.56 mmol), and the mixture was stirred at 110 °C for 12 h under N2 atmosphere. The mixture was concentrated, diluted with H2O (20 mL), and extracted three times (10 mL) with EtOAc. The combined organic layers were concentrated, and the residue was purified by reversed-phase chromatography (ACN and an aqueous solution containing 0.1% v / v FA) to give the desired product (265 mg, 22.5%, purity 82%), which was a yellow oil. MS(ESI): m / z = 378.1 [M+H] + .

[1402] BB155

[1403] 4-[5-(4-piperidinoxy)-2-(trifluoromethyl)phenyl]morpholine trifluoroacetate

[1404] TFA (1.0 mL) was added to a DCM (3 mL) solution of 4-[3-morpholino-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (400.0 mg, 0.93 mmol), and the reaction mixture was stirred at 25 °C for 12 h. The reaction mixture was concentrated under vacuum to provide a crude product (300 mg), which was a yellow oil and was used directly for the next step without further purification. MS (ESI): m / z = 331.2 [M+H] + .

[1405] Step a) 4-(3-bromo-4-(trifluoromethyl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1406] To a THF (8.5 mL) solution of 3-bromo-4-(trifluoromethyl)phenol (500.0 mg, 2.54 mmol, CAS RN1214385-56-4) and 1-BOC-4-hydroxypiperidine (512 mg, 2.54 mmol, CAS RN 106-52-5), PPh3 (1000.9 mg, 3.82 mmol) and diethyl azodicarboxylate (664.53 mg, 3.82 mmol) were added, and the mixture was stirred at 25 °C for 12 h. The mixture was purified by silica gel chromatography using PE:EA = 5:1 as the eluent to provide the desired product (503 mg, yield 46.6%) as a pale yellow oil. MS (ESI): m / z = 369.2 [M-56+H]+ .

[1407] Step b) 4-(3-morpholine-4-(trifluoromethyl)phenoxy)piperidine-1-carboxylic acid tert-butyl ester

[1408] A mixture of tert-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid (500.0 mg, 1.18 mmol), morpholine (154 mg, 1.77 mmol, CAS RN 110-91-8), (R)-(+)-2,2′-bis(diphenylphosphino)-1,1′-bidinaphthalene (146.77 mg, 0.24 mmol, CAS RN 76189-55-4), cesium carbonate (1.15 g, 3.54 mmol), and tris(dibenzylideneacetone)palladium(0) (172.47 mg, 0.240 mmol, CAS RN 76971-72-7) was stirred in DMF (10 mL) for 12 h at 110 °C. The mixture was then poured into H2O and extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the residue was purified by column chromatography (containing an EtOAc gradient of 5% to 33% PE) to obtain the desired product (480 mg, 94.6%) as a pale yellow solid. MS (ESI): m / z = 431.1 [M+H] + .

[1409] BB156

[1410] 4-(4-chloro-3-(1,2,4-triazol-1-yl)phenoxy)piperidine trifluoroacetate

[1411] TFA (1.01 mL, 13.13 mmol) was added to a DCM (5 mL) solution of 4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (196.0 mg, 0.520 mmol) at 0 °C, and the mixture was stirred at 20 °C for 1 h. The mixture was concentrated to give the title compound (178 mg, 87.6%) as a brown oil. MS (ESI): m / z = 279.1 [M+H] + .

[1412] Step a) 4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1413] A mixture of tert-butyl 4-(3-bromo-4-chlorophenoxy)piperidine-1-carboxylic acid (500.0 mg, 1.28 mmol, BB102, intermediate a), 1,2,4-triazole (176.8 mg, 2.56 mmol), CuI (24.3 mg, 0.130 mmol), cesium carbonate (1250.9 mg, 3.84 mmol), and dimethylglycine (1.0 mL, 1.28 mmol) was stirred in DMF (10 mL) for 12 h at 120 °C. The mixture was concentrated to remove DMF, diluted with H2O (50 mL), and extracted three times with EtOAc (20 mL each). The combined organic layers were evaporated, and the residue was purified by reversed-phase rapid chromatography (ACN and an aqueous solution containing 0.1% v / v FA) to give the title compound (196 mg, 37.1%) as a colorless oil. MS(ESI): m / z = 323.0 [M-56+H] + .

[1414] BB157

[1415] 4-[3-Cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine trifluoroacetate

[1416] TFA (1.8 mL) was added to an 18 mL solution of 4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (360.0 mg, 0.930 mmol) in DCM. The mixture was stirred at 25 °C for 12 h. The mixture was then concentrated under vacuum to provide the desired compound as a pale yellow gel (370 mg, 99.2%). MS (ESI): m / z = 286.2 [M+H] + .

[1417] Step a) 4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1418] A mixture of tert-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid (500.0 mg, 1.18 mmol, BB103, intermediate b), cyclopropylboronic acid (151.86 mg, 1.77 mmol), Na2CO3 (374.74 mg, 3.54 mmol), and Pd(PPh3)4 (13.6 mg, 0.010 mmol) was stirred for 12 h in 1,4-dioxane (10 mL) and H2O (1 mL). The mixture was poured into H2O (50 mL) and extracted three times with EtOAc (50 mL each). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, and then filtered. The filtrate was concentrated under vacuum and purified by column chromatography (PE:EtOAc = 20:1 to 5:1) to obtain the desired product (380 mg, 83.7%), which was a colorless gel. MS (ESI): m / z = 330.1 [M-56+H] + .

[1419] BB158

[1420] 4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine trifluoroacetate

[1421] TFA (0.5 mL) was added to a DCM (5 mL) solution of 4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester (180.0 mg, 0.440 mmol). The mixture was stirred at 25 °C for 12 h and then concentrated under vacuum to give the desired product (180 mg, 96.7%), which was a pale yellow gel. MS (ESI): m / z = 312.1 [M+H] + .

[1422] Step a) 4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidine-1-carboxylic acid tert-butyl ester

[1423] A mixture of tert-butyl 4-[3-bromo-4-(trifluoromethyl)phenoxy]piperidine-1-car...

Claims

1. A compound of formula (I) (I) Or its medicinal salt, in: (i) X is C-R 3 ; m is 0 or 1 ; n is selected from 0, 1 and 2; and L is selected from - (CH2) p -, -0-, -OCH2-, -(CR 16 R 17 ) q -CH2O-, -CH2OCH2-, -CF2CH2-, and -CH=CH-; or (ii) X is N; both m and n are 1; and L is –(CH2). p –; p is 1 or 2; q is 0 or 1; A is selected from: (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aryl; (ii) by R 7 R 8 and R 9 Replaced by 5- to 14-membered heteroaryl groups; and (iii) by R 10 R 11 and R 12 Substituted 3- to 14-membered heterocyclic alkyl groups; R 1 It is hydrogen or C 1-6 -alkyl; R 2 It is hydrogen or C 1-6 -alkyl; R 3 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl; R 4 Selected from halogens, cyano groups, SF5, and C 1-6 -alkyl, C 1-6 -alkylyl group, C 1-6 -alkoxy group, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl, 3- to 14-membered heterocycloalkyl, R 14 and R 15 Substituted 3- to 14-membered heterocyclic alkyl groups, 5- to 14-membered heteroaryl groups, halogenated -C6-C 14 -Aryl and C6-C 14 -Aryloxy; R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1-6 -alkoxy, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl, 5- to 14-membered heteroaryl and halogenated -C6-C 14 -Aryl; R 6 It is hydrogen or halogen; R 7 Selected from hydrogen, C 1-6 -alkyl, C6-C 14 -Aryl, halogenated-C6-C 14 -Aryl, halogenated-C6-C 14 -Aryloxy groups and halogenated-C 1-6 -alkyl; R 8 Selected from hydrogen, halogens, C 1-6 -alkyl and halogenated-C 1-6 -alkyl; R 9 It is hydrogen; R 10 It is a halogen; R 11 It is a halogen; R 12 It is hydrogen; R 14 Selected from halogens, C 1-6 -alkyl and C 1-6 -alkoxy group; R 15 It is hydrogen or halogen; and R 16 and R 17 Together with the carbon atoms they are attached to, they form C 3-10 -Cycloalkyl.

2. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is a compound of formula (Ia): (him) Where A, L, X, m, n, R 1 and R 2 As defined in claim 1.

3. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is a compound of formula (Ib): (One) Where A, L, X, m, n, R 1 and R 2 As defined in claim 1.

4. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein: X is CR 3 ; Both m and n are 0; or Both m and n are 1; and L is selected from –(CH2) p –、–O–、–OCH2– and –CH2O–.

5. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein p is 2.

6. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein q is 0.

7. The compound of formula I according to any one of claims 1-3, or a pharmaceutical salt thereof, wherein A is selected from: (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aromatic; and (ii) by R 7 R 8 and R 9 Replaced by 5 to 14 heteroaryl groups.

8. The compound of formula I according to any one of claims 1-3, or a pharmaceutical salt thereof, wherein A is selected from: (i) by R 4 R 5 and R 6 Substituted phenyl; (ii) by R 7 R 8 and R 9 Substituted oxazolyl group; and (iii) by R 7 R 8 and R 9 Substituted pyridinyl group.

9. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 1 It is hydrogen.

10. The compound of formula I according to any one of claims 1-3, or a pharmaceutical salt thereof, wherein R 2 It can be hydrogen or methyl.

11. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 3 Selected from hydrogen, halogens and C 1-6 -alkyl.

12. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 3 Selected from hydrogen, fluorine, and methyl.

13. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 4 Selected from halogens, SF5, C 1-6 -alkyl, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -Cycloalkyl and 3- to 14-membered heterocyclic alkyl groups.

14. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 4 Selected from chlorine, SF5, methyl, methoxy, OCF3, CF3, cyclopropyl and 2-azaspiro[3.3]heptane-2-yl.

15. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl and halogenated-C6-C 14 -Aryl.

16. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 5 It is selected from hydrogen, cyano, fluorine, chlorine, methyl, CF3, pyrrolyl, cyclopentyl, cyclopropyl and chlorophenyl.

17. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 6 It is hydrogen.

18. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 7 C 1-6 -alkyl or halogenated-C 1-6 -alkyl.

19. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 7 It is tert-butyl or CF3.

20. The compound of formula I according to any one of claims 1-3, or a pharmaceutical salt thereof, wherein R 8 Hydrogen or halogenated -C 1-6 -alkyl.

21. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein R 8 It is hydrogen or CF3.

22. The compound of formula I or a pharmaceutical salt thereof according to any one of claims 1-3, wherein: X is CR 3 ; Both m and n are 0; or Both m and n are 1; L is selected from –(CH2) p –、–O–、–OCH2– and –CH2O–; p is 1 or 2; A is selected from: (i) by R 4 R 5 and R 6 Replacement C6-C 14 -Aromatic; and (ii) by R 7 R 8 and R 9 Replaced by 5- to 14-membered heteroaryl groups; R 1 It is hydrogen; R 2 It is hydrogen or C 1-6 -alkyl; R 3 Selected from hydrogen, halogens and C 1-6 -alkyl; R 4 Selected from halogens, SF5, C 1-6 -alkyl, C 1-6 -alkoxy, halogenated-C 1-6 -alkoxy, halogenated-C 1-6 -alkyl, C 3-10 -cycloalkyl and 3- to 14-membered heterocycloalkyl; R 5 Selected from hydrogen, cyano, halogen, C 1-6 -alkyl, halo-C 1-6 -alkyl, 3- to 14-membered heterocyclic alkyl, C 3-10 -Cycloalkyl and halogenated-C6-C 14 -Aryl; R 6 It is hydrogen; R 7 C 1-6 -alkyl or halogenated-C 1-6 -alkyl; R 8 Hydrogen or halogenated -C 1-6 -alkyl; and R 9 It is hydrogen.

23. The compound of formula I according to any one of claims 1-3, wherein: X is CR 3 ; Both m and n are 0; or Both m and n are 1; L is selected from –(CH2) p –、–O–、–OCH2– and –CH2O–; p is 1 or 2; A is selected from: (i) by R 4 R 5 and R 6 Substituted phenyl; (ii) by R 7 R 8 and R 9 Substituted oxazolyl group; and (iii) by R 7 R 8 and R 9 Substituted pyridinyl group; R 1 It is hydrogen; R 2 It can be hydrogen or methyl; R 3 Selected from hydrogen, fluorine, and methyl; R 4 Selected from chlorine, SF5, methyl, methoxy, OCF3, CF3, cyclopropyl and 2-azaspiro[3.3]heptane-2-yl; R 5 Selected from hydrogen, cyano, fluorine, chlorine, methyl, CF3, pyrrolyl, cyclopentyl, cyclopropyl, and chlorophenyl; R 6 It is hydrogen; R 7 Selected from tert-butyl, methyl and CF3; R 8 It is hydrogen or CF3; and R 9 It is hydrogen.

24. A compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound is selected from: (+)-(4aR,8aS)-6-(4-((4-(tert-butyl)thiazo-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aR,8aS)-6-(4-((4-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-[4-[(4-tert-butylthiazolyl-2-yl)methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; Racemic-(4aR,8aS)-6-(4-((4-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (-)-(4aS,8aR)-6-(4-((4-(tert-butyl)thiazolyl-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (-)-(4aS,8aR)-6-(4-((4-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aR,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; Racemic-(4aR,8aS)-6-(4-((4-chlorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(4-(4-chlorobenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-(4-(4-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(4-(4-(trifluoromethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aS,8aS))-6-(4-(4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aRS,8aS)-6-[4-(phenoxymethyl)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; Racemic-(4aR,8aS)-6-(4-((5,6-dihydro-4H-cyclopentadieno[d]thiazolyl-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aS,8aS)-6-(4-(4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(4-((3-phenyl-1,2,4-oxadiazol-5-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (-)-(4aR,8aR)-6-(4-(4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (-)-(4aS,8aR)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; Racemic-(4aR,8aS)-6-(4-(4-(trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(4-(4-chlorobenzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (-)-(4aS,8aR)-6-(4-((2-chloro-4-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-[4-[[5-(trifluoromethyl)-2-pyridinyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(4-((4-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-fluorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aS,8aR)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(4-(trifluoromethoxy)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2,4-difluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(4-chloro-3-fluorobenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-4-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidinyl]methyl]benzonitrile; (+)- or (-)-(4aR,8aS)-6-(4-(4-chlorobenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[3-[[4-(trifluoromethyl)phenyl]methyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-(4-((4,4-difluoropiperidin-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((5-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[4-[(2-fluoro-4-methoxyphenoxy)methyl]piperidin-1-carbonyl]hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-chloro-4-(trifluoromethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aS,8aR)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(((6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(3-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aS,8aR)-6-[4-[[2-chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-[4-[[2-chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aS,8aR)-6-[4-[(2-chloro-4-fluoro-phenoxy)methyl]-4-methyl-piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aS,8aR)-6-(4-((2,4-difluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-chloro-2-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-2-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidinyl]methoxy]-5-fluorobenzonitrile; (+)- or (-)-(4aR,8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-fluorophenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-3-chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile; (+)- or (-)-(4aR,8aS)-6-(4-((4-(trifluoromethyl)-1H-imidazol-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-fluoro-2-methylphenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-(tert-butyl)-1H-pyrazol-1-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (2R,4aR,8aS)-2-methyl-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-(4-(benzo[d]oxazol-2-ylmethyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4',6-dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-(1H-pyrazol-4-yl)-4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-[3-[(2,4-dichlorophenyl)methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-methoxy-4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[5-methyl-6-(trifluoromethyl)pyridin-3-yl]oxymethyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(3-chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(2-chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(2-chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(3-chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(4-chlorophenoxy)methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(4-chlorophenyl)methoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-methyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[4-(trifluoromethyl)phenyl]methyl]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-fluoro-5-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[2-methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-chloro-4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(2-chloro-4-fluorophenoxy)methyl]-3-fluoroazacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-(trifluoromethyl)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-methylazacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2,4-difluoro-5-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-5-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-fluoro-4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-methoxy-4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[4-chloro-2-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[2-methyl-3-[[4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[4-chloro-3-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-(4-chloro-3-cyclopropylphenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-(4-chloro-3-morpholin-4-ylphenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[2-methyl-4-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; 2-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]piperidin-4-yl]oxy-5-(trifluoromethyl)benzonitrile; (4aR,8aS)-6-[4-(oxazolo[5,4-c]pyridin-2-ylmethyl)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[(2-chloro-4-fluorophenoxy)methyl]azacycloheptane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]azacycloheptane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[3-pyrazol-1-yl-5-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[3-(1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[4-chloro-3-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-(4-chloro-3-pyrazol-1-ylphenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(4-(3-morpholin-4-(trifluoromethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-[4-[4-chloro-3-(1,2,4-triazol-1-yl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[3-pyrazol-1-yl-4-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-(4-chlorophenoxy)piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2,6-difluoro-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[4-chloro-3-(4-chlorophenyl)-2-fluoro-phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-chloro-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-6-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[4-methyl-2-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR, 8aS)-6-[3-[2-[2-methoxy-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[2-acetyl-4-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR, 8aS)-6-[3-[2-[2-bromo-4-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[6-fluoro-4-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[6-fluoro-5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(3,4-dichlorophenyl)methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(2,5-dichlorophenyl)methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-(trifluoromethoxy)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[2-methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[2-methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[2-methyl-3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[5-(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[rel-(3R,4R)-3-methyl-4-[[5-methyl-6-(trifluoromethyl)-3-pyridinyl]oxymethyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[rel-(3S,4S)-3-methyl-4-[[5-methyl-6-(trifluoromethyl)-3-pyridinyl]oxymethyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[4,5-bis(trifluoromethyl)-2-pyridinyl]oxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxymethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-2-methyl-azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(4-chloro-2-phenoxy-phenyl)methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(pentafluoro-λ6-thioalkyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[1-(2,4-dichlorophenyl)cyclopropyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[6-(4-fluorophenoxy)-4-(trifluoromethyl)-2-pyridinyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[6-(4-fluorophenoxy)-5-(trifluoromethyl)-2-pyridyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[4-(4-fluorophenyl)thiazolyl-2-yl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-4-(trifluoromethyl)phenyl]methoxy]-3-(trifluoromethyl)pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[racemic-(2R,3S)-3-[2-bromo-5-(trifluoromethyl)phenoxy]-2-methyl-pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[rel-(2R,3S)-3-[2-bromo-5-(trifluoromethyl)phenoxy]-2-methyl-pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[rel-(2S,3R)-3-[2-bromo-5-(trifluoromethyl)phenoxy]-2-methyl-pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[[2,4-bis(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[4-[2-fluoro-4-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-(3-bromo-2-chloro-phenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-chloro-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-5-[[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]-4-piperidinyl]oxy]-2-(trifluoromethyl)benzonitrile; (+)-5-[1-[(4aR,8aS)-3-oxo-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazine-6-carbonyl]azacyclobutane-3-yl]oxy-2-(trifluoromethyl)benzonitrile; (+)-(4aR,8aS)-6-[3-(3-bromo-4-chlorophenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(3-methylazacyclobutane-1-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(3,3-difluoroazacyclobutane-1-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(3-fluoro-3-methyl-azacyclobutane-1-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(6,6-difluoro-2-azaspiro[3.3]heptane-2-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(5-oxa-2-azaspiro[3.5]nonane-2-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-2-chloro-phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[2-chloro-3-(3-methylazacyclobutane-1-yl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[2-chloro-3-(3-fluoro-3-methyl-azacyclobutane-1-yl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-(3-(3-(3-(tert-butoxy)azacyclobutane-1-yl)-2-chlorophenoxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.4]octane-2-yl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonane-2-yl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-5-chloro-phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-[3-(3-chloro-5-pyrrolidone-1-ylphenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[4-fluoro-2-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2,2-difluoro-2-[4-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-(trifluoromethoxy)phenyl]methyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-chloro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[(3R or 3S)-3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[(3S or 3R)-3-[2-fluoro-5-(trifluoromethyl)phenoxy]pyrrolidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-((3-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((2,3-dimethylbenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((2,4-dimethylbenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((2-methyl-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-(4-hydroxy-2-(trifluoromethyl)phenethyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; and (4aR,8aS)-6-[3-[[4-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one.

25. A compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound is selected from: (+)-(4aR,8aS)-6-(4-((4-(tert-butyl)oxazol-2-yl)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)-(4aR,8aS)-6-[4-[[4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-fluorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(4-(trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(4-chloro-3-fluorobenzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-chloro-4-(trifluoromethyl)phenoxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(3-(trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[4-[[2-chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-chloro-2-fluorophenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[4-[[2-cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-3-chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-(trifluoromethyl)phenoxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-fluoropiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4',6-dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(cis-4-((2-chloro-4-fluorophenoxy)methyl)-3-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-chloro-4-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-chloro-4-fluorophenoxy)methyl)-4-methylpiperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-[3-[(2,4-dichlorophenyl)methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-chloro-4-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-fluoro-5-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[2-fluoro-6-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; 6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidin-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((2-fluoro-4-(pentafluoro-λ6-thioalkyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-4-(trifluoromethyl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; (4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; Racemic-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; Racemic-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidin-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptane-2-yl)-2-chloro-phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonane-2-yl)phenoxy]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azacyclobutane-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one; and (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azacyclobutane-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazine-3(4H)-one.

26. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is: 。 27. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is: 。 28. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is: 。 29. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is: 。 30. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is: 。 31. The compound of formula (I) according to claim 1, or a pharmaceutical salt thereof, wherein the compound of formula (I) is: 。 32. A method for producing a compound of formula (I) according to claim 1 or a pharmaceutical salt thereof, the method comprising: The first amine of formula 1, wherein R 1 As described in claim 1, It reacts with the second amine 2 in the presence of a base and a urea-forming agent, wherein A, L, m, n, X, and R... 2 As described in claim 1; To form the compound of formula (I).

33. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 31 or a pharmaceutical salt thereof, and a therapeutically inert carrier.

34. A compound of formula (I) according to any one of claims 1 to 31 or a pharmaceutical salt thereof, or a pharmaceutical composition according to claim 33, for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

35. A compound of formula (I) according to any one of claims 1 to 31 or a pharmaceutical salt thereof, or a pharmaceutical composition according to claim 33, for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms in mammals.

36. Use of the compound of formula (I) or a pharmaceutical salt thereof according to any one of claims 1 to 31 for the preparation of a medicament for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or mental disorders in mammals.

37. Use of the compound of formula (I) or a pharmaceutical salt thereof according to any one of claims 1 to 31 for the preparation of a medicament for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon cancer, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or pain-related spasms.

Citation Information

Patent Citations

  • Active ingredient-releasing cyclic siloxanes

    WO2005066187A1

  • System for testing olfactory perception

    WO2011059118A1

  • Benzoimidazole derivatives as pad4 inhibitors

    WO2016185279A1